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ABSTRACT 
 
Chronic pain alters sensory responses and carries a strong emotional component.  
Persistent pain can heighten pain experiences, resulting in hyperalgesia and allodynia.  
Further, patients suffering from chronic pain are more prone to experience a range of 
affective disorders including depression, sleep dysregulation, panic disorders, anxiety 
abnormalities and stress-related disorders including post-traumatic stress disorder 
(PTSD).  Hence while pain serves a protective function to prevent additional 
physiological harm by driving behavioral and cognitive responses, chronic or persistent 
pain can lead to maladaptive nociceptive responses and exacerbate psychopathologies.  
Among brain regions, the amygdala is centrally situated to integrate the many descending 
and ascending signals to modulate the sensory and emotional components of pain.  The 
amygdala is well studied for its role in fear and stress-related behavioral processes.  The 
central nucleus of the amygdala (CeA), and in particular the lateral capsular subdivision 
of the CeA (CeLC), receives prominent ascending pain neurotransmission via the spino-
parabrachioamygdaloid tract.  In this pathway, peripheral nociceptive signals carried via 
primary sensory Aδ- and C-fibers terminate in the dorsal horn where second order 
neurons send projections via the spino-parabrachial pathway to the lateral parabrachial 
nucleus (LPBn).  Thus, the LPBn collects cutaneous (mechanical and thermal), deep 
(muscular and articular) and visceral nociceptive signals and relays the information in a 
highly organized manner principally to the CeLC for nociceptive processing.  In pain, the 
CeA and the LPBn-CeLC projections have been shown to undergo plasticity in the forms 
of enhanced synaptic transmission and alterations in neurotransmitter and receptor 
expression.  Accordingly, the neurocircuit intersections in the CeA can modulate the 
sensory and emotional responses to pain.  Yet despite these associations, the mediators 
and mechanisms underlying the emotional consequences of pain are poorly understood.   
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neural and 
endocrine pleiotropic peptide important in the development and homeostatic regulation of 
many physiological systems.  Recently, the expression of PACAP and its cognate PAC1 
receptor has been shown to be upregulated in specific limbic regions by chronic stress.  
PACAP infusions into several limbic regions is anxiogenic, and altered blood PACAP 
levels and PAC1 receptor polymorphism have been associated with PTSD and other 
stress-related disorders.  Here, we establish that CeLC PACAP originates from the LPBn 
as part of the spino-parabrachoamygdaloid pathway.  Chronic pain enhanced PACAP 
expression along LPBn-CeLC projections, indicating it may be a component of pain-
related plasticity.  CeA PACAP signaling was sufficient to induce nociceptive 
hypersensitivity and anxiety-like behaviors.  In a chronic neuropathic pain model, CeA 
PACAP signaling was found to contribute to heightened anxiety-like behaviors and 
nociceptive responses.  Further, we characterized one prominent intracellular signaling 
mechanism through which CeA PACAP signaling influences these behaviors.  
In these experiments we provide evidence that CeA PACAP signaling plays an 
important role in the emotional components of pain and that alterations in CeA PACAP 
signaling are part of pain-related plasticity.  This work establishes novel molecular 
mechanisms that underlie the emotional component of pain and may contribute to the 
development of chronic pain and associated affective disorders. 
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 Chapter 1. 
Literature Review 
 
1.1. General Introduction 
Chronic pain is one of the greatest medical health problems in the developed 
world affecting approximately 19% of the adult population (Breivik et al., 2006). From 
an economic standpoint, chronic pain presents an enormous burden.  In 2010, the 
estimated additional health care costs due to pain ranged from $261-300 billion within 
the United States, and with the loss in productivity, the total costs increase to an 
estimated $560-635 billion (Gaskin & Richard, 2012).  In relative terms, the annual cost 
of chronic pain is greater than that for heart disease ($309 billion), cancer ($243 billion), 
and diabetes ($188 billion) (Gaskin & Richard, 2012).  While readily available and 
highly efficacious treatments for acute pain exist, successful treatment options for those 
suffering chronic pain still remain elusive, with current medications reducing pain 
severity by only 30-40% in fewer than 50% of patients treated (Turk, 2002).   
Pain is an adverse sensory and emotional experience associated with real or 
potential tissue damage.  Under normal conditions, pain serves a protective function, 
driving a set of responses that prevent the body from incurring additional harm.  Pain is 
multidimensional, acting both as an immediate sensory-discriminatory indicator and as an 
emotional-affective drive that promotes defensive and vigilant behaviors.  Poignantly 
illustrative of this protective function are the accounts from case reports of individuals 
with a congenital insensitivity to pain.  Individuals with a set of rare nonsense mutations 
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in the SCN9A gene, encoding for the α-subunit of Nav1.7 channel, display normal 
reactions to touch, warmth, cold, and pressure, but completely lack any kind of reaction 
to painful stimuli.  These individuals live in constant threat of injury, displaying frequent 
bruises, cuts, damage to lips and tongue (from biting themselves during early years of 
life), and are at risk for early mortality from accidental injury (Cox et al., 2006). 
While acute pain serves a clear protective function, pain can outlast the injury and 
the normal healing process and become chronic.  In these cases, pain is detrimental to an 
individual’s quality of life, without any physiological benefit.  Clinically, chronic pain 
has often been defined as pain that persists for at least 3 to 6 months; however, very often 
chronic pain lasts much longer.  One study reported that those seeking treatment at 
chronic pain treatment facilities did so for 7 years on average (Flor et al., 1992).  There is 
a crucial need to determine both the mechanisms underlying the transition from acute to 
chronic pain, and the mechanisms that maintain and reinforce chronic pain.  One of the 
key concepts to emerge from the efforts to understand the mechanisms of chronic pain is 
that of central sensitization.  Sustained noxious input can result in the prolonged increase 
in excitability and synaptic efficacy in neurons along central nociceptive pathways.  The 
enhancement of nociceptive transmission is manifested as pain hypersensitivity, in which 
pain can result from a normally non-painful stimulus (allodynia) or pain is enhanced from 
a painful stimulus (hyperalgesia).  Since central sensitization results from changes 
occurring in central neurons, the increased responsiveness may become decoupled from 
the peripheral noxious stimulus and could result in the persistence of pain in the absence 
of injury (Latremoliere & Woolf, 2009).  Thus, discovering the mechanisms underlying 
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the sensitization of nociceptive central circuits appears crucial to the understanding the 
pathogenesis of chronic pain and will provide opportunities to develop treatments for 
chronic pain. 
Further increasing the burden of chronic pain sufferers is that pain often co-exists 
with psychiatric illness.  One study found that 59% of those being treated for chronic 
back pain had at least one concurrent diagnosis of psychiatric illness compared to 15% in 
the general population, and 77% had at least one lifetime psychiatric diagnosis compared 
to 29-38% in the general population (Kroenke & Price, 1993).  Epidemiological studies 
have found a strong association between chronic pain and anxiety disorders.  A nationally 
representative sample (n=5877) of those who suffered chronic pain found that they were 
2-3 times as likely to have an anxiety disorder compared to the general population.  The 
rate of posttraumatic stress disorder (PTSD) was present 3.7 times more often in those 
with chronic pain than in the general population, and the rate of panic disorder (PD) was 
4.3 times that of the general population (McWilliams et al., 2003).  A large cross-national 
mental health survey (n=85,088) found similar results, with chronic back or neck pain 
being associated with PTSD, PD, and generalized anxiety disorder (GAD) 2-3 times the 
rate in the general population (Demyttenaere et al., 2007).  This relationship appears to 
hold true across several different types of pain, as migraine, arthritis, and back pain 
sufferers were found to have 2-4 times the rate of anxiety disorders compared to the 
general population (McWilliams et al., 2004).  Furthermore, pain may precipitate stress-
related disorders, as it has been shown that the level of peritraumatic pain in patients 
admitted to a trauma center is highly predictive of the development of PTSD at 4 and 8 
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months following hospital admission (Norman et al., 2008).  PTSD symptoms were 
significantly positively correlated with pain ratings, with PTSD sufferers having higher 
subjective pain and more pain-related disability (Phifer et al., 2011).  Interestingly, PTSD 
sufferers also have altered reactions to acute pain, with higher pain thresholds to acute 
noxious stimulation, but greater intensity of pain with suprathreshold noxious stimulation 
(Defrin et al., 2008; Geuze et al., 2007). 
Theoretical models have been proposed to explain the relationship underlying the 
concurrence of chronic pain and anxiety-related disorders.  The mutual maintenance 
model holds that both disorders interact in a way that reinforces the persistence of the 
other (Asmundson & Katz, 2009).  In the mutual maintenance model, the physiological, 
affective, and behavioral components of anxiety disorders interact to maintain or 
exacerbate symptoms of pain.  Similarly, the various physiological and affective 
components of pain interact to maintain or exacerbate symptoms of anxiety disorders.  
For instance, pain sensations in a chronic pain sufferer could act as a persistent, 
conditioned reminder of trauma, resulting in increased anxiety.   Alternatively, the shared 
vulnerability model posits that individual factors may predispose people to develop both 
anxiety disorders and chronic pain.  These factors, such as feelings of loss of control or 
low threshold for alarm, may be genetically influenced (Asmundson & Katz, 2009).  
While these models offer explanations for how pain and stress interact, the biological 
mechanisms that underlie these relationships are still largely unknown. 
In examining function of neuropeptide signaling within the nervous system, the 
laboratories of Dr. Victor May and Dr. Sayamwong Hammack have recently identified 
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pituitary adenylate cyclase activating polypeptide (PACAP) and its cognate PAC1 
receptor as a mediator of the stress response system.  Increased PACAP expression is 
found following a repeated variate stress (RVS) paradigm within the bed nucleus of the 
stria terminalis (BNST) and the paraventricular nucleus of the hypothalamus (PVH) 
(Hammack et al., 2009).  Infusion of PACAP into the BNST is anxiogenic, increasing 
anxiety-like behaviors and hypothalamic pituitary axis (HPA) activation, and producing 
an anorexic response (Hammack et al., 2009; Kocho-Schellenberg et al., 2014; Lezak et 
al., 2014).  Blocking BNST PACAP signaling during RVS can significantly attenuate 
heightened anxiety-like behaviors and stress-induced anorexia (Roman et al., 2014).  
PACAP signaling may be relevant to human anxiety-disorders, as a single nucleotide 
polymorphism (SNP) in the PAC1 receptor gene, ADCYAP1R1, has been correlated with 
PTSD symptoms in women, and PAC1 receptor methylation has been found to be 
associated with PTSD symptoms in both sexes (Ressler et al., 2011).  In aggregate, these 
findings implicate limbic PACAP signaling as a central mediator of the stress response 
system.  In the course of our investigation, we noted dense PACAP immunoreactivity in 
the nerve terminals within the central amygdala (CeA).  Subsequently, we found that 
CeA PACAP corresponded to nociceptive input originating from the parabrachial nucleus 
(PBn).  Thus, PBn PACAP released in the CeA could serve as a mechanism linking 
nociceptive input to amygdala-mediated emotional responses.   
To further understand the pathways described above, we investigated whether 
CeA PACAP signaling mediates the emotional components of pain, first, by establishing 
PACAP in the PBn-CeA projections, and next by examining whether CeA PACAP was 
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involved in pain-related emotional responses.  Further, we characterized the potential 
molecular pathways through which CeA PACAP signaling may be acting.  These 
investigations were aimed at understanding the molecular and anatomical substrates 
underlying the relationship of pain and emotional behaviors.  The coexistence of pain 
with affective disorders may not only result in substantial disease burden, but also lead to 
the amplification and perpetuation of pain.  The mechanisms linking these two systems 
may be particularly effective targets for the development of treatments for affective 
disorders comorbid with chronic pain. 
In interest of clarity, the background and introduction are divided into three main 
sections: 1) mechanisms of nociception - reviewing the detection and transmission of 
nociceptive information; 2) amygdala and its functions in pain; and 3) PACAP signaling 
in pain.  The subsequent two chapters are primary research studies in manuscript form, 
which is then concluded with a comprehensive discussion.   
 
1.2. Neurobiology of Pain 
Detection of painful stimuli 
The detection of stimuli of a thermal, mechanical, or chemical nature is performed 
by a set of sensory afferent fibers in the body containing a set of specialized receptors 
that transduce sensory stimuli into electrical currents.   For thermal stimuli, a clear 
demarcation between innocuous warmth and noxious heat exists and typically rests 
around 42.5 C.  At this temperature lies the approximate thermal activation threshold for 
the transient receptor potential cation channel subfamily vanilloid member 1 (TRPV1) 
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receptor.  A member of the transient receptor potential (TRP) ion channel family, TRPV1 
receptor activation results in the perception of a burning sensation.  Capsaicin, the 
pungent ingredient in “hot” chili peppers, is a TRPV1 agonist.   On the other end of the 
thermal spectrum, TRPM8 and possibly TRPA1 receptors are sensitive to noxious cold 
stimuli and display an affinity to natural cooling agents such as menthol (Basbaum et al., 
2009).  Mechanical stimuli are detected through multiple mechanisms including high-
threshold mechanoreceptors that terminate in free nerve-endings in the skin, low-
threshold mechanoreceptors that terminate on hair fibers, as well as Merkel cells and 
Pacinian corpuscles, which detect texture, vibration, and light pressure.  It is predicted 
that these structures contain ion channels that are activated directly by force underlie 
mechanotransduction; however the identity of these channels has been difficult to 
determine.  Recently, piezo channels, piezo 1 and piezo 2, have been shown to be 
potential candidates for mechanotransduction (Coste et al., 2010).  Piezo channels are 
extremely large proteins comprised of more than 2000 amino acids with 30 to 40 
transmembrane segments, and exist in an even larger structural complex, as the functional 
channels appear to be tetramers.   Initial evidence suggests that piezo1 might be 
particularly important in vascular architecture as a shear-stress-evoked ionic current (Li 
et al., 2014).  Piezo 2 has been shown to be important in low-threshold 
mechanotransduction, mediating innocuous touch sensation (Ranade et al., 2014).  The 
channels mediating high-threshold, noxious mechanosensation are still unknown.  
Noxious chemical stimuli can consist of environmental agents such as capsaicin, 
menthol, and isothiocyanates that bind to receptors that transduce noxious stimuli, 
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including TRPV1, TRPM8, and TRPA1 respectively.   Additionally, noxious chemical 
stimuli can be substances that are endogenously released after tissue damage or 
physiological stress.  These include signaling molecules, such as calcitonin gene related 
peptide (CGRP) and substance P, and factors released from mast cells and macrophages, 
such as bradykinin, prostaglandin E2, interleukin-6 (IL-6) and tumor necrosis factor – α 
(TNFα).  These molecules bind to receptors on the cell surface to activate or sensitize 
nociceptors directly, thereby inducing pain or lowering the threshold for pain perception 
(Basbaum et al., 2009).   
 
Nociceptive pathways 
After detection of noxious stimuli and transduction into electrical currents, two 
main classes of fibers convey nociceptive information, medium diameter, lightly 
myleinated Aδ fibers and small diameter, unmyleinated C-fibers.  Aδ-fibers range in 
diameter from 2-6 µm with a conduction velocity of 12-30 m/s, while C-fibers have a 
diameter of 0.4 to 1.2 µm with a conduction velocity between 0.5-2 m/s.  Whereas Aδ 
afferents convey acute, well-localized pain, C-fibers are responsible for more diffuse, 
slow onset pain.  Each fiber type can be further divided into subpopulations.  Aδ-fibers 
can be divided into type I fibers that respond to mechanical stimuli but have a high heat 
threshold, and type II fibers that have a low heat threshold but high threshold for 
mechanical stimuli.  Many C-fibers are polymodal, responding to both mechanical and 
thermal stimuli; however subsets of these fibers may have modality specificity.  Based on 
molecular characterization, C-fibers consist of a peptidergic population that expresses 
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substance P and calcitonin-gene related peptide (CGRP), and a nonpeptidergic population 
that binds IB4 isolectin and express G protein-coupled receptors of the Mrg family 
(Basbaum et al., 2009).  Although still a matter of debate, there might be modality 
specificity as it was recently found that selective ablation of these peptidergic fibers 
reduced sensation to noxious heat and capsaicin, without impairing mechanosensation 
(McCoy et al., 2013).  Nociceptive fibers originate from pseudo-unipolar somatosensory 
neurons that have cell bodies residing in the dorsal root ganglion (DRG) or the trigeminal 
ganglion.  The peripheral terminals of these neurons transduce nociceptive information 
and convey it to the central terminals that synapse in the outer layers of the dorsal horn of 
the spinal cord, specifically Rexed laminae regions I, II, and V.  Subtypes of afferents 
synapse with regional specificity creating a distinct laminar organization.  Projections 
from dorsal horn neurons within laminae I and III-VI form the main connections to 
brainstem and brain (Todd, 2010).   
Within the dorsal horn, second order neuronal projections form multiple parallel 
pathways to convey nociceptive information to higher order central nervous system 
(CNS) regions.  The afferent pain pathways can be separated on a phylogenetic basis into 
two different systems, ancient and more evolutionarily recent pathways.  The 
evolutionarily ancient pathways run through the medial brainstem consisting of the 
paleospinothalamic, spinoreticular, spinomesencephalic, spinoparabrachio-amygdaloid, 
and spinohypothalamic tracts.  In contrast, evolutionarily recent pathways traverse the 
lateral region of the brainstem and consist of the neospinothalamic and spinocervical 
tracts (Almeida et al., 2004).  These tracts form the main projections from the superficial 
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dorsal horn to brainstem and brain.  The main targets of dorsal horn projection neurons 
within the brainstem include the caudal ventrolateral medulla (CVLM), which is an 
integrative center of cardiovascular response and nociception, and a site of origin for 
many of the descending projections back to the dorsal horn.   The nucleus of the solitary 
tract (NTS) is a second major target involved in cardio-respiratory integration, as well as 
a major target for visceral nociceptive information arriving via the vagus nerve.  The 
periaqueductal grey (PAG) in the medulla is involved in the descending modulation of 
dorsal horn circuits, one of the key regions for the actions of analgesics, and critical in 
stress-induced analgesia through descending output from the amygdala (Butler & Finn, 
2009).  The lateral PBn (LPBn) is a major target of lamina I input, and LPBn neurons 
have axonal projections to the amygdala, hypothalamus, and BNST; these projections 
will be discussed further in the next section.  Another major target of nociceptive lamina I 
projections neurons is the thalamus.  In particular, several regions in the thalamus receive 
nociceptive information, including the ventral posterolateral nucleus (VPL), which 
receives nociceptive information from the body, and the ventral posteromedial nucleus 
(VPM), which receives nociception information from the face via the trigeminal nerve.  
The VPL and VPM have direct projections to the primary somatosensory cortex, and are 
involved in the sensory-discriminative aspects of pain.  Another set of thalamic nuclei the 
posterior group and posterior triangular nucleus of the thalamus (PoT) also receive 
nociceptive information and project primarily to the insular cortex, secondary 
somatosensory cortex, and amygdala.  These regions are thought to be involved the 
aversive emotional aspects of pain (Gauriau & Bernard, 2004).  Studies in rodents have 
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examined the anatomical distribution for each spinal pathway by injecting retrograde 
tracers into each brain region and quantifying the number of lamina I neurons labeled 
(Spike et al., 2003; Todd, 2010).  Upon examination, lamina I of the L4 segment of the 
rat spinal cord contains approximately 400 projection neurons, which is about 5% of the 
total number of neurons in lamina I.  A majority of the neurons project to the 
contralateral side of the brain; however about 25% have bilateral projections.  The vast 
majority of lamina I neurons exhibit extensive collateralization projecting to multiple 
regions.  Hence, of all L4 lamina I projections neurons, an estimated 85% project to the 
LPBn, 85% project to the CVLM, 30% project to the PAG, 25% project to the NTS, and 
less than 5% project to the thalamus (Spike et al., 2003).  The very small proportion of 
projections to the thalamus may be unique to the lumbar region, because the cervical 
spinal cord contains a greater number of spinothalamic projection neurons and fewer 
spinoparabrachial projection neurons (Al-Khater & Todd, 2009).    
 
Parabrachial nucleus (PBn) anatomy and connectivity 
The PBn is an anatomical area surrounding the superior cerebellar peduncle 
(SCP), or brachium conjunctivum, located in the dorsolateral rostral pons and caudal 
midbrain.  The PBn can be divided into medial (MPBn) and lateral (LPBn) nuclei, with a 
third ventrolateral extension called the Kölliker-Fuse nucleus.  The PBn can be further 
divided into 10 distinct subnuclei based on cytoarchitecture (Figure 1.1).  Immediately 
ventromedial to the SCP is the MPBn subnucleus containing a heterogenous cell 
population.  In contrast, the external MPBn subnucleus contains larger multipolar 
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neurons and is interposed between the MPBn and Kölliker-Fuse nucleus.  The LPBn is 
made up of several homogeneous groups of cells, including the superior lateral, internal 
lateral, central lateral, ventral lateral, dorsal lateral, external lateral, and extreme lateral 
nuclei, which are delineated by morphology and spatial distribution (Fulwiler & Saper, 
1984).  Individual subdivisions can also be differentiated based on connectivity.  The 
primary projections of the PBn include several hypothalamic regions (the medial preoptic 
hypothalamus (MPO), ventromedial hypothalamus (VMH), lateral hypothalamus, and 
paraventricular hypothalamus (PVH)), the nucleus of the solitary tract (NTS), several 
thalamic regions including the intralaminar nuclei and paraventricular nucleus of 
thalamus (PVT), and the extended amygdaloid complex including the BNST and CeA 
(Fulwiler & Saper, 1984).  Within the amygdaloid complex, the central medial amygdala 
(CeM) receives projections mainly from the MPBn and ventral lateral subnucleus.  The 
central lateral amygdala (CeL) and the BNST receives projections from the central LPBn 
and the outer portion of the external LPBn subnucleus.  The central laterocapsular 
amygdala (CeLC) receives projections primarily from the external and dorsal LPBn 
(Bernard et al., 1993).  Reconstruction of axonal branching patterns have found that, 
while the LPBn has projections that travel exclusively to either the BNST or CeA, the 
LPBn projections in passage to the CeA can also send collaterals to the BNST (Sarhan et 
al., 2005).  After leaving the LPBn, the efferent fibers can travel through the dorsal and 
central tegmental tracts, and then join the medial forebrain bundle and ansa lenticularis.  
Here, the fibers can branch and course via dorsal or ventral pathways.  In the ventral 
pathway, the fibers immediately turn laterally to reach the CeLC and CeL.  In the dorsal 
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pathway, the fibers can continue to travel rostrally sending collaterals to the lateral BNST 
and traveling back around through the stria terminalis to reach the CeL and CeLC (Figure 
1.2).   
 
Spino-parabrachio-amygdaloid tract 
The LPBn is a key site of convergence for nociceptive input.  It is one of the 
largest targets of nociceptive dorsal horn projection neurons, relayed primarily through 
the dorsal lateral funiculus, and receives nociceptive information broadly from the body.  
Besides the substantial input from lamina I, the PBn also receives input from the 
trigeminal nucleus, carrying nociceptive information from the face, and from the NTS 
relaying visceral nociceptive inputs.  Thus, the LPBn may integrate both peripheral and 
visceral nociceptive signals.   
To examine the role of the parabrachio-amygdaloid projections in nociception, 
PBn neurons from anesthetized rats were examined using extracellular 
electrophysiological recordings (Bernard et al., 1996).  Antidromic stimulation of the 
CeA was used to identify PBn-CeA projecting neurons and to examine the 
responsiveness of these neurons to mechanical thermal or visceral stimuli.  
Approximately 70% of PBn-CeA neurons were exclusively excited by noxious stimuli, 
whereas innocuous somatic or gustatory stimuli did not alter firing of these neurons.  
These neurons tended to have large excitatory receptive fields, often covering several 
areas of the body, suggesting that these neurons are likely not encoding specific spatial 
information to allow for sensory discrimination.  A subpopulation (30%) of PBn-CeA 
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neurons had a smaller receptive field and were only excited when noxious stimuli were 
applied to a specific part of the body.  Subthreshold or non-noxious stimuli were found to 
inhibit responses in the nociceptive-responsive PBn-CeA neurons.  Noxious thermal 
stimuli tended to induce a stronger excitatory response than noxious mechanical stimuli.  
Morphine was found to have multiple effects blocking the excitatory response to thermal 
stimuli in PBn-CeA neurons and reducing c-fos expression in a subset of lamina I spino-
parabrachial neurons following noxious stimulation (Huang et al., 1993; Jasmin, Wang, 
Tarczy-Hornoch et al., 1994).   
 
Central pain processing 
While this review primarily focuses on the role of the amygdala in pain processes, 
the experience of pain is multifactorial and utilizes a large distributed brain network 
commonly referred to as the pain matrix (Tracey & Mantyh, 2007).  It can be divided into 
two main systems, one lateral sensory-discriminatory and the other medial affective-
cognitive.  The majority of the research on these systems has been based on 
neuroimaging studies to determine which brain regions are more or less active depending 
on the interplay of particular conditions and factors, including the type of injury, mood, 
and cognitive components.  As such, the pain matrix is not precisely defined, nor is it 
always consistent as to which regions are included or excluded.  Rather, the pain matrix 
may be more a pain signature, reflective of individual and subjective experiential 
differences (Tracey & Mantyh, 2007).  During acute pain, the most common regions 
involved are the thalamus, primary and secondary somatosensory cortices, insular cortex, 
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anterior cingulate cortex, and prefrontal cortex (Apkarian et al., 2005).  Within the pain 
matrix, the regions responsible for emotional components of pain, including those related 
to anxiety and depression, may act to further amplify the pain experience.  Commonly 
associated regions in the processing of the emotional aspects of pain regions include the 
anterior cingulate cortex, insular cortex, hippocampus, and amygdala (Yalcin et al., 
2014).  Thus, in the context of the larger pain matrix, the amygdala might serve to impart 
an emotional context to pain.   
 
1.3. Amygdala in Pain Processes 
Anatomy 
The amygdala refers to a group of nuclei deep within the temporal lobe, vital in 
the processing of emotion-related responses.  The amygdala can be divided on the basis 
anatomy and function into several major divisions; the basolateral nuclei, cortical-like 
nuclei, and centromedial nuclei.  The basolateral nuclei (BLA) consist of the lateral 
nucleus (LA) and the basal nucleus (BA).  The BLA is bordered laterally by the external 
capsule and medially by the central amygdala (CeA).  The cortical-like nuclei are the 
most superficial group consisting of the nucleus of the lateral olfactory tract, bed nucleus 
of the accessory olfactory tract, periamygdaloid cortex, anterior cortical nucleus, and 
posterior cortical nucleus.  The centromedial group consists of the CeA and medial 
nucleus (MeA).  The CeA can be further divided into central medial (CeM), central 
lateral (CeL), and central lateral capsular (CeLC) (Sah et al., 2003).  Further, it has been 
argued on the basis of structural and functional homology that the centromedial group 
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should be extended rostrally and medially to include the bed nucleus of the stria 
terminalis (BNST) and the caudodorsal regions of the substantia innominata to form what 
is referred to as the extended amygdala complex (Alheid, 2003).  This distinction is on 
the basis of similarities between efferent and afferent connections and histochemical 
architecture in these regions.  Another amygdala group, the intercalated neurons, does not 
form a distinct nucleus but occurs as numerous dense clusters found in the external 
capsule on the lateral border of the BLA, and two clusters in the intermediate capsule 
between the BLA and CeA. 
 
Intrinsic and extrinsic connectivity 
The amygdala has fairly extensive intrinsic connections.  In general, information 
in the amygdala tends to flow in a lateral to medial direction, with sensory and 
multimodal input from cortical association areas arriving in the LA.  The main output is 
from the CeM, where the amygdala is strongly connected to autonomic and modulatory 
centers of the hypothalamus and brainstem, including the paraventricular hypothalamus 
(PVH), lateral hypothalamus (LH), the periaqueductal grey (PAG), PBn, NTS and dorsal 
vagal complex.  Between the LA and CeM are few to no direct connections, instead 
projections to the CeL, CeLC and intercalated cells are thought to function to gate 
sensory input to modulate fear behavior under particular environmental conditions 
(Duvarci & Paré, 2014).  The BLA is primarily composed (~80%) of large glutamatergic 
projection neurons with the remaining neurons belonging to a diverse set of GABAergic 
interneurons that form local circuits.  These glutamatergic projections neurons synapse 
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primarily onto CeL, CeLC and intercalated neurons.  The CeA is composed primarily of 
GABAergic neurons, with the CeM neurons having large soma and sparsely branching 
dendrites, and the CeL and CeLC neurons having smaller soma and dendritic trees that 
branch profusely (Ehrlich et al., 2009).  Neurons within the CeL and CeLC project to the 
CeM, with few to no reciprocal projections (Petrovich & Swanson, 1997).  Within the 
CeL and CeLC are microcircuits with GABAergic interneurons synapssing on a second 
GABAergic interneuron.  In turn, these interneurons then project to the CeM and can 
result in the activation of the CeM through disinhibition.  These two populations of 
interneurons have been defined genetically by the presence of protein kinase Cδ.  During 
a fear-evoking stimulus, one CeL/CeLC interneuron population is selectively activated 
(CeL-On), whereas a second population is inhibited (CeL-Off). The CeL-Off population 
projects to the CeM, and the inhibition of CeL-Off neuron during fear results in 
disinhibition of the CeM and evokes fear-related behaviors (Ciocchi et al., 2010; 
Haubensak et al., 2010).  In aggregate, this suggests that the CeL and CeLC form a 
complex inhibitory gate on the CeM, allowing for multiple points of modulation.  One 
input to the CeLC and CeL is through the previously described projection from the LPBn 
to CeL and CeLC.  These nociceptive inputs bypass the BLA completely.  Additionally, 
while the CeM is the source of the largest output from the amygdala, projecting to 
multiple regions in the brainstem and hypothalamus, the CeL and CeLC also modulate 
behavior through a set of direct projections to the BNST (Dong et al., 2001).     
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Amygdalar neuronal circuits for fear and anxiety 
Fear and and anxiety serve a protective function driving behavioral responses 
aimed at avoiding potential harm.  The amygdala has been long held to be a key mediator 
of emotional behaviors.  The pioneering studies in this area were of macaques with a 
temporal lobe lesion wherein the amygdala was ablated.  Following the lesions, there 
were behavioral alterations including amnesia, inability to recognize familiar objects, 
docility and a striking lack of emotional responses.  This was most apparent by the 
complete absence of fear responses in these macaques (Klüver & Bucy, 1937).   Since 
then, the role of the amygdala in fear has become a focus of a substantial body of 
research.  Due to relative simplicity and robustness of response, fear conditioning 
paradigms remain on the forefront of our ability to understand the brain at the level of 
neural circuits.  The fundamental framework of the amygdalar fear conditioning network 
posits that information about both the unconditioned stimulus (US) and conditioned 
stimulus (CS) converge onto neurons in the LA.  The LA then projects to the CeA, the 
main output, which then has projections to various brainstem regions that generate fear 
responses (Ledoux, 2000).  In this model, the LA receives information related to the CS, 
such as context cues from the hippocampus or tone information from the auditory cortex. 
Concurrently, the LA is also receiving information related to the US, such as the aversive 
information from electrical shock via the thalamus.  Hence, in this model there is a 
convergence of the US and CS in the LA, and synaptic plasticity within this region is 
thought to be critical for the formation of the association between the US and CS, or fear 
acquisition.  The fundamentals of this model are still valid; however, numerous updates 
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and clarifications have been made surrounding the basic circuitry.  Between LA neurons, 
which receive sensory input, and the CeA output neurons in the CeM, there are little to no 
direct connections.  Rather, the LA projects to three intermediaries including the CeLC 
and CeL, ITC cells and the BLA, where each one in turn projects to the CeM (Duvarci & 
Paré, 2014; Tovote et al., 2015) (Figure 1.3).  Additionally, while there is significant 
synaptic plasticity occurring in the LA following fear conditioning, synaptic plasticity in 
the CeA also appears important in the acquisition of fear (Paré et al., 2004).  The 
infralimbic (IL) and prelimbic (PL) regions of the medial prefrontal cortex appear critical 
in the suppression of fear responses via projections of the IL to the ITC cells, and the PL 
to the BLA.  These circuits appear particularily important in learned suppression of fear 
response, as occurs during fear extinction (Tovote et. al. 2015).  Of particular relevance 
to the current work, is the recognition of direct nociceptive projections from the LPBn to 
the CeLC and CeL, which completely bypass the BLA and thalamus (Veinante et al., 
2013).  Further, it has emerged that the amygdala may play a central role in the response 
to short, phasic fear-evoking stimuli. However, in response to sustained sustained fear-
evoking stimuli, more akin to anxiety, it is thought that the BNST becomes the primary 
mediator (Davis et al., 2010; Walker et al., 2009).  The current work involving the 
amygdala in fear has begun to utilize novel genetic manipulations to dissect 
subpopulations of neurons that may represent circuits with specific functions.  One of the 
ideas to emerge from this work is that within the BLA specific circuits might encode 
either a positive or negative valence, that either heightens or dampens the overall fear 
response (Namburi et al., 2015; Redondo et al., 2014).     
 20 
Nociceptive input 
Due to its integration of a wide range of emotionally salient sensory stimuli, 
extensive nociceptive input, and its prominent role in the production of emotional 
behaviors, the amygdala is thought to be a key region in the processing and production of 
the emotional components of pain.  As a whole, the amygdala is thought to attach an 
emotional valence to sensory stimuli and initiate behavioral and affective responses.  In 
the context of the pain matrix, the amygdala would likely function to attach a negative 
emotional valence to nociceptive stimuli, resulting in compensatory behavioral changes.  
Within the amygdala, the CeA is situated at the interface of two nociceptive pathways 
(Figure 1.3).  The first pathway carries nociceptive information originating from the 
cerebral cortex and thalamus and relayed by the BLA.  The BLA receives nociceptive 
information from the ventroposterior, posterior, triangular, and posterior intralaminar 
thalamic nuclei, the secondary somatosensory area, and the insular cortex (Sah et al., 
2003; Shi & Davis, 1999).  The BLA then projects to the CeLC and CeL or to the 
intercalated cell masses, which, in turn, project to the CeM.  This nociceptive information 
has gone through the thalamus and cerebral cortex, where it can be integrated with other 
sensory, affective, and cognitive influences to become a highly polymodal and processed 
form of information.  While the BLA receives a majority of its input from the cortex and 
thalamus, there is, however, a small projection from these cortical and thalamic areas that 
directly innervates the CeA (Shi & Davis, 1999).  The second main nociceptive input is 
the spinoparabrachio-amygdaloid pathway that sends direct and less processed 
nociceptive information to the CeLC and CeL.  Additionally, there is also a sparse 
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projection directly from lamina I in the dorsal horn to the CeA.  Nociceptive information 
both directly through the PBn-CeA pathway and indirectly through the BLA-Ce A 
pathway converges in the CeLC and CeL (Neugebauer et al., 2004).   
There is substantial evidence that neurons in CeA respond to nociceptive 
information.  Using in vivo electrophysiology, CeA neurons of anesthetized rats were 
examined for their responsiveness to noxious stimuli, defined as stimuli that would be 
painful in an awake subject.  The majority of responsive neurons were located in the 
CeLC with approximately 80% of neurons displaying responses exclusively or 
predominantly to noxious stimulation of superficial or deep body tissue (Bernard et al., 
1992; Neugebauer & Li, 2002).  Of the approximately 80% of nociceptive responsive 
neurons, 46% were excited by noxious stimulation and the remaining 34% of CeA 
neurons were inhibited in the presence of noxious stimulation (Bernard et al., 1992). The 
excited neurons tended to be located in the CeLC, and inhibited neurons tended to be 
located in the CeL and CeM.  In light of recent understanding of CeA microcircuitry, in 
which a population of CeLC and CeL neurons have inhibitory projections onto neurons in 
the CeL and CeM, increased excitatory drive on these GABAergic CeLC neurons could 
be directly inhibiting CeM and CeL neurons and explain the heterogeneity of response.  
Three main types of neurons were described based on their responses to nociceptive 
stimulation.  Nociceptive-specific neurons are activated exclusively by noxious 
stimulation.  Multireceptive neurons respond to both nociceptive and innocuous stimuli, 
and nonresponsive neurons do not respond to noxious stimulation at all.  The majority of 
responsive neurons have large, often bilateral, receptive fields that include large portions 
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of the body.  In response to differing intensities of mechanical and nociceptive stimuli, 
responsive neurons display a sigmoidal response curve rather than increasing 
monotonically, suggesting poor resolution of intensity.  Similar to the PBn, this suggests 
that CeA neurons are unlikely to encode a sensory-discriminative component of pain 
(Bernard et al., 1992; Neugebauer & Li, 2002; Neugebauer et al., 2004).   
Human brain imaging supports involvement of the amygdala in pain.  In 
experimental settings, application of an infrared laser thermal stimulus or colorectal 
distention leads to increased amygdala activity (Bonaz et al., 2002; Bornhovd, 2002).  
Although a few studies have reported either reduced activation or no change in the 
amygdala with noxious stimuli, a meta-analysis found that the majority of experiments 
applying noxious stimulation supported increased amygdala activation (Simons et al., 
2012).   
 
Pain-related plasticity 
In states of persistent pain, the amygdala undergoes considerable synaptic, 
neurochemical, and transcriptional plasticity.  Increases in the immediate early gene c-fos 
have been repeatedly found across different models of pain.  Amygdala c-fos mRNA was 
increased one hour following intra-plantar injection with formalin or following 
intraperitoneal injection with acetic acid (Nakagawa et al., 2003).  c-fos 
immunoreactivity increased in the amygdala with esophageal acid exposure, and 
increased c-fos immunoreactivity was found in the CeLC 4 hours following 
cyclophosphamide-induced cystitis (Bon et al., 1998; Suwanprathes et al., 2003).  
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Glutamatergic signaling is increased in the CeA, as demonstrated in models of arthritic 
pain or neuropathic pain where increased expression of the metabotropic glutamate 
receptors mGluR1 and mGluR5 were found, as well as increased phosphorylation of the 
NR1 subunit of the NMDA receptor (Bird et al., 2005; Neugebauer et al., 2003).  A 
model of neuropathic pain was associated with increases in glucocorticoid receptor 
mRNA expression, and higher levels of corticotropin-releasing hormone (CRH) mRNA 
and peptide immunoreactivity in the CeA, suggesting involvement of several of these key 
mediators of the stress response system (Rouwette et al., 2012; Ulrich-Lai et al., 2006).  
Interestingly, one study raised the possibility that neurogenesis may be a component of 
pain-related plasticity in the amygdala.  Two months following induction of neuropathic 
pain, bromodeoxyuridine (BrdU) incorporation was found in both BLA and CeA cells.  
While BrdU+ cells were found in astrocytes in both control and neuropathic pain 
conditions, the increase in BrdU+ cells under pain conditions also included  cells that 
colocalized with neuronal markers, evidence suggesting that either enhanced 
neurogenesis or increased neuronal migration contributes to pain-related plasticity in the 
amygdala (Goncalves et al., 2008).    
Electrophysiological recordings from rodent brain slices from models of 
persistent pain have demonstrated synaptic alterations.  One of the most prominent 
changes is an enhancement of evoked PBn-CeA and BLA-CeA transmission.  Using 
patch-clamp recordings of CeLC neurons, the regions of PBn or BLA afferents were 
electrically stimulated to characterize PBn-CeA or BLA-CeA transmission.  An increase 
in PBn-CeA transmission was identified following neuropathic pain, arthritic pain, acid-
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induced muscle pain, and visceral pain (Cheng et al., 2011; Han & Neugebauer, 2004; 
Ikeda et al., 2007; Neugebauer et al., 2003).  The potentiation of these synapses 
heightened nociceptive input via the PBn and emotional-salience input via the BLA, 
leading to the amygdala being more reactive with chronic pain.  This hypothesis has also 
been supported by human brain imaging studies, where changes in amygdala activity 
were identified in people suffering from arthritis, neuropathy, or irritable bowel 
syndrome (Bonaz et al., 2002; Kulkarni et al., 2007; Petrovic et al., 1999).   
 
1.4. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 
PACAP and its receptors 
PACAP is a neuropeptide with diverse roles in neurotransmission, development, 
trophic support, and homeostatic function.  This important neuropeptide was first 
identified in 1989 by Akira Arimura and colleagues, who were searching for 
undiscovered hypothalamic peptides capable of stimulating adenylate cyclase activity and 
cyclic AMP production in anterior pituitary cells (Miyata et al., 1989).  In humans, the 
PACAP, ADCYAP1, gene is at chromosomal locus 18p11 and is comprised of five exons.  
The cDNA encodes for a 176-amino-acid prepro-protein, which is then 
endoproteolytically cleaved by prohormone convertases into either a 38-amino-acid or a 
27-amino-acid form.  Subsequently, peptidylglycine α-amidating monooxygenase 
converts the protein into a bioactive peptide.  Within the central nervous system, 
PACAP38 peptide is approximately 10- to 100-fold more abundant than PACAP27 
(Vaudry et al., 2009).  The highest expression of PACAP transcript within the central 
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nervous system is within several hypothalamic nuclei, habenular nuclei, the pontine 
nucleus, the LPBn and the vagal complex (Hannibal, 2002).   
PACAP is the most conserved member of the VIP/secretin/glucagon superfamily 
of peptides across animal species.  Its amino acid sequence is well conserved across the 
mammals that have been studied.  Among chicken and frogs, PACAP differs by only a 
single amino acid, and PACAP cDNA cloned from tunicates has 96% nucleotide identity 
with human cDNA.  The closest related peptide, vasoactive intestinal peptide (VIP) 
shares 68% amino acid homology.  It is thought that PACAP is the ancestral precursor to 
the VIP/secretin/glucagon family.  The highly conserved nature of PACAP suggests that 
it might have functions essential for survival (Sherwood et al., 2000). 
PACAP signals through three G-protein coupled receptor subtypes; PAC1, 
VPAC1 and VPAC2 receptors.  Both the VPAC1 and VPAC2 receptors bind to PACAP 
and VIP with near equal affinity; however the PAC1 receptor has a much higher affinity 
for PACAP than VIP.  The alternative splicing of the PAC1 receptor results in multiple 
variants to allow greater signaling diversity.  Alterations in the N-terminal extracellular 
regions result in short receptor isoforms that can affect ligand-binding specificity.  
Alternative splicing also results in the presence or absence of two 84 base pair cassettes 
termed “hip” and “hop” within the PAC1 receptor corresponding to the third cytoplasmic 
loop resulting in the generation of at least 4 variants; PAC1-null (neither hip nor hop), 
PAC1-hip, PAC1-hop, and PAC1-hiphop.  PAC1 receptor signaling can activate 
adenylate cyclase (AC) through Gs activation and phospholipase C (PLC) through Gq 
activation; variants in the third cytoplasmic loop of PAC1 receptors can result in the 
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differential engagement of AC and PLC signaling (Blechman & Levkowitz, 2013). 
 
PACAP expression in nociceptive pathways 
A variety of bioactive neuropeptides participate in the formation, transmission, 
modulation, and perception of pain.   Substance P and neurokinin A of the tachykinin 
family of peptides and CGRP, for example, have expression patterns along nociceptive 
pathways and the ability to initiate and modulate nociceptive transmission (Basbaum et 
al., 2009).  Although appreciated as a sensory peptide within a few years after discovery, 
the recent accumulation of evidence has generated renewed interest in PACAP as a 
nociceptive peptide critical in mediating the development of chronic pain and pain-
related behavioral responses. 
The initial evidence that PACAP plays a role in nociception stemmed from its 
distribution and expression patterns within the peripheral nervous system.   
Complementing other sensory peptides, PACAP expression has been identified in both 
DRG and trigeminal ganglion neurons through immunocytochemical and in situ 
hybridization histochemical studies (Moller et al., 1993; Mulder et al., 1994).  Under 
normal physiological conditions, PACAP immunoreactivity in DRG neuronal soma and 
peripheral axons has been identified in small to medium-sized unmyelinated capsaicin-
sensitive C-fiber nociceptor afferents, along with other sensory peptides, including CGRP 
and substance P.   In addition, PACAP expression within a defined subset of peptidergic 
DRG neurons has been confirmed using single-cell RNA sequencing (Usoskin et al., 
2015).  In the spinal cord, the central axons of PACAPergic DRG neurons are largely 
 27 
confined to lamina I and II of the dorsal horn, corresponding to projections important for 
nociceptive transmission (Jongsma et al., 2000; Moller et al., 1993; Zhang et al., 1996).  
In addition to DRG, there is also a population of PACAP-expressing neurons in lamina I 
and II of the spinal cord dorsal horn, raising the possibility that PACAP may be 
expressed in second order neurons in the nociceptive pathway (Beaudet et al., 1998; 
Pettersson et al., 2004).  Based on in vitro receptor autoradiography and in situ 
hybridization, PAC1 receptors have been shown to be densely expressed in laminae I and 
II of the dorsal horn in correspondence with PACAP DRG central axon projections.   
While the distribution of PACAP fibers, PACAP neurons and PAC1 receptors in the 
superficial layers of the dorsal horn is suggestive, the potential functional ‘PACAP to 
PACAP’ connectivity between DRG and second order dorsal horn PACAPergic neurons 
is still unclear.   Based on ultrastructural studies, PACAP signaling on PACAP 
expressing neurons has been suggested in the enteric nervous systems (Nagahama et al., 
1998).   Only a few isolated neurons in the ventral horn appear to express PAC1 receptors 
(Pettersson et al., 2004).  PAC1 receptors are not apparent in DRG neurons implying that 
PACAP does not act in an autocrine or paracrine manner in the ganglion or 
presynaptically in the dorsal horn (Jongsma et al., 2000). 
 
Plasticity following injury 
Among several sensory peptides, PACAP demonstrates phenotypic plasticity in 
various peripheral models of injury- and inflammation-induced pain.   Across different 
experimental paradigms, including axotomy, nerve compression and adjuvant treatments, 
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DRG PACAP transcripts, peptide levels and cell numbers can be dramatically induced 
(Jongsma et al., 2000; Jongsma Wallin et al., 2003; Mabuchi et al., 2004; Pettersson, et. 
al., 2004; Zhang et al., 1995; Zhang et al., 1998; Zhang et al., 1996).  Notably, depending 
on the nature of insult, there appears to be an induction of PACAP within select DRG 
neuronal populations with concurrent changes in central and peripheral axon peptide 
immunoreactivity.   PACAP is normally identified in a subpopulation of small and 
medium-sized nociceptive cells and following inflammatory insult, the induction of 
PACAP appears to be confined to the same small-sized neuronal population (Jongsma 
Wallin et al., 2003).  Accordingly, inflammatory cyclophosphamide-induced cystitis 
augments DRG PACAP neuronal numbers and immunoreactive fiber density in the 
superficial layers of the dorsal horn, consistent with projections from DRG small neuron 
induction of PACAP (Vizzard, 2000).   By contrast, axotomy shifts PACAP expression in 
different DRG populations, resulting in decreased peptide expression in small DRG 
neurons and increased peptide expression in the medium and large-sized DRG neurons 
(Jongsma et al., 2000;  Zhang et al., 1996).  Large DRG neurons project to deeper layers 
of the dorsal horn and in coherence with axotomy-mediated induction patterns, PACAP-
immunoreactivity in fibers appear reduced in the superficial layers of the dorsal horn but 
enhanced in the deeper laminae.   However, whether or not the decrease in PACAP fiber 
immunoreactivity in the superficial dorsal horn laminae reflects heightened C-fiber 
PACAP secretion has not been determined.   Nerve compression increases PACAP levels 
in both small and large neuronal populations (Pettersson et al., 2004).  The mechanisms 
underlying the various PACAP induction patterns to different injuries and the 
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consequences of the dynamics in fiber projections in pain remain unclear but are 
supported in recent transgenic animal studies (see below).   Whether the second order 
PACAP neurons in laminae I and II of the dorsal horn also demonstrate plasticity under 
the different injury models is unknown, although no overt changes were observed 
following axotomy (Pettersson et al., 2004).   In contrast to DRG PACAP inductions, 
PACAP binding in the dorsal horn after injury was diminished without apparent changes 
in PAC1 receptor transcript levels (Jongsma et al., 2000).  Although the expression 
patterns for PACAP and PAC1 receptors exhibit an inverse relationship in some studies, 
the loss of PACAP binding may reflect higher PAC1 receptor internalization and 
turnover following heightened signaling (May et al., 2014; Merriam et al., 2013).  
Likewise, VPAC1 receptor expression is decreased but VPAC2 receptors are increased 
following neuropathic pain (Dickinson & Fleetwood-Walker, 1999).   While the changes 
in PACAP expression in the multiple experimental models may be related to enhanced 
nociceptive neurotransmission, the interpretations are complicated by cellular stress-
induced plasticity responses to the various injury challenges.   PACAP/PAC1 receptor 
activation can engage neurotrophic pro-survival signals to promote regeneration (Vaudry 
et al., 2009); hence induction in DRG PACAP expression in the neuropathic and 
inflammatory pain paradigms may have distinct, dual or overlapping activities in 
nociception and trophic support. 
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PACAP and PAC1 receptors in nociceptive signaling 
Based on PACAP and PAC1 receptor expression, distribution and plasticity 
observed in experimental injury models, the PACAPergic system was implicated in the  
facilitation of nociceptive responses.  While seemingly straightforward, the results of 
PACAP infusion studies were equivocal as to whether PACAP was pro- or anti-
nociceptive.  At peripheral nerve terminals, the actions of PACAP appeared largely anti-
nociceptive.  While intraplantar PACAP injections alone had no effect on thermal or 
mechanical sensitivity in naïve animals, intraplantar PACAP injections proved anti-
allodynic, anti-nociceptive and anti-hyperalgesic in experimental models of somatic and 
visceral inflammatory pain (Sándor et al., 2009).  However, PACAP at knee joint 
afferents resulted in increased mechanical sensitivity (Sándor et al., 2009).  Intrathecal 
PACAP injections was reported to inhibit spinal and inflammatory nociceptive responses 
(Yamamoto & Tatsuno, 1995; Zhang et al., 1996; Zhang et al., 1993), whereas PACAP 
administration was reported by others to be anti-nociceptive in the early phase of 
formalin induced pain, but transitioned to pro-nociception in the late phase of the 
inflammatory response (Shimizu et al., 2004). 
The pro-nociceptive actions of PACAP, however, are compelling.  Intrathecal 
PACAP infusions to naïve rats produced hyperalgesia in thermal hypersensitivity and tail 
flick latency tests, and amplified pain neurotransmission to the dorsal horn via NMDA 
mechanisms (Narita et al., 1996; Ohsawa et al., 2002).  The intrathecal nociceptive 
effects of PACAP were gradual but long lasting, which were in contradistinction to the 
rapid and transient effects of substance P (Shimizu et al., 2004).  Demonstrating a direct 
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effect of PACAP signaling, PACAP application to spinal cord neurons increased 
excitability of multireceptive cells in lamina III-V of the dorsal horn (Dickinson et al., 
1997).  Importantly, in comparable studies, blockade of PACAP signaling with the 
PAC1/VPAC2 receptor antagonist PACAP(6-38) or neutralizing PACAP antibodies 
attenuated the thermal hypersensitivity and nocifensive responses in a variety of 
neuropathic and inflammatory pain models (Davis-Taber et al., 2008; Ohsawa et al., 
2002).  Further, while PACAP(6-38) had no effects alone or upon non-noxious 
stimulation, the receptor antagonist blocked the increased excitation of dorsal horn 
neurons to noxious stimuli (Dickinson & Fleetwood-Walker, 1999).  The effects of C-
fiber stimulation on spinal nociceptive reflex responses were facilitated by PACAP 
administration and inhibited with a specific PAC1 receptor antagonist (Sakashita et al., 
2001; Xu & Wiesenfeld-Hallin, 1996).  The causes for the observed discrepancies in the 
PACAP nociceptive effects in the various experimental models are not well understood 
but may be related to dose and temporal parameters, and route or site of PACAP 
administration, especially after pain initiation.  Under specific circumstances, PACAP 
may have activated autoregulatory or descending inhibitory pathways or stimulated anti-
inflammatory responses by blocking immune cell cytokine release into the peripheral 
milieu of pain mediators to produce anti-nociceptive effects.  Based on PACAP and 
PAC1 receptor expression and distribution in the sensory pathways, and the 
preponderance of electrophysiological and behavioral data, however, the central effects 
of PACAP in injury appear to result in system sensitization and are pro-nociceptive.   
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Nociception studies in PACAP/PAC1 receptor knockout mice 
The most convincing evidence for PACAP involvement in pain stems from 
studies using transgenic PACAP (PACAP -/-) and PAC1 receptor (PAC1R -/-) knockout 
mice, which have been coherent in demonstrating the facilitatory roles of PACAP 
signaling in chronic pain (Table 1.1).  PACAP-/- mice display a range of physiological 
and neuropsychiatric phenotypes, including decreased locomotor activities, decreased 
feeding behaviors, altered memory performance, and attenuated stress responses, 
reflecting the multifaceted roles of PACAP (Girard et al., 2006; Hitoshi Hashimoto et al., 
2001; Hattori et al., 2012).  In several experimental models, PACAP-/- mice exhibited 
important deficits in neuropathic pain development.  Under control conditions, naïve 
PACAP-/- mice showed unaltered or slightly decreased sensitivity responses to thermal 
or mechanical stimuli (Mabuchi et al., 2004; May & Vizzard, 2010; Sándor et al., 2010).  
However, following chronic pain with intraplantar noxious stimulus, PACAP-/- mice 
displayed a marked loss in the induction of mechanical or thermal hypersensitivity, and 
nocifensive behaviors (Mabuchi et al., 2004; Sándor et al., 2010).  Similarly, PACAP-/- 
mice failed to develop thermal or mechanical hypersensitivity in response to spinal nerve 
transection or sciatic nerve ligation, and demonstrated substantially attenuated writhing 
responses in response to intraperitoneal acetic acid injection (Botz et al., 2013; Mabuchi 
et al., 2004; Sándor et al., 2010).  The diminished nociceptive responses in the PACAP-/- 
mice to either formalin or acetic acid treatments were accompanied by decreased c-fos 
expression in the somatosensory cortex and periaqueductal grey (PAG), indicating a 
tangible decrease in nociceptive transmission rather than an absence of behavioral 
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responses (Sándor et al., 2010).  Interestingly, following intraplantar TRPV1 agonist 
resiniferatoxin injection into PACAP-/- mice, a reduction in mechanical sensitivity but an 
immediate enhancement of thermal nociception was observed, which suggests differential 
roles for PACAP in central versus peripheral nociceptive signaling. 
PACAP activation of multiple different receptor subtypes and PAC1 receptor-
mediated intracellular signaling appear central to nociceptive mechanisms.  This was 
supported by studies where PACAP nociceptive responses were recapitulated with the 
PAC1 receptor selective agonist maxadilan and blocked by the specific receptor 
antagonist max.d.4 (Sakashita et al., 2001).  Accordingly, as in PACAP -/- animals, mice 
with PAC1 receptor deficiency (PAC1R -/-) under naïve conditions also exhibited normal 
responses to acute thermal or mechanical stimuli, but demonstrated reduced nocifensive 
responses to intraplantar formalin administration and decreased abdominal responses to 
intraperitoneal acetic acid injection (Jongsma et al., 2001; Martin et al., 2003).  The 
knockout studies conducted to date have not addressed the different potential sites of 
PACAP/PAC1 receptor action mediating the nociceptive responses; however, 
PAC1CamKCre2 mice with forebrain-specific deletions of the PAC1 receptor (PAC1 
receptor deletions in the forebrain cortical areas, hippocampus and olfactory bulb) did not 
demonstrate diminished chemical and visceral pain responses (Martin et al., 2003).  Thus, 
the nociceptive actions of PACAP likely reside within the peripheral pathways, spinal 
cord and brainstem, or possibly in combinations these regions.  The PACAP knockout 
studies do not exclude possible roles for VIP, or PACAP on VPAC1/VPAC2 receptor 
signaling in pain responses, as VIP is an important mediator of inflammatory processes, 
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and VIP administration is often potently anti-inflammatory (Delgado, Pozo, & Ganea, 
2004).  Nevertheless, these studies in aggregate implicated PACAP and PAC1 receptor 
involvement in the development of nociceptive hypersensitivity across several models of 
chronic pain. 
 
PACAP and PAC1 receptors in emotional behaviors 
In the peripheral and central nervous systems, PACAP and the PAC1 receptor are 
expressed in structures that orchestrate a diverse set of responses following stressor 
exposure.  In autonomic pathways, PACAP appears to be one of the principal regulators 
of sympathetic function (Braas et al., 2007; May et al., 1998).  In the brain, some of the 
highest levels of PACAP expression have been identified in hypothalamic and related 
limbic structures, and PACAP has been shown to regulate classical stress mediators 
(Piggins et al., 1996).  PACAP stimulates hypothalamic CRH transcription, c-fos 
expression, and CREB phosphorylation, and can augment plasma corticosterone levels 
(Agarwal et al., 2005; Tsukiyama et al., 2011).  Although previous work has shown that a 
variety of acute stress paradigms do not alter hypothalamic PACAP transcript levels, 
more recent studies have shown that chronic stress can increase PACAP and the PAC1 
receptor transcript levels in the paraventricular nucleus (PVN) of the hypothalamus and 
the BNST (Hammack et al., 2009; Hannibal et al., 1995).  Further, PACAP infusions into 
the BNST can mimic chronic stress-related responses by increasing startle and anxiety-
like behavior on the elevated plus maze, decreasing weight gain and feeding (anorexia), 
and elevating circulating corticosterone levels (Hammack et al., 2009; Roman et al., 
F
i
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2014; Kocho-Schellenberg et al., 2014; Lezak et al., 2014).  A role for PACAP signaling 
in mediating these chronic stress responses was supported by the demonstration that 
PACAP receptor antagonists can attenuate all of these responses.  To complement these 
observations, PACAP and PAC1 knockout mice exhibit decreased anxiety- like 
behaviors, have attenuated corticosterone responses, and show impairments in 
hypothalamus CRH regulation in response to stress (Girard et al., 2006; Hashimoto, 
2006; Hattori et al., 2012).  Evidence has also been found linking PACAP to disease.  In 
humans, altered blood PACAP levels and PAC1 receptor polymorphism was associated 
with PTSD and other stress-related disorders (Ressler et al., 2011).  In sum, these 
observations implicate PACAP/PAC1 receptor signaling in anxiety-related behaviors. 
 
Signaling through extracellular signaling regulated kinase (ERK) activation 
A signature of nociceptive signaling is extracellular signaling-regulated kinase 
(ERK) activation, which participates in the neuroplasticity that promotes the 
manifestation of chronic pain and stress-related disorders (Ji et al., 2009).  Both 
inflammation and axotomy injury have been shown to increase pERK+ neurons in the 
DRG; following inflammatory or neuropathic pain, increased pERK levels are found in 
lamina I and II neurons of the spinal cord, and the ensuing development of 
hypersensitivity can be abrogated upon blockade of ERK phosphorylation by intrathecal 
application of a mitogen-activated protein kinase kinase (MEK) inhibitor (Ji et al., 1999; 
Obata et al., 2003).  ERK signaling has been shown to contribute to pain-related 
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enhancement of PBn-CeLC synaptic neurotransmission and inhibition of CeA ERK 
activation attenuates pain-related behavioral hypersensitivity (Carrasquillo & Gereau, 
2007; Cheng et al., 2011; Ji et al., 2009).  PACAP and PAC1 receptor signaling can 
stimulate and sustain ERK activation potently and efficaciously (May et al., 2014; May et 
al., 2010).  There are multiple intracellular PAC1 receptor effector mechanisms that 
activate ERK, including PKA and PKC (Barrie et al., 1997; Bouschet et al., 2003; May et 
al., 2014), but, more recently, it has been suggested that PAC1 receptor internalization 
and endosomal signaling provide a means to sustain cellular ERK levels (May et al., 
2014; Merriam et al., 2013). 
 
PACAP and glutamate signaling 
In addition to stimulation of ERK-mediated neuroplasticity, PACAP signaling 
may also regulate postsynaptic neuronal function by modulating glutamatergic 
neurotransmission.  PACAP is coexpressed with glutamate in a variety of systems, 
including retinal ganglion cells and the suprachiasmatic nucleus (Engelund et al., 2010; 
Hannibal et al., 2000).  Furthermore, in the developing dorsal horn of the spinal cord, the 
same transcription factors that determine glutamatergic cell fate also appear to control 
PACAP expression (Guo et al., 2012).  The co-release of PACAP with glutamate may 
function to modulate excitatory neurotransmission, since NMDA receptor blockade in the 
ventromedial hypothalamus (VMH) leads to diminished PACAP-induced hypophagia 
(Resch et al., 2014).  The attenuation of fear conditioning by intra-BLA PACAP(6-38) 
administration was mediated through altered NMDA signaling (Schmidt et al., 2015).  
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Intrathecal PACAP-mediated pain resulted in a dose-dependent enhancement of NMDA-
induced aversive behaviors and potentiated NMDA currents in dorsal horn neurons 
(Ohsawa et al., 2002).  In addition, transgenic PACAP-/- mice failed to develop 
mechanical allodynia to NMDA, but allodynia could be restored by co-infusion of 
PACAP with NMDA (Mabuchi et al., 2004).  There are multiple mechanisms by which 
PACAP could potentially modulate glutamatergic signaling.  In the dorsal horn, there is 
evidence that PACAP may promote the functional coupling of nitric oxide synthase to 
NMDA receptors (Mabuchi et al., 2004).  In the hippocampus, PACAP has been found to 
enhance synaptic NMDA trafficking and surface expression through Gq, PKC and Src 
signaling mechanisms (Chowdhury et al., 2013; Macdonald et al., 2005; Trepanier et al., 
2012).  In the amygdala, PACAP resulted in potentiation of BLA-CeA transmission 
through a postsynaptic mechanism involving synaptic targeting of GluR1 subunit-
containing AMPA receptors.  Alternatively, PACAP may enhance glutamate signaling by 
regulating mGluR function (Kammermeier, 2008).   
 
1.5. Summary 
Pain is a multidimensional experience comprised of both sensory-discriminative 
and emotional homeostatic components.  Despite the high comorbidity between chronic 
pain and stress-related behavioral disorders, the neurocircuits, neurochemical mediators, 
and mechanisms underlying these responses are not well understood.  The current work 
tests the hypothesis that PACAP expression, plasticity and signaling in nociceptive 
 38 
pathways intersect with those in the amygdala and related limbic systems to drive the 
maladaptive behavioral responses. 
The detection of noxious stimuli is performed by sensory nerve afferents that 
transduce noxious stimuli into electrical currents which are then relayed centrally.  The 
second order projection neurons then relay the information via sets of spinal tracts to a 
wide range of brainstem and subcortical regions.  The diffuse network of regions that 
process pain information is thought to result in the diverse sensory and emotional 
experiential components of pain.  Maladaptive neurochemical and neuroplastic processes 
can produce central nociceptive network sensitization leading to the potentiation of 
nociceptive transmission and the amplification and persistence of pain.   
In these studies, we identified PACAP expression in the spino-
parabrachioamygdaloid nociceptive tract.  As the amygdala is a critical structure for fear 
and anxiety-like behavior, the convergence of nociceptive input in the amygdala allows 
for the integration of pain with emotional information.  We found that PACAP signaling 
in the amygdala produced both pain and anxiety-like behaviors.  In a model of 
neuropathic pain, PACAP expression was found to be upregulated at multiple locations 
along the spinoparabrachio-amygdaloid tract.  The increase in CeA PACAP signaling in 
neuropathic pain contributed to both heightened anxiety-like and hypersensitivity 
behaviors as the PAC1/VPAC2 receptor antagonist PACAP(6-38) attenuated the chronic 
pain-induced responses.  Further, we demonstrated that PACAP signaling may modulate 
nociceptive hypersensitivity through ERK via the internalization of PACAP receptors.  
The adverse emotional consequences of chronic pain may result in the exacerbation and 
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perpetuation of both pain and anxio-depressive disorders.  Understanding the 
mechanisms that link pain to its emotional consequences may offer novel approaches for 
the rational development of therapeutics to alleviate suffering.   
The studies in this dissertation were divided into four main aims. The experiments 
in Aim 1 examined if PACAP is expressed in the PBn-CeA projections, as components of 
the spino-parabrachioamygdaloid tract. Aim 2 examined if CeA PACAP signaling is 
capable of altering pain or emotion-related behaviors. Aim 3 evaluated whether chronic 
pain heightened PACAP expression in the spino-parabrachioamygdaloid and whether 
these plasticity responses in CeA PACAP signaling contribute to heightened pain and 
anxiety-related behaviors. Lastly Aim 4, examined the potential downstream mechanism  
of CeA PACAP signaling.  The results of these studies are presented in manuscript form 
in the following sections. 
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1.6. Figures 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Subnuclear organization of the parabrachial nucleus (PBn).  The PBn can 
be divided into the lateral PBn (LPBn, blue), medial PBn (MPBn, pink), and the Kölliker-
fuse nucleus (kf, green).  The MPBn consists of the medial (m) and external medial (em) 
subnuclei.  The LPBn can be divided into the external (eL), ventral (vL), central (cL), 
dorsal (dL), internal (iL) lateral subnuclei, as well as the superior lateral subnucleus (not 
shown).  scp: superior cerebellar peduncle, D: dorsal, V: ventral, M: medial, L: lateral. 
Nomenclature adapted from (Fulweir et. al., 1985).   
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Figure 1.2. Diagram of the spino-parabrachioamygdaloid tract.  Convergences and 
divergences of the spinoparabrachio-amygdaloid pathway are illustrated.  In red is one 
particular pathway that nociceptive information travels, beginning at the detection of 
noxious stimulus and ending at the CeLC.  The pathways in black show known 
alternative or variations on the pathway to the CeLC, including ipsilateral projections 
from the spinal cord, the convergence of projections multiple spinal cord segments in the 
LPBn, and an alternative LPBn-CeLC pathway that gives off collaterals to the 
anterolateral BNST (BNSTal) before returning to the CeLC.  Dotted line illustrates 
contralateral projections.  DRG: dorsal root ganglion. 
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Figure 1.3. Afferent pathways and connections involved in pain processes in the 
amygdala.  The CeA (blue region) receives direct, highly processed, polymodal pain 
information from thalamus via the basolateral amygdala (green region) consisting of the 
basal (B) and lateral (LA) nuclei of the amygdala. Circuits from the LA known to 
enhance fear expression are shown, including BA to centromedial subdivision (CeM), via 
the inhibitory cells of the intercalated cell mass (ITC), and through interneurons in the 
centrolateral capsular (CeLC) and centrolateral (CeL) amygdala subdivisions. Direct, and 
less processed nociceptive information arrives in the CeLC and CeL as part of a spinal 
tract from the PBn.  The main output is CeM, in a addition to some direct projections 
from the CeL/CeLC to a number of brain regions including the bed nucleus of the stria 
terminalis (BNST), periaqueductal gray (PAG) and a reciprocal projection back to the 
PBn. 
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Gene 
Deleted 
Phenotype 
PACAP Baseline thermal or mechanical sensitivity (Mabuchi et al., 2004) 
Early and late nocifensive behaviors to formalin (Sandor et al., 2010) 
Somatic sensitivity (May & Vizzard 2010) 
Mechanical hypersensitivity following neuropathic pain (Mabuchi et 
al., 2004) 
Acetic acid induced writhing (Sandor et al., 2010) 
NMDA induced allodynia (Mabuchi et al., 2004) 
c-fos expression in somatosensory cortex and brainstem following 
formalin or acetic acid pain (Sandor et al., 2010) 
Thermal hypersensitivity to resiniferatoxin (immediate) (Sandor et al., 
2010) 
Mechanical hypersensitivity to resinferatoxin (delayed) (Sandor et al., 
2010) 
PAC1 R Baseline thermal sensitivity (Jongsma et al. 2001) 
Acetic acid induced writhing (no change in forebrain specific deletion) 
(Martin et al., 2003) 
Morphine withdrawal symptoms (Martin et al., 2003) 
Late phase of formalin induced nocifensive behaviors (Jongsma et al., 
2001) 
Galanin expression in DRG following nerve crush (Jongsma et al., 
2001)                                                                       
Table 1.1. Summary of pain-related behaviors in PACAP or PAC1 receptor gene 
knockout studies 
 
n.c. 
n.c. 
n.c.:no change 
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2.1. Abstract 
The intricate relationships that associate pain, stress responses and emotional 
behavior have been well established.  Acute stressful situations can decrease nociceptive 
sensations and conversely, chronic pain can enhance other pain experiences and heighten 
the emotional and behavioral consequences of stress.  Accordingly, chronic pain is 
comorbid with a number of behavioral disorders including depression, anxiety 
abnormalities and associated stress-related disorders including posttraumatic stress 
disorder (PTSD).  The central nucleus of the amygdala (CeA) represents a convergence 
of pathways for pain, stress and emotion, and we have identified pituitary adenylate 
cyclase activating polypeptide (PACAP) immunoreactivity in fiber elements in the lateral 
capsular division of the CeA (CeLC).  The PACAP staining patterns colocalized in part 
with those for calcitonin gene related peptide (CGRP); anterograde fiber tracing and 
excitotoxic lesion studies demonstrated that the CeLC PACAP/CGRP immunoreactivities 
represented sensory fiber projections from the lateral parabrachial nucleus (LPBn) along 
the spino-parabrachioamygdaloid tract.  The same PBn PACAP/CGRP fiber system also 
projected to the BNST.  As in the BNST, CeA PACAP signaling increased anxiety-like 
behaviors accompanied by weight loss and decreased feeding.  But in addition to 
heightened anxiety-like responses, CeA PACAP signaling also altered nociception as 
reflected by decreased latency and threshold responses in thermal and mechanical 
sensitivity tests, respectively.  From PACAP expression in major pain pathways, the 
current observations are novel and suggest that CeA PACAP nociceptive signaling and 
resulting neuroplasticity via the spino-parabrachio- amygdaloid tract may represent 
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mechanisms that associate chronic pain with sensory hypersensitivity, fear memory 
consolidation and severe behavioral disorders. 
 
2.2. Introduction 
Chronic neuropathic pain alters sensory responses and carries an emotional 
subtext that can have severe effects on behavior.  Persistent pain can heighten pain 
experiences from hyperalgesia and allodynia (Rouwette et al., 2012; Veinante et al., 
2013).  Further, patients suffering from chronic pain are more prone to experience 
depression, sleep dysregulation, panic disorders, obsessive compulsive behavior, anxiety 
abnormalities and stress-related disorders including post-traumatic stress disorder (PTSD) 
(Asmundson and Katz, 2009).  The intricate relationship between pain and behavior has 
been well studied and among brain regions, the amygdala is centrally situated to integrate 
the many descending and ascending signals to modulate the sensory and emotional 
components of pain.  Highly processed descending polymodal nociceptive information is 
conveyed from the somatosensory cortex and thalamus to the basolateral amygdala 
(BLA) which in turn projects to the central nucleus of the amygdala (CeA).  The resulting 
CeA efferents signals are relayed to other central nuclei, including those traveling with 
hypothalamic e periaqueductal grey projections for autonomic control and anti-
nociception to dampen pain stimuli (Veinante et al., 2013).  Among several ascending 
pathways carrying pain transmission to the CeA, the most prominent is the spino-
parabrachioamygdaloid tract (Bernard et al., 1996; Gauriau and Bernard, 2002; Rouwette 
et al., 2012; Veinante et al., 2013).  Peripheral nociceptive signals carried via primary 
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sensory Aδ- and C-fibers terminate in the dorsal horn where second order neurons send 
projections via the spino-parabrachial pathway to pontine lateral and external medial 
parabrachial nuclei (PBn) (Todd, 2010).  Hence the PBn collects cutaneuous (mechanical 
and thermal), deep (muscular and articular) and visceral nociceptive signals and relays 
the information in a highly organized topographical manner principally to lateral capsular 
division of the CeA (CeLC).  The roles of the CeA/CeLC in nociceptive processing have 
been examined from a number of vantages.  In vivo electrophysiological studies have 
shown that noxious stimuli and chronic pain paradigms increase spontaneous and evoked 
CeA neuronal activity (Bernard et al., 1992; Ji and Neugebauer, 2009; Neugebauer and 
Li, 2003), and synaptic transmission at PBn-CeA and BLA-CeA synapses (Ikeda et al., 
2007; Neugebauer et al., 2003).  Visceral, inflammatory and chronic neuropathic pain can 
induce CeA neuron stress peptide and c-fos expression (Bon et al., 1998; Nakagawa et 
al., 2003; Suwanprathes et al., 2003; Ulrich-Lai et al., 2006; Rouwette et al., 2011) and 
increase glutaminergic NR1 receptor phosphorylation in CeA neurons (Bird et al., 2005).  
Further, human brain imaging studies have implicated the amygdala in pain (Simons et 
al., 2014).  Hence the neurocircuit intersections in the CeA can modulate the sensory, 
emotional and affective responses to pain. 
 Pituitary adenylate cyclase activating polypeptide (PACAP) is a well studied 
neural and endocrine pleiotropic peptide important in the development and homeostatic 
regulation of many physiological systems (reviewed in Vaudry et al., 2009).  In the 
central and peripheral nervous systems, PACAP is neurotrophic to promote neuronal 
survival, proliferation and differentiation in development and regeneration, participates in 
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sensory and autonomic signaling, is important in hippocampal learning and memory 
processes and regulates a variety of hypothalamic/limbic stress-related behavioral 
responses.  PACAP binds to several G protein-couple receptor subtypes (Braas and May, 
1999; Harmar et al., 2012; Spengler et al., 1993).  PACAP binds selectively at the PAC1 
receptor; both PACAP and VIP bind the VPAC receptors with equal high affinity.  
Recently, the expression of PACAP and its cognate PAC1 receptor has been shown to be 
upregulated in specific limbic regions by chronic stress (Hammack et al., 2009).  PACAP 
infusions into the bed nucleus of the stria terminalis (BNST) is anxiogenic, and altered 
blood PACAP levels and PAC1 receptor polymorphism have been associated with PTSD 
and other stress-related disorders (Almli et al., 2013; Chen et al., 2013; Ressler et al., 
2011; Uddin et al., 2013; Wang et al., 2013).  In sum, these observations have implicated 
limbic PACAP/PAC1 receptor signaling in stress- and anxiety-related behaviors. 
In evaluating PACAP expression in other limbic structures, we noted high levels 
of PACAP immunoreactivity in fiber terminals and varicosities within the CeLC, 
suggesting that the CeLC may be a target of distant PACAP projections.  The CeLC is 
heavily innervated by the lateral PBn (LPBn) and PACAP has been localized to many 
sensory pathways.  From these observations, we have hypothesized that LPBn PACAP 
signaling to the CeLC has both sensory and behavioral consequences.  In examining the 
localization and roles of PACAP to the CeLC, our current work demonstrates that 
PACAP is a component of the parabrachioamygdaloid pathway and that PACAP/PAC1 
receptor signaling in the CeA elicits nociceptive and behavioral responses.  The 
integration of these nociceptive and  
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emotion pathways may represent a set of neural circuits that mediate the adverse sensory 
and emotional consequences of chronic pain. 
 
2.3. Methods 
Animals 
Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) 
were habituated to the animal facility for 1 week before experimentation.  Rats were 
single-housed and maintained on a 12 h light/dark cycle (lights on at 0700 h).  Food and 
water were available ad libitum.  All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Vermont. 
 
Chronic variate stress 
Following acclimation, each animal was randomly assigned to either a control or 
chronically stressed group.  Control group animals were handled and remained in their 
home cages until euthanasia.  The chronically stressed group of animals underwent a 
chronic variate stress paradigm in which rats were exposed to one of 5 different stressors 
(oscillation, forced swim, restraint, pedestal standing and foot- shock) each day for 7 
days, as described previously (Hammack et al., 2009; Roman et al., 2012, 2014).  All 
animals within the group were exposed to the same order of stressors for the same 
duration. 
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Immunocytochemistry 
The brains from perfusion fixed animals were postfixed in 4% paraformaldehyde 
at 4C for 24 h, washed and equilibrated in 30% surcrose before embedding in Tissue-Tek 
OCT compound for cryosectioning.  The sections (30 µm) were mounted onto subbed 
slides, permeabilized with 0.3% Triton X-100, blocked with 1% BSA and incubated in 
primary antibody for 48 h at 4C.  CRH immunoreactivity was localized using an affinity 
purified rabbit antibody (1:100, No. G-019-06, Phoenix Pharmaceuticals, Burlingame, 
CA).  CGRP immunoreactivity was examined using a polyclonal antibody raised against 
the full length CGRP(1-37) peptide (1:1500, Ian Dickerson, Univ Rochester) for 
visualization with AlexaFluor 488 conjugated donkey anti-rabbit IgG (1:200, Jackson 
Immunoresearch).  PACAP immunoreactivity was detected using a mouse PACAP 
monoclonal antibody (1:10, Jens Hannibal, Bisperg Hospital, Copenhagen, Denmark) 
followed by tyramide signal amplification (Hannibal, 2002).  Following primary PACAP 
antibody incubation, the tissues were incubated in biotinylated horse anti-mouse antibody 
(1:200, 2 h; Vector Laboratories, Burlingame, CA) and treated with streptavidin-HRP 
(1:200, 30 min) before application of tyramide-biotin reagent (1:100, 10 min; Perkin 
Elmer, Waltham, MA).  After extensive washing, the PACAP immunoreactivity was 
localized with Cy3-conjugated streptavidin (1:200, 2 h; Jackson Immunoresearch, West 
Grove, PA).  In dual localization studies, the sections were incubated in PACAP and 
CGRP or CRH antisera concurrently.  Tissue sections from BDA anterograde tracing and 
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excitotoxic lesion studies were also processed for immunocytochemistry using the same 
procedures.  Images from immunocytochemistry, excitotoxic lesion and anterograde 
tracing experiments were acquired sequentially with appropriate filter sets using a Nikon 
E800 point scanning confocal microscope.  Image analyses were performed using NIH 
ImageJ (Schneider et al., 2012) to threshold, determine signal area (pixel number in 
staining area) and calculate Pearson's and Mander's correlation coefficients.  In within 
subject excitotoxic lesion studies, the area of immunoreactivity on the side of the lesion 
was compared to the vehicle control contralateral side. 
 
Transcript analyses 
 Quantitative PCR (QPCR) was performed exactly as described previously (Girard 
et al., 2002, 2006; Hammack et al., 2009).  Briefly, after euthanasia by rapid decapitation, 
the coronal rat brain sections were prepared using a rodent brain matrix (Ted Pella, Inc. 
Redding, CA) and the micropunched amygdala tissues were quickly frozen on dry ice for 
total RNA extraction using STAT-60 RNA/mRNA isolation reagent (Tel-Test “B”, 
Friendswood, TX).  All RNA were reverse transcribed simultaneously using random 
hexamer primers with the SuperScript II Preamplification System (Invitrogen, Carlsbad, 
CA) to obviate variability.  Real-time QPCR was performed as described using SYBR 
Green I detection (Girard et al., 2002, 2006; Hammack et al., 2009).  Briefly, cDNA 
templates were diluted 5-fold to minimize the inhibitory effects of the reverse 
transcription reaction components and assayed on an ABI Prism 7500 Fast Real-Time 
PCR System (Applied Biosystems, Foster City, CA) using SYBR Green I JumpStartTM 
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Taq ReadyMix (Sigma, St. Louis, MO) containing 3.5 mM MgCl2, 200 µM dATP, 
dGTP, dCTP and dTTP, 0.64 U Taq DNA polymerase and 300 nM of each primer in a 
final 25 µl reaction volume.  Oligonucleotide primer sequences were: PACAP (S) 5'-
CATGTGTAGCGGAGCAAGGTT-3' (AS) 5'- GTCTTGCAGCGGGTTTCC-3'; CRH 
(S) 5'-TGGATCTCACCTTCCACCTTCTG-3' (AS) 5'-
CCGATAATCTCCATCAGTTTCCTG-3'.  The melting profiles for amplified DNA 
fragments were performed to verify unique product amplification in the quantitative PCR 
assays.  For data analyses, a standard curve was constructed by amplification of serially 
diluted plasmids containing the target sequence (Girard et al., 2002, 2006).  The increase 
in SYBR Green I fluorescence intensity (DRn) was plotted as a function of cycle number 
and the threshold cycle (CT) was determined by the software as the amplification cycle at 
which the DRn first intersects the established baseline.  The transcript levels in each 
sample were calculated from the CT by interpolation from the standard curve to yield the 
relative changes in expression.  For each target sequence, all samples from the same brain 
region were amplified together in the same assay to minimize variability.  All data were 
normalized to 18S RNA. 
 
Surgical procedures 
Anterograde tracing 
Rats were anesthetized with isoflurane (1.5-3.5%), and secured into a stereo- 
tactic apparatus (David Kopf Instruments, Tunjunga, CA).  The skull was exposed from a 
midline incision and a micropipette (30-50 µm tip diameter) filled with 10% biotinylated 
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dextran amine (BDA; 10 kDa) was lowered into the LPBn using coordinates (from 
bregma in mm) AP: -9.3, ML: ±2.3, DV: -8.0, for iontophoretic tracer application (5 µA, 
7 s on and 7 s off, 20 min total).  The process was repeated on the contralateral LPBn.  
After 14 days, the 4% paraformaldehyde perfusion-fixed rat brains were processed and 
the cryosections incubated in 1:200 streptavidin-Cy2 (Jackson Immunoresearch) for BDA 
tracer localization.  The anterograde tracing studies were sometimes performed in 
conjunction with peptide immunocytochemistry for concurrent localizations (Section 
2.3).  As for most peptide antisera, the PACAP antibody preferentially labeled fibers than 
soma which precluded immunocytochemistry of retrogradely labeled LPBn neurons from 
the CeLC. 
 
Excitotoxic lesion 
Adult male rats were surgically prepared as above and a microsyringe (1 µl, 
Hamilton Co., Reno, NV) was unilaterally placed into the LPBn (from bregma in mm, 
AP: -9.3, ML: ±2.3, DV: -7.9) for automated pump infusion of 2 mg NMDA in 200 nl 
over 4 min.  The syringe was left in place for an additional 4 min and following 
postsurgical recovery the rats were returned to their home cages and for 7 days.  NMDA 
excitotoxic lesion at the targeted site was verified by processing the brain cryosections 
for neuron specific nuclear protein (anti-NeuN, 1:1500) immunoreactivity as visualized 
using Cy3-coupled secondary antisera (Roman et al., 2012).  Only brains that displayed 
LPBn neuronal loss were used for further analyses. 
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Intra-amygdalar PACAP infusion 
 Rats were anesthetized and secured in a stereotactic apparatus as described above.  
Four screws were secured into the exposed skull and two stainless steel cannulae (22 GA, 
PlasticsOne, Roanoke, VA) were targeted to the CeA bilaterally using coordinates (from 
bregma in mm) AP: -2.6, ML: ±4.5, DV: -7.2.  A dental cement skullcap was formed to 
secure the cannula and during the 7 day postsurgical recovery the rats were routinely 
wrapped in a towel to habituate handling.  For treatments, the rats were similarly 
restrained in a towel and PACAP or vehicle (0.05% BSA in saline) was slowly infused (1 
µg/0.5 µl each side) at 0.25 µl/min (Harvard Apparatus, Holliston, MA) through an 
internal cannula that projected 1 mm from the guide cannulae; the PAC1 receptor specific 
agonist maxadilan (from Ethan Lerner, Harvard/Massachusetts General Hospital) was 
similarly infused in some studies.  The peptide concentrations and treatment procedures 
were similar to those described in previous work (Hammack et al., 2009; Kocho-
Schellenberg et al., 2014; Roman et al., 2014).  The infusion cannula were left in place 
for an additional minute before removal.  Animal body weights were determined before 
and 24 h after infusions for all experiments (Kocho-Schellenberg et al., 2014).  At the end 
of each study, the rats were perfused with 4% paraformaldehyde and the brains 
cryosectioned for cresyl violet staining to confirm cannulae placement.  Only data from 
correct CeA cannulae placements are described in Results.  PACAP infusions into 
misplaced targets outside of the CeA, including the basolateral amygdala, had no effects 
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on stress-related behavior, body weight, food consumption and water intake. 
 
Behavioral assessments 
Elevated plus maze 
 The plus maze was elevated 75 cm from the floor and consisted of two opposing 
open and two opposing closed arms (each arm 50 cm long and 10 cm wide) that extended 
perpendicularly from a central square platform (10 x 10 cm).  The length of the closed 
arms were walled with black opaque plastic panels 30 cm in height.  Illumination using a 
red bulb was 6 lux at the center of the maze.  The rats were first room habituated for 10 
min and then individually placed in the center of the maze facing a closed arm for free 
exploration for 5 min.  A ceiling mounted camera digitally captured all movements 
during each session for analyses. 
 
Mechanical sensitivity testing 
 Mechanical sensitivity assessment was performed using von Frey mono- 
filaments (Stoelting, Wood Dale, IL).  All rats were first habituated in the clear acrylic 
testing chamber 20 min/day for 4 days with a fan to generate ambient noise.  On day of 
testing, the rats were placed in the acrylic testing chamber on top of a metal mesh floor 
(IITC Life Science Inc., Woodland Hills, CA) and habituated again for 10 min before the 
application of von Frey filaments to the lateral plantar surface of the hindpaw.  In 
ascending diameter thickness, each filament was applied until bent at 30° for 5-7 s.  The 
smallest filament that evoked a paw withdrawal in at least 3 of 5 trials was used as the  
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mechanical threshold for that trial.  Thresholds from both the left and the right hindpaws 
were measured. 
 
Thermal sensitivity testing 
 Responses to thermal stimuli were tested using a Hargreave's apparatus (Plantar 
Analgesia Meter, IITC Life Science Inc., Woodland Hills, CA).  Prior to behavioral 
testing, the rats were first habituated in the acrylic testing chamber for 4 days.  On day of 
testing, the rats were placed in an elevated clear acrylic testing chamber on top of a glass 
floor with an internal heating element that heated the glass to a consistent 30 °C.  Using a 
guide light to target the hindpaw, a beam of focused radiant light (4-6 mm, set to 25% of 
active intensity) from the apparatus beneath the glass floor was delivered to the plantar 
surface of the paw.  Upon rat awareness of the heat stimuli, as indicated by withdrawal or 
licking of the hindpaw, the heat source was immediately terminated and the reaction time 
automatically recorded.  An automatic cut-off timer set at 30 s was built into the system 
to prevent tissue damage.  Each time point represented the latency average of 3 trials 
from both the left and right hindpaw separated by 5 min inter-trial intervals.  The 
PACAP, maxadilan and vehicle treatment groups exhibited comparable average baseline 
latency scores (PACAP, 12.9 s; maxadilan, 12.5 s; vehicle, 12.3 s). 
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Experimental treatment and testing procedures 
 
Experiment 1 - behavioral effects of amygdala PACAP infusions on elevated plus maze 
 Adult male rats were cannulated for amygdala infusions as described in Surgical 
procedures.  The rats were handled daily for habituation and after 7 day postsurgery 
recovery, the rats were randomly assigned to vehicle or PACAP groups (n = 10 per 
group).  On experimental day, the rats were weighed for baseline measures and bilaterally 
injected with vehicle or PACAP38 as described in random order.  The injection needle 
was left in place for 1 min after which the rats were returned to their home cages for 30 
min and habituated in the testing room (10 min) before evaluation on the elevated plus 
maze.  The rats were allowed to freely roam the maze for 5 min and all data were 
captured digitally.  At the same time the following day, the vehicle and PACAP-treated 
rats were re-weighed to assess weight change over 24 h; food and water consumption 
were also measured.  All weight change measures in this and subsequent experiments 
were performed between 0900 and 1000 h.  All behavioral tests were completed between 
0900 and 1500 h; behavioral testing was randomized and counter balanced for order and 
time of testing. 
 
Experiment 2 - nociceptive effects of PACAP after amygdala infusions 
 Adult male rats were surgically prepared and handled as described in Experiment 
1 above.  The rats received 2 days of baseline thermal and mechanical sensitivity testing, 
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and on experiment day, the rats were weighed and received either vehicle or PACAP38 
amygdala infusions (n = 6 per group) as described in random order.  After 30 min, the 
rats were tested for mechanical sensitivity using von Frey filaments and evaluated for 
thermal sensitivity on a Hargreave's apparatus at subsequent time points (1 h, 4 h and 24 
h).  As before, weight change in the vehicle and PACAP-infused rats was assessed after 
24 h; food and water consumption was also determined.  As robust PACAP-induced 
thermal sensitivity was noted at 1 h, a separate study was prepared to better establish 
amygdala PACAP thermal nociception onset and persistence (30 min and 72 h time 
points) using exactly the same procedures (n = 7-8 per group).  The thermal sensitivity 
data at the different time points from the two cohorts were combined for analyses in a 
linear mixed model using an autoregressive covariate structure as described in statistical 
methods. 
 
Experiment 3 - the nociceptive effects of amygdala maxadilan infusions 
 Adult male rats were surgically prepared, handled and treated exactly as described 
for the first study in Experiment 2 except for the application of maxadilan (n = 7 - 8 per 
group).  Thirty min after amygdala maxadilan infusion, the rats were tested for 
mechanical sensitivity using von Frey monofilaments; at subsequent time points the rats 
were evaluated on a Hargreave's apparatus for thermal sensitivity. 
 
Statistics 
 Statistical Student's t-tests were performed using GraphPad PRISM v.6.  For 
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analyses of thermal withdrawal thresholds, a linear mixed model using an autore- 
gressive covariate structure was employed to allow combined analysis of two cohorts 
with differing timepoints, followed by pairwise comparisons between groups using 
Sidak-Holmes correction for multiple comparisons (MIXED procedure of the SAS 
System for Windows version 9.2; SAS Institute Inc, Cary, NC).  All values represent the 
mean change ± SEM. P < 0.05 was considered significant. 
 
2.4. Results 
PACAP and CGRP are expressed in the CeA and BNST 
 Our previous studies identified regulated PACAP expression in the BNST 
(Hammack et al., 2009).  In evaluating PACAP expression in other limbic structures, we 
observed significant levels of PACAP immunoreactivity restricted to the lateral capsular 
division of the CeA (CeLC; Fig. 2.1).  A number of neuropeptides have been identified in 
the CeA including corticotropin releasing hormone (CRH) which has been shown to 
regulated by psychological stressors (Makino et al., 1999).  However, unlike PACAP in 
the CeLC, CRH immunoreactivity in the amydala was prominent in the adjacent lateral 
(CeL) and medial (CeM) subdivisions of the CeA, recapitulating the apparent dichotomy 
of PACAP and CRH peptidergic pathways in the limbic system (Roman et al., 2014).  
Further, the pattern of PACAP and CRH expression following repeated stress appeared 
converse of that in the BNST.  Whereas BNST PACAP was augmented after stress 
(Hammack et al., 2009; Roman et al., 2014), chronic stress increased CRH 
immunoreactivity levels in the CeA approximately 2-fold without altering CeA PACAP 
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expression (Fig. 2.1A-C).  The stress-mediated changes PACAP and CRH staining in the 
CeA mirrored transcript expression patterns (Fig. 2.1D) and in aggregate were suggestive 
of their distinct but complementary roles in stress pathways and behaviors. 
 A number of neuropeptides exhibit distinct expression patterns within the CeA 
(Cassell et al., 1986).  From staining patterns the immunoreactivity for PACAP in the 
CeLC was largely punctate which appeared characteristic of terminals and varicosities of 
neuronal PACAP fiber projections from distal nuclei.  As the CeLC is heavily innervated 
by the PBn in the spino-parabrachioamygdaloid tract (Bernard et al., 1996; Gauriau and 
Bernard, 2002; Rouwette et al., 2012; Veinante et al., 2013) and PACAP is highly 
expressed in sensory neurons in many pathways (Beaudet et al., 1998; Mulder et al., 
1994; Pettersson et al., 2004b; Zhang et al., 1995), we examined whether the PACAP 
immunoreactivity in the CeLC reflected parabrachioamygdaloid projections.  Further, as 
fibers in the CeLC have been described to contain CGRP immunoreactivity (Dobolyi et 
al., 2005), we also compared the relative distribution of PACAP and CGRP in the 
parabrachioamygdaloid tract. 
 In these studies, PACAP and CGRP immunoreactivities displayed considerable 
overlap in fiber elements (Fig. 2.2A-C) that appeared to form basket-like networks 
suggestive of axosomatic innervation of CeLC neurons.  Given the heavy density of the 
peptide immunoreactivites, both Pearson's and Mander's correlation coefficients were 
determined for the acquired images to assess the extent of CeLC PACAP and CGRP 
colocalization.  For both measures, scores closer to 1 represent greater degrees of overlap 
and from 4 independent studies, Pearson's r was >0.7 and Mander's coefficient was >0.6 
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(Mander's CGRP/PACAP ratio = 0.625; PACAP/CGRP ratio = 0.631). 
Since the bed nucleus of the stria terminalis (BNST) is part of the central extended 
amygdala and has been described to display both PACAP and CGRP expression and 
function (Hammack et al., 2009; Sink et al., 2011), the relationship between PACAP and 
CGRP within the BNST was also investigated.  BNST PACAP and CGRP expression 
was highest within the oval nucleus (BNSTov) and as in the CeLC, PACAP and CGRP 
immunoreactivities were coexpressed in a majority of the fiber elements (Fig. 2.2D-F).  
Image analyses were performed as before and from 3 independent experiments, Pearson's 
coefficient for PACAP and CGRP colocalization was approximately 0.7, and Mander's 
coefficient was approximately 0.6 (Mander's CGRP/PACAP ratio = 0.57; PACAP/CGRP 
ratio 1= 0.56).  Hence the two statistical measures were in good agreement and suggested 
that more than half of the PACAP or CGRP neuronal fibers projecting to the CeLC and 
BNSTov expressed both peptides. 
 
PACAP and CGRP immunoreactives in the CeLC and BNST are localized to projection 
fibers from pontine parabrachial nucleus (PBn) 
 From several considerations, our evaluations for the potential origins of the 
PACAP- and CGRP-expressing neurons projecting to the CeLC and BNSTov narrowed 
to the LPBn.  The external LPBn contains a large population of PACAPergic neurons that 
may transmit signals to the amygdala (Das et al., 2007; Hannibal, 2002; Resch et al., 
2013).  Further, CGRP expression in the CeLC and BNSTov has been suggested 
previously to originate from PBn neurons (Dobolyi et al., 2005).  Hence from these 
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observations, we examined whether PACAP- and CGRP-expressing fibers to the CeLC 
and BNSTov were components of the parabrachioamygdaloid tract. 
 For these studies, we first evaluated whether anterograde fibers from the LPBn to 
the amygdala and BNST expressed PACAP.  From injection site analyses, the BDA 
infusions into the LPBn was confined to a small area (Fig. 2.3A).  In the amygdala, the 
neuroanatomical tracer was confined to the CeLC and upon immunocytochemical 
processing, a subset of the BDA-labeled fibers in the CeLC expressed PACAP-
immunoreactivity (Fig. 2.3B).  Although these results provided evidence for CeLC 
PACAP immuonoreactivity originating from the LPBn, the small focal size of the PBn 
BDA injection resulted in a modest number of labeled fibers in the CeLC.  Hence the 
number of BDA labeled fibers was not as extensive as that observed for PACAP-
immunoreactivity which precluded estimations of the relative contribution of CeLC 
PACAP immunoreactive fibers originating from the PBn.  From the same limitations, the 
BDA-labeled fibers from the PBn to the BNST appeared low (data not shown). 
 As an independent means of assessing peptide expression in LPBn projection 
fibers and to facilitate dual PACAP and CGRP immunocytochemistry in the same tissues, 
the LPBn was lesioned before amygdala and BNST immunocytochemistry (Fig. 2.4).  As 
the BDA anterograde fiber labeling studies demonstrated that the external lateral PBn 
projected only to the ipsilateral amygdala, only one side of the PBn was lesioned so that 
the contralateral LPBn and limbic structures could remain intact and serve as vehicle 
controls.  Accordingly, one side the LPBn was lesioned by excitotoxic NMDA injection 
(2 µg NMDA in 0.2 µl) and after postsurgery recovery for 7 days, coronal brain 
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cryosections were prepared to assess the extent of PBn lesion and altered peptide 
immunocytochemistry in the ipsilateral CeLC/BNST compared to staining patterns on the 
contralateral side.  Only brain lesions with neuronal loss in the external LPBn as 
identified by diminished neu-N staining (Fig. 2.4A and B) were used in subsequent 
analyses. 
 Following external LPBn lesion, PACAP and CGRP immunoreactivities in both 
the CeLC and BNSTov were greatly reduced.  The tissue sections were simultaneously 
processed for PACAP and CGRP immunoreactivities and within subjects, CeLC PACAP 
immunoreactivity was diminished 70% ± 5% on the side ipsilateral to the PBn lesion 
compared to staining levels in the contralateral CeLC in which the corresponding PBn 
received vehicle injection (t(2) = 4.41, p = 0.048; Fig. 2.4C-D and 2.5A).  The same 
changes were observed in the BNSTov.  PACAP staining levels in the BNSTov ipsi-
lateral to the PBn lesion were diminished 59% ± 11% compared to the contralateral 
BNSTov with PBn vehicle injections (t(2) = 5.77, p = 0.029; Fig. 2.4G-H and 2.5B).  As 
PACAP and CGRP demonstrated significant colocalization in these structures (Fig. 2.2), 
a similar change in CGRP staining was therefore anticipated.  From analyses, LPBn 
lesions resulted in a 64% ± 8% loss in CGRP immunoreactivity in the CeLC (t(2) = 7.49, 
p = 0.017) and 72% ± 6% in the BNSTov (t(2) = 8.90, p = 0.012) compared to contra-
lateral structures with vehicle injections into the PBn (Fig. 2.4E-F, 2.4I-J, 2.5A and 5B).  
Hence the anterograde labeling/lesion studies complement immunocytochemical data to 
demonstrate that PACAP and CGRP can be colocalized in the LPBn and that their 
projections are substantial components in the fibers innervating the CeLC and BNSTov. 
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PACAP signaling in the amygdala alters emotional behaviors and pain responses 
 Our previous work demonstrated that PACAP signaling in the BNST enhances 
anxiety-related responses including increased baseline startle responses, decreased open 
arm entries on the elevated plus maze, decreased open field crossings, decreased 
exploratory behavior in novelty tests and decreased weight gain (Hammack et al., 2009; 
Kocho-Schellenberg et al., 2014; Roman et al., 2014).  To examine whether PACAP 
expression and signaling in the central amygdala produced similar stress-related 
behavioral responses, we implanted bilaterally cannulae targeting the CeA for PACAP 
infusions (1 µg/0.5 µl) following previous treatment protocols (Hammack et al., 2009; 
Kocho-Schellenberg et al., 2014; Roman et al., 2014; Experiment 1).  Similar to PACAP- 
elicited responses in the BNST, amygdala PACAP infusions induced anxiety-like 
responses as shown by decreased open arm time (54.2 vs 88.3 s, t(18) = 2.71; p = 0.01) 
and open arm entries (5.9 vs 13.8; t(18) = 4.39, p = 0.0003) compared to vehicle-treated 
animals on the elevated plus maze (Fig. 2.6A).  Unlike the BNST where PACAP had no 
apparent effects on locomotor activity, PACAP injections into the CeA appeared to 
produce a small but significant decrease in total distance traveled during the test period 
not attributed to spontaneous freezing behavior.  To mitigate this potential confound, 
open arm preference (open : total arm entries) was calculated for each animal as this 
measure is less prone to locomotor vagaries.  Whereas vehicle control animals had no 
preference for either open or closed arms (open : total arm entries = 0.51 ± 0.03), CeA 
PACAP- infused animals demonstrated diminished open arm preference (Fig. 2.6B, open 
: total arm entries = 0.32 ± 0.04; t(18) = 3.70, p = 0.0015).  These PACAP-mediated 
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changes were comparable to those observed following BNST PACAP injections 
suggesting that PACAP signaling in the BNST and CeA can contribute to stress- related 
behaviors. 
 Similar to stress-mediated behaviors, BNST PACAP infusions were also capable 
of inducing anorexia-like responses resulting dramatic animal weight loss over the next 
24 h which approximated 5-8% of body weight and was reflected by decreased food 
consumption.  Accordingly, animal weight changes were also monitored during the CeA 
PACAP infusion studies (Experiments 1 and 2).  After 24 h, animals with CeA PACAP 
injections demonstrated a small (~1%) but significant decrease in body weight compared 
vehicle treated animals (t(45) = 2.63, p = 0.012).  Given the small weight changes, we 
sought to establish these observations using the PAC1 receptor selective agonist 
maxadilan (Experiment 3).  CeA maxadilan infusions again produced a small decrease in 
body weight (1.5% decrease; t(13) = 2.81, p = 0.014) which was accompanied by 
diminished food intake (17.5% decrease; t(13) = 2.66, p = 0.018) without apparent 
changes in water consumption (t(13) = 1.47, p = 0.163).  These changes largely reflected 
the propensity for vehicle treated animals to gain a small amount of weight during the 24 
h period while the PACAP treated animals experienced a slight weight loss.  Hence, in 
apparent contrast to the BNST, the effects of CeA PACAP signaling on stress related 
anxiety-like responses did not appear to be strongly associated with weight and feeding 
changes. 
 The fiber projections from the LPBn to the CeLC are part of the spino-
parabrachial amygdaloid pathway conveying nociceptive information from the dorsal 
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horn to the amygdala.  PACAP has been identified at many sensory pathway intersections 
including the dorsal root ganglion, layers 1 and 2 of the dorsal horn, and from previous 
and current work, the LPBn.  The CeLC responds to noxious stimuli and in modulating 
pain perception may contribute to the affective component of the pain experience.  Hence 
from its attributes as a sensory peptide and its localization in the CeLC, we examined 
whether PACAP signaling in the amygdala also altered spinal pain-associated reflexes.  
As before, cannulae were placed into the amygdala bilaterally and following recovery, 
the rats were habituated for Hargreave's thermal nociception tests (Experiment 2).  A 
baseline latency for hindpaw thermal withdrawal was first determined for each rat; 
PACAP was subsequently infused into the CeA and the temporal changes in hindpaw 
withdrawal to the same thermal stimuli were examined over the next 72 h.  Following 
PACAP infusion, there was a significant reduction in paw withdrawal latency at 30 min 
(35% decrease in latency; veh, 13.0 ± 1.0s vs PACAP 9.1 ± 0.9s, p = 0.002; Fig. 2.7A) 
and at 1h (31% decrease in latency; veh, 11.8 ± 0.9 s vs PACAP, 7.9 ± 0.6 s, p = 0.011).  
The PACAP-induced responses persisted at 4 h (21% decrease in latency; veh, 11.3 ± 0.8 
s vs PACAP 8.9 ± 0.7 s; p = 0.015) and returned to baseline by 24 h.  There was a small 
but significant decrease in latency at 72 h post injection compared to the corresponding 
vehicle control group (p = 0.021); whether this reflected any PACAP-mediated plasticity 
in the CeA remains to be examined.  Again, the thermal sensitivity responses were 
recapitulated with the PAC1 receptor-specific agonist maxadilan (Experiment 3).  CeA 
maxadilan infusions decreased paw withdrawal latency approximately 24% (veh, 11.7 ± 
0.9 s vs maxadilan, 8.9 ± 0.6 s; p = 0.002; Fig. 2.7B) at 1 h which returned to baseline by 
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24 h.  Overall, the PACAP and maxadilan results were robust and well reproducible 
across trials suggesting that intra-amygdalar PACAP signaling can facilitate thermal 
hyperalgesia. 
 To assess whether CeA PACAP infusion would elicit similar changes on 
mechanical threshold, the same animals were also evaluated using von Frey hair 
stimulation tests (Experiment 2).  From baseline tests, all animals demonstrated decreases 
in mechanical threshold after repeated trials over time.  Although mechanical threshold in 
the PACAP-and maxadilan-treated rats appeared decreased compared to vehicle control 
animals after 30 min, analyses revealed a trend rather than statistical difference (PACAP, 
t(10) = 1.7, p = 0.11; maxadilan, t(13) = 1.65, p = 0.12) which reflected in part the high 
variability within the assay.  These apparent PACAP changes in mechanical threshold 
dissipated by 2 h post-peptide infusion.  As thermal and mechanical pain are transduced 
by separate mechanisms, these differences may have contributed to the observed efficacy 
of PACAP between the two measures.  Nevertheless, the ability for PACAP to modulate 
pain responses via amygdala signaling appears novel and suggests that it may carry 
nociceptive information to impact the behavioral and emotional aspects of pain. 
 
2.5. Discussion 
 The central nucleus of the amygdala integrates nociceptive and stress-related 
signals that may be important for behavioral responses and the formation of emotional 
memory.  In examining PACAP/PAC1 receptor expression and function in the limbic 
system, we identified high levels of fiber PACAP immunoreactivity in the CeLC.  The 
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CeLC is innervated by LPBn neurons that form part of the spino-parabrachioamygdaloid 
pathway and although PBn PACAP expression was previously described, the targets of 
these PBn PACAP neurons were not identified.  Our current work identified PACAP 
immunoreactivity in anterogradely labeled LPBn projection fibers to the CeLC, and 
importantly, LPBn lesions significantly abolished PACAP immunoreactivity in the CeLC 
and BNST.  These studies were also revealing in demonstrating the relationships between 
PACAP and other CeA peptides.  Both CRH and CGRP share functional similarities with 
PACAP in mediating pain, stress and anxiety-like behaviors (Hammack et al., 2002; 
Koob and Heinrichs, 1999; Lee and Davis, 1997; Sink et al., 2011).  Yet the dual 
localization studies demonstrated a dichotomy in PACAP and CRH expression pattern; 
the localization of PACAP predominantly to the CeLC was distinct from CRH in the CeL 
which suggested separate but coordinate functions in intra-amygdalar neurocircuits.  By 
contrast, PACAP and CGRP immunoreactivities in CeLC and BNST fibers were well 
colocalized from image analyses, and PBn lesions abolished much of the staining for both 
peptides in the CeLC and BNST to a comparable extent.  Limbic PACAP and CGRP 
signaling share similarities in feeding and anxiety-like behaviors (Carter et al., 2013; 
Hammack et al., 2009; Kocho-Schellenberg et al., 2014; Sink et al., 2011); how their 
coordinate signaling modulates CeA and BNST functions however, remains to be 
evaluated. 
 Despite the extensive PACAP and CGRP colocalizations (60-70%), PACAP and 
CGRP may also exhibit independent CeLC and BNST functions.  After LPBn lesions the 
remaining PACAP and CGRP immunoreactivities appeared largely dissociate (Pearson's 
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coefficient 0.3-0.4) which may have represented endogenous CeLC/BNST peptide 
expression or PBn subpopulations expressing one of the peptides not affected by the 
lesion procedures.  The former may be consistent with the upregulation of BNST PACAP 
transcripts by chronic stress (Hammack et al., 2009).  PACAP and CGRP 
immunoreactivities in subpopulations of dorsal root ganglion (DRG) neurons for example 
can be separate and overlapping (Mulder et al., 1994), and comparable expression 
patterns may be present in the PBn and limbic structures. 
 The presence of PACAP in the parabrachioamygdaloid pathway has prominent 
implications in its roles modulating the sensory and emotional consequences of pain.  The 
ability for the amygdala to integrate pain processes and the emotional aspects of behavior 
has been well appreciated (Bernard et al., 1992; Gauriau and Bernard, 2002; Ulrich-Lai et 
al., 2006; Morano et al., 2008; Rouwette et al., 2011, 2012; Veinante et al., 2013) and 
among its many functions, the roles of PACAP as a sensory peptide are well recognized.  
PACAP and its PAC1/VPAC receptor subtypes are expressed in central and peripheral 
nervous system regions that mediate nociception.  PACAP is found in small-diameter 
nociceptive DRG and in lamina I/II of the spinal cord neurons (Beaudet et al., 1998; 
Mulder et al., 1994; Pettersson et al., 2004a, 2004b), and neuropathic pain through 
axotomy, chemical induced cystitis or related models of nerve injury, can induce long-
lasting upregulation of PACAP or PACAP receptor expression in these tissues 
(Dickinson et al., 1999; Mulder et al., 1994; Pettersson et al., 2004a; Vizzard, 2001).  In 
the central nervous system, PACAP can be found in many regions such as the 
hypothalamus, limbic system, hippocampus, various brainstem nuclei including the PBn, 
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and a number of thalamic and cortical regions implicated in pain processing (Das et al., 
2007; Hannibal, 2002; Resch et al., 2013). 
 However, the early investigations on PACAP in mediating pain were equivocal 
resulting in hyperalgesia in some experimental paradigms and hypoalgesia in others.  
These divergent responses likely reflected differences in the time course used in pain 
assessments in the different experimental models, and the peripheral vs central actions of 
PACAP.  Peripheral intraplantar PACAP injections, for example, appeared to produce 
mechanical hypoalgesia in both the early and late stages of inflammatory pain (Sandor et 
al., 2009) whereas intrathecal injections were hyperalgesic (Ohsawa et al., 2002).  In 
detailed studies, intrathecal PACAP administration resulted in an immediate analgesic 
response as measured by tail flick latencies, but transitioned into a long lasting 
hyperalgesia as demonstrated by increased aversive responses (Shimizu et al., 2004).  By 
contrast, the studies using PACAP and PAC1 receptor knockout mice demonstrated 
unequivocally a role for PACAP signaling in the development of persistent pain.  Mice 
deficient in PACAP or PAC1 receptor do not develop normal pain responses after 
arthritic pain or neuropathic pain (Jongsma et al., 2001; Mabuchi et al., 2004).  PACAP 
knockout mice do not display thermal hyperalgesia or mechanical allodynia after 
intraplantar carrageenan injection or spinal nerve transection, but show normal acute 
nociceptive processes compared to wildtype mice (Mabuchi et al., 2004).  In congruence, 
PAC1 receptor null mice exhibit dramatic decreases in thermal and mechanical 
nociceptive responses in the late phase of the formalin test, but preserve acute nociceptive 
processes in unchallenged states (Jongsma et al., 2001).  Hence PACAP/PAC1 receptor 
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signaling and resulting neuroplasticity appear critical in the central sensitization and 
development of persistent pain states. 
 Fibers from the lamina I spinal cord neurons carry thermal and mechanical 
noxious stimuli and project heavily via the spino-parabrachioamygdaloid tract to the 
lateral and external medial PBn (Gauriau and Bernard, 2002; Todd, 2010).  From the 
convergence of these projections onto the PBn, the sensory representations on the PBn 
neurons are therefore necessarily large, covering several areas of the body.  The majority 
of PBn neurons then project onto the lateral division of the BNST, the ventral medial 
hypothalamus (VMH), and the CeA; interestingly, as in the dorsal horn, high levels of 
PACAP expression are found within all of these regions.  The LPBn prominently 
innervates the CeLC and consistent with the modalities conveyed by the tract, in vivo 
electrophysiological studies demonstrate that these CeLC neurons are selectively 
activated by thermal and mechanical nociceptive stimuli with receptive fields that can 
encompass the entire body.  Hence from the broad body areas capable of stimulating the 
PBn and CeLC, the stimulus-response profiles, and the demonstration that spino- 
parabrachioamygdaloid tract lesions in the dorsolateral funiculus does not modify 
noxious stimuli response latency/threshold, the amygdala does not appear to mediate 
sensory discrimination but the affective-emotional and behavioral consequences of pain. 
 Many models of visceral, inflammatory and neuropathic pain have been shown to 
increase not only CeA neuronal excitability and PBn-CeA transmission, but also CeA c-
fos expression and ERK activation (Veinante et al., 2013) which may play roles in pain- 
related neuroplasticity.  Among bioactive peptides, CeA infusions with oxytocin, 
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neurotensin and galanin have produced anti-nociceptive responses (Dobner, 2006; Jin et 
al., 2010; Robinson et al., 2002); interestingly, CRH and CGRP have been described to 
produce either nociceptive or antinociceptive processes which may have been related to 
dose and temporal parameters (Cui et al., 2004; Han et al., 2010; Ji et al., 2013; Xu et al., 
2003).  To facilitate understandings of PACAP roles in the CeLC, our current studies 
demonstrated that PACAP infusions into the CeA heightened noxious stimuli responses, 
especially in thermal reactivity tests.  The effects of PACAP can be mediated by 
PAC1/VPAC receptors and notably, the PACAP-elicited CeA stress and nociceptive 
effects were recapitulated using maxadilan to implicate specific activation of the PAC1 
receptor in these responses.  Although the studies did not discriminate hyperalgesia from 
allodynia or spontaneous pain, the decrease in hindpaw withdrawal latency after CeA 
PACAP treatment was robust to clearly demonstrate altered sensory responses.  The CeA 
PACAP effects in mechanical sensitivity assessments, however, appeared smaller which 
may have reflected assay variability in the testing protocol or neuronal responses to 
specific sensory modalities.  The PBn responses to thermal stimuli are greater than those 
from mechanical stimuli (Bernard et al., 1996) and whether these mechanistic signals to 
the CeLC resulted in smaller PACAP-mediated mechanical responses remain to be 
established.  The CeLC has major projections to the BNST, the dorsal substantia 
innominata and the medial CeA (CeM) which represents the major output of the CeA.  
The CeM has reciprocal projections to other nociceptive effector centers including 
thalamic nuclei, periaqueductal gray, lateral hypothalamus, ventromedial reticular 
formation, substantia nigra, rostral tegmental area, locus coeruleus, and dorsal raphe 
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complex; hence in aggregate, the CeA is well integrated within ascending and descending 
pathways to influence nociceptive signal processing and responses. 
 The amygdala assigns emotional valence to extrinsic challenges and has been well 
studied with respect to fear.  The prominent nociceptive inputs to the CeLC and in 
particular the high levels of PACAP expression carrying nociceptive information in the 
spino-parabrachioamygdaloid tract provide important mechanistic insights on how 
chronic pain can initiate and/or amplify stress- related behavioral abnormalities, 
including depression and anxiety disorders.  As in the BNST, PACAP signaling in the 
amygdala promoted anxiety-like responses.  CeA PACAP infusions decreased open arm 
time, entries and preference on the elevated plus maze which appeared comparable in 
efficacy compared to that observed from BNST signaling.  Although CeA PACAP 
infusions may have induced nociceptive sensitivity to decrease locomotion and affect 
behavior, mitigating the potential confound by open arm preference analyses still 
demonstrated PACAP-mediated increases in anxiety-like behaviors.  Conversely, there is 
also a small possibility that CeA PACAP-induced stress- and anxiety-related behaviors 
may have contributed to the heightened nociceptive responses described above; this 
consideration is being pursued in ongoing studies.  However, unlike the overt BNST 
PACAP-elicited anorexia that accompanied the stress-related behavioral responses, CeA 
PACAP signaling had modest effects on feeding and weight change.  These observations 
suggested that the PACAP effects on stress-related behaviors and feeding may be not be 
strongly associated mechanisms or circuits; the small changes in weight, for example, 
may have reflected PACAP effects on thermogenesis (Hawke et al., 2009).  Interestingly, 
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the PBn PACAP projections to the BNST also implicate direct nociceptive transmission 
to the BNST and in agreement, the anterolateral BNST has been shown to participate in 
pain and stress-induced nociceptive hypersensitivity (Morano et al., 2008; Rouwette et 
al., 2011; Tran et al., 2012).  As in the BNST (Roman et al., 2014), preliminary 
experiments have shown that PACAP6-38, a PAC1/VPAC2 receptor antagonist, is 
capable of attenuating the effects of CeA PACAP signaling (data not shown).  Although 
the neurocircuits and mechanisms underlying the CeA PACAP effects have not been 
examined extensively, one PACAP function has been suggested to potentiate excitatory 
transmission at the BLA-CeL synapse by enhancing post-synaptic AMPA receptor levels 
(Cho et al., 2012).  The identities of PACAP targets in the CeLC, the functional 
mechanisms and consequences of PACAP CeLC signaling, and the functional 
relationships between PACAP and CGRP and CRH activities all remain to be 
investigated. 
 In summary, our results suggest that PACAP signaling via nociceptive fibers in 
the spino-parabrachioamygdaloid and associated tracts to the CeA and BNST may 
represent mechanisms that associate chronic pain with hypersensitivity and behavioral 
abnormalities including depression and anxiety-related disorders.  Previous studies have 
shown that PACAP is a pleiotropic peptide with neurotransmitter, hormonal and 
neurotrophic functions which can facilitate neuroplasticity in development and 
regeneration after injury.  PACAP signaling in chronic stress, fear and pain may facilitate 
the neuronal remodeling and plasticity in the limbic system that promote the maladaptive  
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behavioral responses, and transition short-term memory to long term forms that appear 
necessary for fear memory consolidation associated with PTSD. 
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2.6. Figures 
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Figure 2.1. PACAP and CRH immunoreactivities are differentially distributed and 
regulated in the CeA.  Tissue sections from control (A) and chronically stressed (B) rats 
were examined for CeA PACAP (Cy2, green) and CRH (Cy3, red) staining patterns.  In 
both groups, CeA fiber PACAP immunoreactivity was predominantly in the lateral 
capsular region (CeLC) with diffuse staining extending into the lateral division (CeL); 
CRH immunoreactivity was localized predominantly to the CeL.  From quantitative 
image analyses, only CRH immunoreactivity was augmented by chronic variate stress (C, 
n = 3).  These results complemented quantitative PCR measurements which also 
demonstrated increased CRH transcript expression after stress (D, n = 6).  Data represent 
mean ± SEM. Asterisk, significantly different from control at p < 0.05. Scale bar, 250 
µm.  
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Figure 2.2. PACAP and CGRP immunoreactivities can be colocalized in the CeLC 
and BNST.  Tissue sections for the amygdala (A-C) and BNST (D-F) were processed 
for dual PACAP (Cy3, red) and CGRP (Alexa488, green) immunocytochemical 
localization.  The merged micrographs demonstrate that in both regions, PACAP and 
CGRP immunoreactivities were largely colocalized (yellow) in the same fiber 
structures.  Amygdala, representative micrograph from 4 independent experiments; 
BNST, representative micrograph from 3 experiments.  LV, lateral ventricle; CPu, 
caudate-putamen.  Correlation coefficients described in text.  Scale bar, 200 µm for 
corresponding tissues.   
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Figure 2.3. PBn projection fibers to the CeLC demonstrate PACAP 
immunoreactivity.  Biotinylated dextran amine (BDA, 10 kD; 10%) was injected 
iontophoretically into the LPBn for anterograde transport into the CeLC over 14 days.  
BDA at the LPBn injection site (A) and in the projection fibers to the CeLC (B) were 
detected using streptavidin- conjugated Cy2 (green).  Processing of the same CeLC 
sections for PACAP immunoreactivity (Cy3, red) demonstrated that the LPBn projection 
fibers can contain PACAP (B, merge in yellow).  Representative data from 3 separate 
preparations.  scp, superior cerebellar peduncle.  Scale bar, 200 µm for corresponding 
tissues.   
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Figure 2.4. Excitotoxic LPBn lesions diminish PACAP and CGRP fiber 
immunoreactivities in the CeLC and BNST.  The LPBn was unilaterally lesioned with 
NMDA as described in Methods; the contralateral LPBn received vehicle.  After 7 days, 
the PBn sections were processed for neuron-specific nuclear NeuN immunoreactivity 
(Cy3, red) to assess the specificity and extent of the lesion.  Whereas vehicle injections 
had no apparent effects (A), NMDA injections produced substantial LPBn neuronal loss 
(B, dashed circled area).  Representative vehicle treated and contralateral NMDA 
excitotoxic lesioned PBn in the same animal are shown; the lesioned image was flipped 
to facilitate comparison.  CeA and BNST tissue sections from the NMDA excitotoxic 
lesioned animals were processed for dual PACAP and CGRP immunocytochemical 
localizations.  Similar to Fig. 2.2, tissue sections ipsilateral to LPBn - vehicle injections 
(left panels) demonstrated substantial PACAP (Cy3, red) and CGRP (AlexaFluor 488, 
green) colocalization in the CeLC (C and E) and BNST (G and I); colocalization in 
merged micrographs illustrated in yellow.  By contrast, the same CeLC and BNST 
regions in the contralateral half that received LPBn NMDA excitotoxic lesion (PBn - 
lesion) demonstrated marked decreases in both PACAP and CGRP immunoreactivities.  
Again, micrographs from the stained CeLC and BNST regions from the PBn - lesioned 
side were flipped for comparisons with the control vehicle e injected side from the same 
animals to facilitate comparisons.  These data were consistent with the colocalization of 
PACAP and CGRP in Fig. 2.2 scp, superior cerebellar peduncle; CPu, caudate putamen.  
Representative figures from 3 separate animals.  Scale bar, 200 µm. 
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Figure 2.5. CeA and BNST peptide immunoreactivities are diminished after PBn 
lesions.  PACAP and CGRP immunoreactivities in the CeA (A) and BNST (B) from 
studies described in Fig. 2.4 were subjected to image analyses as described in Methods.  
The PBn lesions decreased PACAP and CGRP immunoreactivities in the limbic regions 
to a comparable extent compared to levels on the contralateral hemisphere with PBn - 
vehicle injections.  n = 3, data represent mean ± SEM. *, different from vehicle control at 
p < 0.05.  
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Figure 2.6. PACAP infusions into the CeA decrease open arm entries on the elevated 
plus maze.  Adult rats were cannulated as described in Methods for CeA PACAP 
infusions.  Thirty minutes after PACAP injection, the animals were placed in the center 
square of the elevated plus maze, facing a closed arm, for behavior testing during a 5 min 
period.  All movements were tracked digitally for data analyses.  Total open arm entries 
(A) and open arm preference (B, open arm entries/total arm entries) were calculated.  
CeA PACAP signaling significantly increased anxiety-like behavior reflected by 
decreased number of open arm entries and open arm preference.  There were no changes 
in the number of closed arm entries and there were no indications of freezing behaviors.  
n = 10 per group, data represent mean ± SEM, *, different from vehicle control p < 0.05.   
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Figure 2.7. CeA PACAP/PAC1 receptor signaling increases thermal sensitivity.      
A, Rats were habituated in Hargreave's thermal sensitivity apparatus with 2 days of 
baseline assessments (24 and 48 h).  PACAP was subsequently infused into the CeA 
(single injection) for thermal testing at the indicated time (shaded area).  Whereas vehicle 
injection produced no apparent responses changes compared to baseline (white bars), 
CeA PACAP infusions consistently decreased thermal latency responses (black bars) up 
to 4 h post treatment.  The responses dissipated by 24 h; the small but significant 
decrease in thermal latency at 72 h may reflect latent plasticity events.  n = 6 - 8 per 
group, data represent mean response ± SEM, *, different from corresponding vehicle 
control, p < 0.025.  B, the PACAP-induced decrease in thermal latency was mirrored in 
CeA infusions with the PAC1 receptor specific agonist maxadilan.  The maxadilan 
responses observed at 1 h was again dissipated by 24 h n = 7 - 8 per group, data represent 
mean response ± SEM, *, different from corresponding vehicle control, p = 0.002.   
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3.1. Abstract 
 The high coincidence of chronic pain and stress-related psychopathologies, such 
as depression, anxiety-associated abnormalities and posttraumatic stress disorder (PTSD) 
can aggravate the debilitating conditions of both disorders through neurocircuit 
intersections and mechanisms that are still not well understood.  Pituitary adenylate 
cyclase activating polypeptide (PACAP; Adcyap1) and its cognate PAC1 receptor 
(Adcyap1r1) are expressed in peripheral nociceptive pathways, participate in anxiety-
related responses and have been associated with stress-related disorders including PTSD.   
In a partial sciatic nerve ligation chronic constriction injury (CCI) model, we show that 
chronic neuropathic pain increases PACAP expression at multiple levels along the spino-
parabrachioamygdaloid tract and bilaterally augments nociceptive amygdala (CeA) 
PACAP immunoreactivity, ERK phosphorylation and c-fos activation in parallel with 
heightened anxiety-like behavior and nociceptive hypersensitivity.  Acute CeA infusions 
with the PACAP receptor antagonist PACAP(6-38) blocked CCI-induced behavioral 
responses; further, pretreatments with MEK or endocytosis inhibitors to block endosomal 
PACAP receptor ERK signaling attenuated PACAP-induced CeA neuronal activation and 
nociceptive responses.  Accordingly, chronic pain-induced PACAP neuroplasticity and 
signaling in spino-parabrachioamygdaloid projections can impact CeA stress- and 
nociception-associated maladaptive responses, which can be ameliorated upon receptor 
antagonism even during disorder progression.   
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3.2. Introduction 
 Pain carries an aversive emotional component that can severely impact 
physiological and behavioral responses.  Accordingly, chronic pain has been well 
associated with a number of stress-related psychopathologies, including depression, sleep 
dysregulation, panic disorders, obsessive compulsive behavior, anxiety abnormalities and 
post-traumatic stress disorder (PTSD) 1.  The high comorbidity between pain and stress-
related behavioral disorders suggests that the two may be interrelated maladaptive 
processes 2.  Among brain regions, the amygdala is centrally situated to integrate the 
many descending and ascending signals to modulate the sensory and emotional 
components of pain.  Among several direct ascending pathways carrying nociceptive 
transmission to the CeA, the most prominent is the spino-parabrachioamygdaloid tract 3-6.  
Peripheral nociceptive signals carried via primary sensory Aδ- and C-fibers terminate on 
spinal projection neurons in lamina I/II and IV of the dorsal horn where the second order 
neurons send projections via the spino-parabrachial pathway to pontine lateral 
parabrachial nuclei (LPBn) 7.  In turn, the third-order LPBn neurons relay sensory 
information to the lateral (CeL) and lateral capsular (CeLC) subdivisions of the CeA.  
Hence the PBn collects cutaneous (mechanical and thermal), deep (muscular and 
articular) and visceral nociceptive signals and relays the information in a highly 
organized topographical manner principally to the nociceptive amygdala.   
 Although the integration of these inputs with amygdala circuits is a key 
mechanism underlying the emotional aspects of pain, the neurochemistry, neuroplasticity 
and regulatory events that drive the maladaptive responses are still not completely 
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understood.  In the CeA, chronic pain upregulates mGluR1/mGluR5 levels and function, 
increases NMDA NR1 phosphorylation, enhances extracellular-regulated kinase (ERK) 
signaling and c-fos expression, and facilitates LPBn and basolateral amygdala (BLA) 
synaptic transmission to the CeLC8-12 .  Relatedly, the pathophysiology of pain and 
stress-related disorders has been attributed to the decrease or dysregulation of anti-
nociceptive neuropeptide Y (NPY), opioid, endocannabinoid or neuroactive steroid 
actions on GABA signaling 2.  But in addition to diminished inhibitory neurocircuit 
function, persistent pain may also augment stimulatory CeA nociceptive neuropeptide 
levels including corticotropin releasing hormone (CRH) and calcitonin gene-related 
peptide (CGRP) as complementary means to facilitate the stress- and pain-induced 
changes in neural function 6,11,13. 
 Among brain peptides, there is accumulating evidence implicating pituitary 
adenylate cyclase activating polypeptide (PACAP) and its cognate PAC1 receptor in 
mediating the behavioral and physiological responses to a variety of homeostatic 
challenges 14.  Altered PACAP levels and a PAC1 receptor polymorphism have been 
associated with PTSD 15-19.  Mice that lack PACAP or the PAC1 receptor exhibit blunted 
anxiety-like behavior, show hypothalamic-pituitary-adrenal (HPA) axis and autonomic 
system dysregulation, and fail to develop hypersensitivity to nociceptive stimuli in 
inflammatory pain paradigms 20-27.  Furthermore, chronic but not acute stress leads to an 
upregulation of PACAP and PAC1 receptor transcript expression in the bed nucleus of 
the stria terminalis (BNST) 28-30.  BNST PACAP signaling increases anxiety-like 
behaviors and HPA axis activation, and mediates many of the behavioral consequences of 
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chronic stress 28-30. The BNST and the CeA share similar circuit connectivity, architecture 
neurochemistry, and physiology, and may play complementary roles in emotional 
behavior processes.  As in the BNST, dense PACAP immunoreactivity has been 
identified in the neuronal fibers of the CeLC/CeL which from previous work has shown 
to reflect LPBn PACAP projections in the spino-parabrachioamygdaloid tract 31.  
Importantly, infusions of PACAP or a specific PAC1 receptor agonist directly into the 
CeA of naive rats produced both anxiety-like behaviors and nociceptive hypersensitivity, 
suggesting that LPBn PACAP activity via the spino-parabrachioamygdaloid circuit 
carries signals that may in part alter the emotional responses to pain.  Using a partial 
sciatic nerve ligation chronic constriction injury (CCI) model, we examined whether 
persistent neuropathic pain alters PACAP transcript expression in the spino-
parabrachioamygdaloid tract and whether PAC1 receptor antagonism can mitigate CCI-
induced nociceptive hypersensitivity and anxiety-like behaviors.  As PACAP signaling 
potently and efficaciously activates MAPK/ERK, a central mechanism in synaptic 
plasticity and CeA-dependent behaviors and pain hypersensitivity, we also assessed CeA 
PAC1 receptor mechanisms in vivo.  The studies in aggregate suggest that endogenous 
PACAP signaling in the spino-parabrachioamygdaloid pathway and the resulting 
endosomal PAC1 receptor-stimulated activation of ERK in the CeA mediate the adverse 
emotional consequences of chronic pain, and may also explain comorbidities between 
chronic pain and other stress-related pathologies. 
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3.3. Results 
Neuropathic pain augments PACAP expression in the spino-parabrachioamygdaloid 
pathway. 
 Our previous studies identified PACAP in neuronal projections from the LPBn to 
CeLC and demonstrated that CeA PACAP infusions resulted in heightened nociceptive 
sensitivity and anxiety-like behaviors 31.  As previous studies implicated PACAP 
phenotypic plasticity in sensory systems 32,33 we examined whether chronic neuropathic 
pain in a unilateral sciatic nerve CCI model regulated endogenous PACAP expression 
along the spino-parabrachioamygdaloid pathway. The partial sciatic nerve ligation 
procedure reliably heightened nociceptive sensitivity as reflected by decreased thermal 
latency responses and also induced anxiety-like behavior in open field tests 14 days post-
surgery compared to sham controls without compromising locomotor activity (see 
below).  Quantitative PCR analyses of micropunched PBn tissues demonstrated that CCI 
specifically elevated PBn PACAP transcript levels approximately 1.5 fold compared to 
tissues from sham animals (t(12)=2.36, p=0.036); CCI did not augment PACAP 
transcript levels in the CeA,  anterolateral BNST, or the solitary nucleus (NTS)(figure 
S3.1). Additionally, no significant change was found for the PAC1 receptor transcripts in 
the LPBn or CeA (figure S3.1).  As in other peptidergic systems, the 
immunocytochemical localization for PACAP in the nervous system preferentially 
identified bioactive peptides in fibers rather than soma to preclude corresponding 
analyses of neuronal LPBn PACAP peptide changes after CCI.  But as an alternative 
means of evaluating injury-induced PACAP expression in the LPBn, the same unilateral 
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CCI was performed on PACAP-EGFP mice.  LPBn PACAP-EGFP+ cells were identified 
under basal conditions and CCI induced the number of PACAP neurons almost 2-fold 
compared to sham operated animals, main effect of CCI, F(1,22)=7.99, p = 0.01) (Figure 
1A - 1C). The CCI-induced PACAP-EGFP+ neurons appeared throughout the LPBn, with 
the majority confined to the external lateral and central lateral regions.  Notably, the 
LPBn PACAP induction was observed both ipsilateral and contralateral to the injury, 
which reflected bilateral dorsal horn neuronal projections to LPBn (Figure 3.1C), no main 
effect of side main effect (F(1,28) = 0.32, p = 0.6).  
 In good correspondence to the increase LPBn PACAP transcripts and neurons, 
CCI also augmented CeLC fiber PACAP staining from parabrachioamygdaloid 
projections (Figure 3.1D - 1F).  Consistent with previous studies, dense punctate 
PACAP-immunoreactivity characteristic of PACAP fiber terminals and varicosities was 
found primarily in the CeLC that extended into the CeL; image analyses after 
thresholding fluorescence intensity revealed a 1.4-fold increase in PACAP staining 
density in the CeLC of CCI animals compared to that in sham animals F(1,28)=14.74, 
p=0.0006).  As anticipated from bilateral dorsal horn neuronal projections to the LPBn, 
the increase in CeLC PACAP immunoreactivity was also bilateral after unilateral CCI; 
however, there was a notable bias toward greater PACAP immunoreactivity in the right 
CeLC irrespective of the side of the CCI which appeared consistent with CeA 
lateralization described in previous studies 34,35 (Suppl Figure 3.2).  
 Given the role of PACAP in neuroplasticity, we also evaluated whether 
neuropathic pain from CCI similarly affected other PACAPergic neurons within the 
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spino-parabrachioamygdaloid tract in the PACAP-EGFP mice.  While the sciatic nerve in 
sham operated and the contralateral leg of CCI animals demonstrated minimal PACAP-
EGFP fluorescence, the sciatic nerve segment proximal to CCI ligation demonstrated 
pronounced fiber PACAP expression (condition*side F(1,10)=57.22, p<0.0001, post-hoc 
Sham-ipsilateral vs. CCI-ipsilateral, p<0.0001) (Figure 3.2D - 2F).   In mouse, the 
sensory fibers in the sciatic nerve are predominantly peripheral axons from L3 - L5 dorsal 
root ganglia (DRG) with the largest contributions from L4 sensory neurons.  In 
correspondence, CCI increased the number of PACAP-EGFP+ L3 - L5 DRG neurons 
ipsilateral to the injury with the greatest increase in L4 DRGs compared to neurons from 
the same levels under all control conditions (L4 DRG condition*side F(1,8)=93.12, 
p<0.0001, post-hoc Sham-ipsilateral vs. CCI-ipsilateral, p<0.0001).  (Figure 3.2A - 2C, 
L3, and L5 Suppl Figure 3.2).  The CCI-induced increase in DRG PACAP expression 
was also reflected by a dramatic increase in DRG central axon EGFP fluorescence in 
laminae III-V of the ipsilateral dorsal horn and in the gracile fasciculus (Figure 3.2G) 
projecting to higher order central nuclei.  There were no apparent changes in the number 
of second order PACAP-EGFP+ dorsal horn neurons in CCI (data not shown).  
Interestingly, CCI also induced PACAP-EGFP in some ipsilateral ventral horn motor 
neurons which appeared consistent with previous nerve transection studies (Pettersson et 
al., 2004).   Accordingly, these demonstrate that chronic neuropathic pain elevates 
PACAP expression levels along multiple neuronal elements in the spino-
parabrachioamygdaloid pathway.  
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CeA PACAP signaling facilitates neuropathic pain-related anxiety-like behaviors and 
thermal hypersensitivity  
 We next examined if elevated CeA PACAP signaling in CCI contributes to 
heightened anxiety-like behaviors and nociceptive sensitivity. Our previous work 
demonstrated that CeA administration of PACAP or the PAC1 receptor specific agonist 
maxadilan was capable of producing both anxiety-like behaviors and thermal 
hypersensitivity31.  But to evaluate the contribution of sustained endogenous CeA 
PACAP signaling in chronic neuropathic pain, the PAC1 receptor antagonist PACAP(6-
38) was infused bilaterally into the CeA of CCI rats before assessing anxiety-like 
behavior in the open field and thermal nociception testing with the Hargreave’s test 
(Figure 3.3A).  Similar to chronic stress models, CCI attenuated weight gain over the 
course of observation; (Figure 3.3B, main effect of CCI, F(10,280) = 80.80, p < 0.0001).   
In open field tests 14 days post-surgery, CeA PACAP(6-38) infusions into the sham 
control group did not significantly change the number of center field entries compared to 
those receiving vehicle bonferroni’s m.c. t(22)=0.47, p = 0.9) suggesting that the 
antagonist alone had no apparent behavior effects.  Animals with CCI had fewer center 
field entries and these pain-associated stress responses were completely blocked upon 
CeA PACAP(6-38) administration (Figure 3.3C - 3D, bonferroni’s m.c. t(22)=3.12, p = 
0.03).  These responses were paralleled by a trend for PACAP(6-38) to increase center 
field durations times in CCI (bonferroni’s m.c. t(22)=2.22, p = 0.07).  The CCI procedure 
did not impair locomotion or affect the total distance traveled (F(1,20)=0.46, p = 0.6), 
similarly PACAP(6-38) did not alter total distance travelled (F(1,20)=1.22, p = 0.3). 
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 Concurrent with anxiety-related behaviors, CeA PACAP infusions also reliably 
facilitated nociceptive hypersensitivity in Hargreave’s thermal assays that persisted for 
several hours31.  CCI of the sciatic nerve has been well used to produce thermal 
nociceptive responses and comparable to previous work, CCI 14 days post-surgery 
typically decreased thermal latency 40 - 50% in the ipsilateral hindpaw compared to 
sham control groups or to the contralateral hindpaw (Figure 3.3E - 3G, F(1,21)=14.13, p 
= 0.001).  In the same experimental paradigm, all of the CCI animal groups demonstrated 
ipsilateral hindpaw thermal sensitivity prior to treatments; however, 1 h following 
bilateral CeA PACAP(6-38) administration, the PAC1 receptor antagonist attenuated the 
heightened thermal nociceptive responses compared to baseline measures prior to 
antagonist treatments in the ipsilateral hindpaw in the CCI condition (Figure 3.3E, 
interaction of condition*treatment*day (F(1,21) = 7.83, p = 0.009).  The effects were 
more marked when the responses in each animal were normalized to their own latency 
baseline immediately prior to the injections (Figure 3.3H, F(1,21)=16.40,  p = 0.001, 
interaction of condition*treatment F(1,21) = 15.49, p = 0.001). There were no significant 
effects of CeA PACAP(6-38) on the uninjured contralateral hindpaw or in the sham 
operated condition (Figure 3.3F).  Accordingly, these results mirrored previous PAC1 
receptor antagonist studies, demonstrating that PACAP has no apparent behavioral 
effects under control sham handling conditions, but contributes to heightened anxiety-like 
behavior and nociceptive sensitivity in chronic neuropathic pain.  
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CeLC PACAP-mediated ERK signaling in chronic neuropathic pain  
 One of the most consistent amygdala responses to persistent pain is an increase in 
ERK activation in a subset of CeLC neurons.  Enhanced amygdala ERK signaling can 
increase behavioral sensitivity in normal conditions and ERK signaling contributes to 
PBn - CeLC neurotransmission in persistent pain10,36,37. Conversely, MEK/ERK 
inhibition in inflammatory pain can decrease behavioral hypersensitivity10. Comparable 
to previous work and PACAP transcript/immunocytochemistry data above, unilateral CCI 
on either the right or left hind limb increased bilaterally the number of CeLC pERK+ cells 
compared to sham (Figure 3.4A - 4C, main effect of CCI F(1,26)=7.62, p = 0.01); there 
was no apparent difference in response relative to the side of injury ((IL vs CL) no main 
effect of side F(1,26) = 0.01, p = 0.9).  However, for all CCI (left or right hind limb), 
there was an apparent trend towards a greater number of pERK+ cells in the right CeLC 
((left vs right) F(1,26) = 3.15, p = 0.09) (Suppl Figure 3.2). These results signify that 
similar to other pain models, chronic neuropathic pain enhances ERK signaling in the 
CeLC.  
 But to evaluate whether CeA PACAP fibers can affect amygdala ERK activation 
in CCI, dual pERK and PACAP localization was performed (Figure 3.4D - 4E).  Notably, 
the majority of the CCI pERK+ cells (84.5 ± 5.0%) were in immediate apposition (< 2 
µm) with CeLC PACAPergic fibers with a high occurrence of PACAP fibers forming 
perisomatic contacts. The fraction of pERK+ cells with PACAP contacts is likely an 
underestimate given the limitations of section thickness and antibody penetration. Thus, 
PACAP is optimally situated to activate ERK in the CeLC.  In good correspondence with 
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previous characterizations of PACAP neurons, the CeLC PACAP fibers are mainly 
glutamatergic from PACAP colocalization with vGlut2 immunoreactivity; there was little 
overlap with vGlut1 or glutamic acid decarboxylase (GAD) staining (Suppl Figures 3.3  
and 3.5). 
 As the BNST displays structural and functional homology with the CeA and also 
receives LPBn PACAP projections31, the effects of CCI on neuronal pERK were also 
examined in the BNST.  As in the CeLC, CCI induced a robust increase in the number of 
pERK+ cells in the anterolateral BNST, with almost no cellular pERK labeling under 
sham conditions (main effect of CCI, F(1,8) = 15.04, p = 0.005) (Suppl Figure 3.5).   
Similar to the CeLC, the majority of BNST pERK neurons (83.1 ± 0.5%) were in close 
contact with glutamatergic PACAP fibers (Suppl Figures 3.3 and 3.5).  These results 
implied that BNST PACAP signaling may also have roles in the behavioral consequences 
of persistent pain, which complements previous work 38.  
 To establish whether CeA PACAP signaling via ERK can evoke thermal 
hypersensitivity, the MEK inhibitor PD98059 (20 µM) was infused into the CeA prior to 
PACAP38 injection.  While infusions of PACAP38 alone resulted in marked increases in 
CeA c-fos and pERK immunoreactivity in the same neurons (Figure 3.5; co-incidence = 
87%), pretreatment with the MEK inhibitor abolished the PACAP-stimulated responses, 
demonstrating that ERK activation is an essential component of PACAP signaling to 
instigate CeA neuronal activity (Figure 3.5A - 5L).  CeA PACAP infusion and signaling 
within the same study heightened nociception sensitivity as shown by the decreases in 
thermal latency times; the PACAP responses were completely abolished by MEK 
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inhibition, corroborating that PACAP/PAC1 receptor signaling via ERK pathways is 
central to CeA nociception processes (Figure 3.5M - 5N, bonferroni m.c. t(41)=3.59, p = 
0.002). 
 There are several potential mechanisms for PAC1 receptors to engage MEK/ERK 
pathways including PKA and/or PKC activation39-42; however, PAC1 receptor 
internalization into signaling endosomes has also been shown to be an alternative and 
efficacious means of ERK phosphorylation to potentially sustain cell stimulation 41,42.  
Blocking PAC1 receptor internalization at ambient temperature conditions or with 
endocytosis inhibitors substantially attenuated ERK phosphorylation.  Contiguous with 
the previous experiment, a separate experimental group was pretreated with Pitstop 2 (30 
µM), an inhibitor of clathrin-mediated endocytosis, prior to PACAP infusion.  Consistent 
with cell culture data 42, Pitstop 2 pretreatments markedly block PACAP-mediated c-fos 
expression and ERK phosphoryation in the CeA (Figure 3.5).   Importantly, inhibition of 
clathrin-mediated endocytosis reduced PACAP-induced hypersensitivity (Figure 3.5M - 
5N, bonferroni m.c. t(41)=2.57, p = 0.03).  Neither PD98059 nor Pitstop 2 produced CeA 
damage or cellular apoptosis (Suppl Figure 3.6) The efficacy of Pitstop 2 in blocking the 
PACAP-mediated nociceptive responses appeared lower than that for MEK inhibition 
which may reflect in part drug potency in vivo vs in vitro, and ERK activation via PAC1 
receptor PKA or PKC mechanisms.  Nevertheless, these studies in aggregate provide the 
first in vivo evidence that GPCR PAC1 receptor internalization and downstream ERK 
signaling can modulate CeA nociception responses.  
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3.4. Discussion 
 The current studies establish roles for CeA PACAP signaling as an effector 
conveying the behavioral and sensory consequences of chronic neuropathic pain.  Among 
several lines of evidence, CCI increased PACAP transcripts and neurons in the LPBn 
which correlated with enhanced LPBn PACAP projection fiber immunoreactivity in the 
CeLC and increased PACAP expression in the spino-parabrachioamygdaloid tract.  In 
good agreement with previous studies demonstrating the anxiety-related and nociceptive 
hypersensitivity responses following CeA PACAP administration31, blockade of 
endogenous PACAP signaling in CCI with PAC1 receptor antagonist PACAP(6-38) 
attenuated the CCI neuropathic pain-induced heightened anxiety-like behavior in the 
open field tests and nociceptive hypersensitivity in thermal assays.  Importantly, both 
CCI and PACAP stimulated CeA ERK activation and c-fos expression which were 
diminished upon pretreatments with MEK or clathrin-mediated endocytosis inhibitors in 
parallel with diminished PACAP-induced nociceptive hypersensitivity.  These results 
further our understandings of CNS PACAP mechanisms and functions, and how 
maladaptions in PACAP signaling in intersecting stress-related and pain circuits may 
negatively impact the course of psychopathologies. 
 Previous studies have shown PACAP neurophenotypic plasticity and 
demonstrated that central and peripheral neuronal PACAP expression can be upregulated 
in response to diverse homeostatic challenges.  In a chronic stress paradigm, heightened 
PACAP and PAC1 receptor transcript expression was observed in the BNST and 
paraventricular nucleus of the hypothalamus28. In several nerve injury models, PACAP 
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was elevated in sensory, autonomic and motor neurons 32,33,43.  The recent availability of 
the PACAP-EGFP mice illustrated that plasticity; whereas basal endogenous PACAP 
levels appeared low in many neuronal systems, physiological challenges especially nerve 
injury significantly induced PACAP expression.  Consistent with previous results, CCI 
increased DRG PACAP expression, which augmented dramatically PACAP levels in 
both peripheral sensory fibers in the sciatic nerve and central DRG axons in the dorsal 
horn and spinal pathways.  Second order PACAP producing neurons were found in 
lamina I/II of the dorsal horn but notably CCI also increased PACAP expression centrally 
in the LPBn and CeA as a consequence of enhanced nociceptive signaling in the spino-
parabrachioamygdaloid pathway.  The injury mechanisms underlying the induction of 
phenotypically plastic peptides, including PACAP, are not well understood but may 
reflect inflammatory responses or cellular stress from diminished target tissue signaling.  
The same mechanisms may underlie the PACAP induction in the few ventral horn motor 
neurons in CCI; PACAP function in these neurons have not been studied but posited to 
be regenerative or neuroprotective.  Uniquely, these studies demonstrate PACAP 
expression at all levels of the spino-parabrachio-amygdaloid pathway suggesting that 
PACAP is a common mediator at all levels of the nociceptive circuit.  
 The second order dorsal horn neurons project to the brain bilaterally; hence 
unilateral CCI produced bilateral increases in LPBn PACAP expression with 
corresponding increases in CeA PACAP immunoreactivity and pERK activation.  
However, when all data sets were analyzed with reference to tissues ipsilateral or 
contralateral to injury site, PACAP and pERK immunoreactivity was preferentially 
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heightened in the right CeA, irrespective of left or right sciatic nerve ligation.  These 
observations agreed with studies suggesting that the CeA displays a degree of lateralized 
function with the right CeA displaying greater increases in pERK and synaptic 
potentiation in response to pain34,35.  Accordingly, the lateralization of CeA PACAP may 
be consistent with the functional lateralization nociceptive processes in the CeA.  
 The evidence for PACAP functions as a nociceptive neurotransmitter is 
substantive.  PACAP was identified initially as a sensory peptide44 and in agreement with 
current work, other studies have shown that the low basal expression levels of PACAP in 
DRG neurons can be dramatically induced in sensory neurons and sciatic nerve fibers 
after injury.  Furthermore, heightened DRG PACAP is likely released from C-fibers in 
the superficial layers of the dorsal horn, as capsaicin applications decreased dorsal horn 
PACAP immunoreactivity and increased PACAP levels in cerebral spinal fluid perfusate 
44,45. PACAP knockout mice develop significantly less thermal and mechanical 
hypersensitivity from both neuropathic and inflammatory pain models, and have 
decreased somatic sensitivity in normal conditions 26.  Consistent with these findings, 
mice that lack PAC1 receptors display reduced mechanical hypersensitivity during the 
late phase following formalin injection27.  However, the nociception studies after PACAP 
infusion have been more variable depending on the route of peptide administration.  In 
the periphery, direct PACAP injections into the hindpaw was largely anti-nociceptive 
reducing thermal and mechanical sensitization in inflammatory pain46.  However, in 
parallel with our CeA studies, central and intrathecal PACAP administrations were pro-
nociceptive capable of potentiating hypersensitivity under normal conditions, and the 
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responses could be blocked with PACAP(6-38) 31,47,48.  The reasons for the variable 
results are unclear but may be related to PACAP regulation of many homeostatic 
systems.  In addition to expression and function in sensory systems, PACAP also 
regulates autonomic and immune functions; the anti-inflammatory and 
immunosuppressive attributes of PACAP for example, may be contributory to the 
peripheral anti-nociceptive effects.  
 Following CCI, a two week postsurgical recovery period was established to allow 
locomotor return from transient deficits, injury-induced PACAP expression and the 
development of chronic pain hypersensitivity and stress-related behaviors for multiple 
nociceptive and behavioral assessments.  BNST PACAP expression was upregulated in a 
seven day chronic variate stress paradigm but not following one day of acute stress29,30; 
whether a similar time course is necessary for PACAP induction in chronic versus acute 
pain and whether PACAP levels in the spino-parabrachioamygdaloind pathway increase 
incrementally with chronic pain duration have not been established.   As many weeks of 
CCI have been shown to gradually cause anxiodepressive-like disorders 49 and PACAP 
has been implicated in anxiety- and depression-related behaviors 15,29,50,51, the increase in 
PACAP expression and signaling may be a mechanism underlying the development of 
psychopathologies. 
 The current CCI paradigm produced anxiety-like responses in open field tests and 
thermal hypersensitivity in the ipsilateral hindpaw.  To evaluate whether continued CeA 
PACAP signaling participates in these heightened pain and behavioral responses, the 
PAC1/VPAC2 receptor antagonist PACAP(6-38) was infused into the CeA before 
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testing.  The infusion of PACAP(6-38) alone into  sham control animals had no effects on 
either pain or stress-related behaviors, suggesting that PACAP signaling under basal 
conditions may be low not to significantly impact the normal course of CeA functions.  
The ability for acute PACAP(6-38) treatments to mitigate anxiety-like behavior and 
thermal hypersensitivity responses during chronic injury suggested that the increase in 
CeA PACAP levels and signaling was sustained during the course of CCI to facilitate the 
pain-related behavioral responses.  The involvement of CeA PACAP only in a state of 
persistent pain and/or stress and not under normal conditions is comparable to 
observations for other CeA systems including CGRP, CRH and mGluR regulated-
functions8,52-54.  The mechanisms through which CCI-induced CeA PACAP may result in 
anxiety-like behaviors is not clear but may involve the potentiation of basolateral 
amygdala (BLA) excitatory postsynaptic transmission to the CeL 55.  Similarly LPBn 
PACAP projections to the BNST may not only have anxiogenic but hyperalgesic 
attributes by interactions with CRH systems 38.  Hence, CCI-induced LPBn PACAP 
expression and release could heighten nociceptive hypersensitivity and anxiety-like 
behaviors via multiple complementary mechanisms with projections facilitating BLA to 
CeL neurotransmission, modulating descending inhibitory signals, altering BNST 
function or enhancing CeLC nociceptive signals to the substantia innominata dorsalis for 
anxiety, aversion and fear responding56.   
 Activation of the ERK pathway is a central means of nociceptive signaling in a 
variety of pain models.  PACAP potently activates ERK through PAC1 receptors which 
may have contributed to the sustained levels of pERK in the CeLC during prolonged 
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CCI.  Both CCI and acute CeA PACAP infusion increased ERK phosphorylation and 
levels of the neuronal activity marker c-fos.  The increase in pERK and c-fos were 
colocalized to the same CeA neurons, and as c-fos stimulation could be abrogated 
concomitantly with pERK levels with MEK inhibitors, the increase in c-fos appeared 
downstream of PACAP signaling.  This was supported by the observation that the 
majority of the pERK neurons was found to be in close apposition to PACAPergic fibers.  
Further, the ability for MEK inhibition to attenuate CeA PACAP-stimulated pERK and c-
fos in parallel with blockade of PACAP-induced thermal sensitivity demonstrated that 
PACAP/PAC1 receptor-mediated ERK signaling is requisite for CeA nociceptive 
hypersensitivity responses.  There are several routes of PAC1 receptor-mediated 
activation of MEK including adenylyl cyclase/cAMP and PLC/PKC.  While these plasma 
membrane initiated cascades may be relatively short lived, the recent observations that 
PAC1 receptor endocytosis and recruitment of scaffolding proteins for endosomal MEK 
signaling may represent a key mechanism for prolonged intracellular ERK activation.  As 
with MEK inhibitors, Pitstop 2, an inhibitor of clathrin mediated endocytosis also 
blocked PACAP-mediated CeA pERK and c-fos levels and attenuated PACAP-mediated 
nociceptive hypersensitivity responses.  The internalization of several GPCR systems 
have been described to participate intracellular signaling; these results may be one 
demonstration of how GPCR internalization and endosomal signaling may relevant in a 
physiological mechanisms and in particular nociceptive mechanisms.   
 In summary, our results demonstrate that spino-parabrachioamygdaloid PACAP 
expression and signaling are augmented in neuropathic pain and that this heightened 
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expression may contribute to adverse pain- and stress-related behaviors.  While clinical 
data have placed considerable emphasis on the dysregulation of inhibitory pathways as 
mechanisms underlying pain-associated psychopathologies, the maladaptations from 
ascending activating pathways including neurophenotypically plastic PACAPergic 
system may be contributory to that process. CeA PAC1 receptor antagonism or inhibition 
of downstream endosomal ERK signaling can blunt PACAP- and CCI-induced 
nociceptive hypersensitivity and associated anxiety-like responses.  As PACAP receptor 
antagonism during CCI advancement can still ameliorate the adverse neuropathic pain 
and behavioral responses, these observations suggest that interventions in PACAP 
signaling during the progression of pain and associated behavioral responses may have 
therapeutic utility in improving disorder outcomes. 
 
3.5. Methods 
Animals 
 Adult male Sprague-Dawley rats were from Charles River Laboratories, 
Wilmington, MA. PACAP promoter-dependent EGFP BAC transgenic mice, generated 
by the GENSTAT (Gene Expression Nervous System Atlas) project were obtained from 
James Waschek (UCLA, Los Angeles, CA).  All animals were housed under a 12-hour 
light/dark cycle (lights on 0700 h) with food and water available ad libitum, and 
habituated to the animal facility for at least one week prior to any experiments. All 
procedures were approved by the Institutional Animal Care and Use Committee at the 
University of Vermont. 
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Neuropathic pain model 
 Chronic constriction injury (CCI) of the sciatic nerve was performed in rats as 
described previously57.  Rats were anesthetized with isoflurane and four loose ties (4-0 
chromic gut sutures, Ethicon) were placed proximal to the trifurcation of the sciatic 
nerve.  In sham surgeries, the sciatic nerve was briefly exposed before incision closing 
with wound clips.  In some experiments with intra-amygdalar infusions, the stereotactic 
surgery for cannula implantation was performed concurrently with CCI.  Only animals 
that developed thermal hypersensitivity in Hargreave’s assay were used for testing and 
analyses.  In PACAP-EGFP mice, the same CCI procedure was followed except only 
three chromic gut sutures were used.  
 
Intra-amygdalar infusion 
 Rats were prepared as described previously29,31 and two stainless steel cannulae 
(22GA, PlasticsONe, Roanoke, VA) were placed targeting the CeA using the coordinates 
(from bregma in mm) AP: -2.6, ML: ± 4.5, DV: -7.2.  For CeA drug administration, rats 
were lightly restrained with a towel and infused with drug or vehicle (0.5 µl/min, Harvard 
Apparatus, Holliston, MA) through an internal cannula with a 1 mm projection beyond 
the end of the guide cannulae.  Infused compounds included PACAP(6-38) (0.3 µg/0.5 
µl), Pitstop 2 (30 µM/0.5 µl) and PD98059 (20 µM/0.5 µl). 
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Immunohistochemistry 
 Anesthetized rats were perfused transcardially with 4% paraformaldehyde and the 
brains were postfixed for 24 h, washed and equilibrated in 30% sucrose before 
embedding in OCT compound (ThermoFisher Scientfic, Waltham, MA) for 
cryosectioning (30 µm).  The sections were mounted onto subbed slides, permabilized 
with 0.3% Triton X-100, blocked with 1% BSA and incubated in primary antibody.  
Immunocytochemical staining for PACAP (1:10, 48 h at 4 C, Jens Hannibal, Bisperg 
Hospital, Copenhagen, Denmark) was enhanced by tyramide signal amplification (Perkin 
Elmer, Waltham, MA) for visualization with Cy3-conjugated streptavidin (1:200, 2 h; 
Jackson Immunoresearch, West Grove, PA) as previously described31.  Detection for 
phosphorylated ERK (1:1000, #4370 Cell Signaling Technology, Danvers, MA) and c-
fos (1:300, sc-52 Santa Cruz Biotechnology, Dallas, TX) were performed using species 
specific AlexaFluor 488 or Cy3-conjugated secondary antibodies. Antibodies to vGlut1 
(1:1000, AB5905), vGlut2 (1:1000, AB2251) and GAD (1:300, AB1511) were all from 
Millipore Billerica, MA.  
 
Image Analysis 
Micrographs were obtained using a Nikon E800 point scanning confocal 
microscope, except in analyses of PACAP immunoreactivity levels in which the images 
were captured using an Olympus fluorescence microscope captured using identical 
parameters.  For quantification of CeA PACAP fiber immunoreactivity, the 
corresponding CeA fields in the different brains were identified using the hippocampus 
 130 
and optic tracts as reference points; area of threshold was used as an indicator of relative 
fluorescence from same sized fields. For enumeration of CeA pERK-, c-fos-, and 
PACAP-EGFP+ cells in fixed areas, a semi-autonomous cell counting method was 
performed in ImageJ.  All data represent mean values ± SEM. 
 
Behavioral Assessments 
Open Field 
Behavioral testing was performed 0.5 h following infusions.  Rats were 
individually placed into the corner of a 75 cm x 75 cm opaque black open arena with 50 
cm walls (United States Plastics Corp., Lima, OH) illuminated at 20 lux using a red bulb.  
Rat arena center entries and total distance traveled over 5 min test sessions were digitally 
captured with a ceiling mounted camera for analyses using EthoVision XT version 
6.1.326 (Noldus Information Technology, The Netherlands). 
 
Thermal Sensitivity Assessment 
A Hargreave’s apparatus (Plantar Analgesia Meter, IITC Life Science, Inc., 
Woodland Hills, CA). was used to assess thermal stimuli responses.  Following 
habituation in the acrylic testing chambers (30 min each day for 2 days), the rats were 
placed in the apparatus chamber with the glass floor maintained at 30 C with an internal 
heating element.  A low intensity guide light (8% active intensity) was used to target the 
plantar surface of the each hindpaw from beneath the glass floor before a beam of 
focused radiant light (4 x 6 mm, 25% active intensity) was switched on.  Upon animal 
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awareness of the heat stimulus, indicated by a withdrawal response or licking of the 
hindpaw, the heat source was terminated and the reaction time automatically recorded.  
An automated 30 sec cut-off was used to prevent tissue damage.  The hindpaws were 
randomly selected at trial initiation and 3 trials separated by 5 min inter-trial intervals 
were performed on each of the left and right hindpaws .  
 
Transcript analysis 
 Quantitative PCR (QPCR) was performed in the same manner as previously 
described28,29 . Following brief isoflurane anesthesia and rapid decapitation, rat brains 
were quickly frozen in OCT compound (ThermoFisher Scientfic, Waltham, MA); 300 
µm cryosections were prepared and 740 µm micropunches from each region were 
harvested.  Total RNA extraction was performed using STAT-60 RNA/mRNA isolation 
reagent (Tel-Test “B”, Friendswood, TX).  Each set of brain regions was reverse 
transcribed simultaneously using random hexamer primers using SuperScript II 
Preamplification System (Invitrogen, Carlsbad, CA).  The cDNA templates were diluted 
10-fold and assayed on an ABI Prism 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA) using SYBR Green I JumpStart Taq ReadyMix (Sigma, St. 
Louis, MO) containing 5.0 mM MgCl2, 200 µM dATP, dGTP, dCTP and dTTP, 0.64 U 
Taq DNA polymerase and 300 nM of each primer in a 25 µl reaction volume. 
Oligonucleotide primers were as follows: PACAP (S) 5’-
CATGTGTAGCGGAGCAAGGTT-3’ (AS) 5’-GTCTTGCAGCGGGTTTCC-3', PAC1 
(S) 5’ -AACGACCTGATGGGACTAAAC-3' (AS) 5’-
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CGGAAGCGGCACAAGATGACC-3'. Following amplification, melting profiles of 
amplicons were used to verify unique product generation. A standard curve constructed 
by amplification of serially 10-fold diluted plasmids containing the target sequence was 
used for analysis. Increase in SYBR Green I fluorescence intensity(ΔRn) was plotted as a 
function of cycle number and threshold cycle (CT) was determined using software as the 
amplification cycle at which the ΔRn intersects the established baseline.  Transcript 
levels were calculated from the CT by interpolation from the standard curve.  For each 
target sequence, all sample from the same brain region were amplified simultaneously.  
All data was normalized to 18s RNA and calculated as a fold change from control.    
 
Statistics 
All statistical tests were performed in SPSS (version 22) and GraphPad PRISM 
(version 6). Two-way analysis of variance (ANOVA) was performed to examine main 
effects and interactions, and Bonferrroni’s multiple comparisons tests were used to 
compare different groups for all experiments, except for those indicated.  A multifactorial 
ANOVA was used to examine PACAP6-38 treatment with CCI condition across side and 
day in tests of thermal sensitivity. Students T tests were performed to compare changes in 
average weight gain and post surgery weight loss.  
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3.6. Figures 
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Figure 3.1. CCI increases LPBn and CeA PACAP levels. Control sham surgery (A) or 
CCI (B) were performed on transgenic PACAP-EGFP mice and native EGFP 
fluorescence was examined in LPBn tissues 2 weeks following surgery.  The number of 
LPBn PACAP-EGFP cells was increased bilaterally in CCI compared to sham with a 
main effect of condition (C; sham ipsilatera/contralateral = 31.0 ± 7.1 cells/26.3 ± 3.5 
cells vs CCI ipsilateral/contralateral = 52.5 ± 9.2 cells/50.8 ± 9.7 cells; F(1,22) = 7.99,    
p = 0.01, n = 6-7 per group, 3 sections enumerated per side per animal).  CeA PACAP 
immunoreactivity was also increased after CCI (E) compared to sham controls (D). From 
image analyses with thresholded area, there was a main effect of CCI (F; sham 
ipsilatera/contralateral = 21.7 ± 2.0 units/20.6 ± 1.3 units vs CCI ipsilateral/contralateral 
= 27.3 ± 0.4 units/ 30.6 ± 1.1, F(1,28) = 14.74, p = 0.0006; n = 8 per group) but no main 
effect (F(1,28)=0.32, p=0.6) or interaction (F(1,28) = 1.17, p = 0.3) with respect to side. 
Data represent mean cells/unit area or fluorescence units/unit area ± SEM; scp, superior 
cerebellar peduncle; IL, ipsilateral; CL, contralateral;  Scale bar = 200 µm.  
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Figure 3.2.  Sensory pathway PACAP expression is enhanced by CCI.  Compared to 
sham surgery controls (A), unilateral partial sciatic nerve CCI (B) induced PACAP -
EGFP expression in the ipsilateral L4 dorsal root ganglion (DRG) sensory neurons (C; 
sham ipsilateral/contralateral = 1.3 ± 0.9 cells/2.0 ± 1.0 cells vs CCI 
ipsilateral/contralateral = 96.0 ± 9.6 cells/1.3 ± 0.3 cells, condition*side F(1,8) = 95.78, 
p<0.0001), *p = 0.0001 Bonferroni’s m.c; n = 3 per group).   L4 DRG represents the 
major contributor to mouse sciatic nerve; similar PACAP-EGFP inductions were 
observed in L3 and L5 DRGs (Suppl Figure 3.3).   The increase in CCI induced DRG 
PACAP expression was also reflected in peripheral and central DRG axons.  The 
ipsilateral sciatic nerve fibers proximal to the ligation demonstrated pronounced PACAP-
EGFP fluorescence (E) compared to sham (D) or contralateral control tissues (F; sham 
ipsilateral/contralateral = 0.8 ± 0.5 units/0.9 ± 0.4 units vs CCI ipsilateral/contralateral    
= 54.7 ± 6.1 units/0.2 ± 0.1 units; interaction side*condition F(1,10)=57.22, p<0.0001;    
n = 3 - 4).  The CCI-induced PACAP-EGFP fluorescence in the central DRG axons were 
observed in the dorsal horn with prominent projections in the dorsal while matter tracts 
(G).  Few PACAP-EGFP neurons were also observed in laminae I of the dorsal horn but 
there were no apparent differences between ipsilateral and contralateral dorsal horn 
PACAP neuronal number after sciatic nerve injury.  CCI also induced PACAP-EGFP 
expression in the ipsilateral ventral horn motor neurons.  Data represent mean cells/unit 
area or fluorescence units/unit area ± SEM; DH, dorsal horn; VH, ventral horn; GF, 
gracile fasciculus.  Scale bars = 200 µm 
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Figure 3.3. Blocking CeA PACAP signaling attenuates CCI-mediated anxiety-like 
behavior and thermal nociceptive hypersensitivity.  CCI and CeA cannulations were 
performed concurrently in rats for behavior and nociception studies in the experimental 
timeline shown (A). The CCI-mediated pain- and stress-related responses were associated 
with attenuated weight gain compared to sham control animals during the post-surgical 
recovery period (B). There was decreased weight gain in the CCI operated animals 
compared to sham,  (main effect of CCI, F(10,280) = 80.80, p < 0.0001, n =8 per group).. 
The pain- and stress-related behavior in CCI was also reflected in decreased center 
entries in open field tests compared to sham controls (C; open bars).  CeA infusions in 
sham operated animals with the PACAP receptor antagonist PACAP(6-38) had no effects 
on center field entries over the 5 min test period (sham-vehicle = 7.5 ± 0.7 vs sham-
PACAP(6-38) = 6.75 ± 1.4, Bonferroni’s m.c. t(22) = 0.47, p = 0.9) but blocked the 
stress- and anxiety-like open field responses in CCI  (CCI-vehicle = 3.7 ± 0.8 vs CCI-
PACAP(6-38) = 9.0 ± 1.3, Bonferroni’s m.c. t(22) = 3.12, p = 0.03; condition*treatment 
F(1,22) = 6.78, p = 0.02, n = 5 - 8 per group).  (D), Representative movement tracks in 
open field area for the 4 groups. There were no significant differences in total distance 
traveled for either condition or treatment. Data represent mean open field entry ± SEM. 
In Hargreave’s thermal nociception assays, CCI increased thermal sensitivity as reflected 
by decreased baseline latency times in the ipsilateral hindpaw compared to the 
contralateral leg or in sham animals (F(1,21) = 14.13, p = 0.001). PACAP(6-38) infusions 
into the CeA attenuated the CCI-induced thermal hypersensitivity compared to baseline 
(E); simple effect of day in CCI-PACAP(6-38) on IL side (baseline: 5.3 ± 0.6s vs. 30 
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min: 7.2 ± 0.7s, F(1,21) = 12.21, p = 0.002) and interaction of condition*treatment*day 
(F(1,21) = 7.83, p = 0.009, n = 5 - 8 animals per group) and within group PACAP(6-38) 
ameliorated the nociceptive sensitivity. The effects were amplified when the responses of 
each animal were normalized to their own baseline measures prior to antagonist treatment 
(G; CCI-Vehicle: -3.4 ± 7.2% vs. CCI-PACAP(6-38): 36.2 ± 6.6%, simple effect of 
treatment F(1,21) = 16.40, p = 0.001, interaction of condition*treatment F(1,21) = 15.49, 
p = 0.001. (H); There were no effects of PACAP(6-38) on thermal latency in the 
contralateral leg (F).  
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Figure 3.4.  PACAPergic fibers contact CeA activated ERK cells in CCI.   
CCI produced a bilateral increase in the number CeLC activated pERK+ neurons (Cy3, 
red) compared to that in the sham condition (A - C; sham ipsilateral/contralateral = 32.1 ± 
4.5 cells/30.6 ± 2.8 cells vs CCI ipsilateral/contralateral = 53.4 ± 12.6 cells/56.6 ± 11.9 
cells, F(1,26)=7.62, p = 0.01, n = 7 - 8 animals per group).  When the same sections were 
dually processed for PACAP immunoreactivity (AlexaFluor 488, green), a majority of 
the CeLC pERK+ neurons were found in apposition to PACAP-immunoreactive fibers 
and varicosities (D - E).  Data represent mean cells/unit area ± SEM; IL, ipsilateral; CL, 
contralateral.  Scales bar = 50 µm 
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Figure 3.5.  PACAP receptor internalization and ERK activation participate in 
CeA-mediate nociceptive hypersensitivity.  Compared to vehicle (A), CeA PACAP 
infusion increased the number of activated phosphorylated ERK neurons (D, Cy3 red) 
which coincided with the increase in neuronal activity marker c-fos (G, J, blue).  
Pretreatments with MEK inhibitor PD98059 (B, E, H) or clathrin-mediated endocytosis 
inhibitor Pitstop 2 (C, F, I) blocked the ability of PACAP to induce ERK 
phosphorylation or c-fos in CeA neurons.  K, The increase in PACAP-stimulated ERK 
activation was attenuated approximately 60 - 70% by PD98059 (vehicle + PACAP = 
149.0 ± 33.1 cells vs PD98059 + PACAP = 41.9 ± 15.9 ± 6.7 cells, (bonferroni’s m.c. 
t(40) = 4.49, p = 0.0001) and Pitstop 2 (veh + PACAP = 149.0 ± 33.1 cells vs Pitstop2 
+ PACAP = 62.7 ± 14.2 cells, bonferroni’s m.c. t(40) = 3.50, p = 0.002), 
pretreatment*treatment(F2,40) = 4.67, p = 0.02.  L, Similarly, the increase in PACAP-
stimulated c-fos levels activation was attenuated approximately 50 - 60% by PD98059 
(cells/unit area, vehicle + PACAP = 148.5 ± 32.3 cells vs. PD98059 + PACAP = 59.8 ±  
18.7 cells, bonferroni’s m.c. t(40) = 3.62, p = 0.002) and Pitstop 2 (vehicle + PACAP = 
148.5 ± 32.3 cells vs. Pitstop2 + PACAP = 74.4 ± 15.8 cells, t(40) = 2.92, p = 0.02) 
pretreatment*treatment (F(2,40) = 3.46, p = 0.04).  Scale bar: 100 µm. Data represent 
mean cell number ± SEM; n = 7 - 8 per group.  Commensurate with ERK activation, 
CeA PACAP injection induced nociceptive hypersensitivity in decreasing thermal 
latency; both MEK and endocytosis inhibition blocked the PACAP-induced thermal 
sensitivity (M; latency in sec, Veh + PACAP = 7.1 ± 0.6 sec vs PD98059 + PACAP = 
11.2 ± 0.8, bonferroni’s m.c. t(41) = 5.05, p < 0.0001; Veh + PACAP = 7.1 ± 0.6 vs 
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Pitstop2 + PACAP = 9.8 ± 0.4, bonferroni’s m.c. t(41) = 3.31, p = 0.004) 
(pretreatment*treatment F(2,41) = 6.64, p = 0.003).   Expressed as percent change from 
baseline measures of each animal before drug administration, both MEK inhibition (% 
latency change from vehicle control;  PACAP = -37.8 ± 5.9% vs. PD98059 + PACAP = 
2.6 ± 4.8%, bonferroni’s m.c. t(41) = 5.58, p=0.0001) and  endocytosis inhibitor Pitstop 
2 (PACAP = -37.8 ± 5.9% vs  Pitstop + PACAP = -13.5 ± 4.9%, bonferroni’s m.c. t(40) 
= 3.36, p = 0.003) attenuated nociceptive hypersensitivity.  Data represent mean ± 
SEM, n = 7 - 8 per group. 
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Supplementary Figure 3.1. CCI increases PACAP transcript in the LPBn. 
Adult male rats underwent either CCI or sham surgery as described in text and 14 days 
following the indicated brain regions were harvested for quantitative PCR analysis.  
Tissue samples for each region were reverse transcribed and normalized against 18s 
RNA. In the LPBn was a significant increase in PACAP transcript (1.47 ± 0.1) fold 
change SEM) compared to tissues from sham animals ((1.00 ± 0.2), t(12) = 2.36, p = 
0.036). Demonstrating that this effect may be specific to the LPBn, there were no 
significant changes in PACAP transcript in the CeA (CCI: 0.96 ± 0.2 vs. sham: 1.00 ± 
0.3, t(12) = 0.12, p = 0.9), anterolateral BNST (CCI:1.06 ± 0.2 vs. sham: 1.00 ± 0.2, t(13) 
= 0.21, p = 0.8), or the solitary nucleus (NTS)(CCI: 1.00 ± 0.2 vs. sham: 0.90 ± 0.3, t(14) 
= 0.29, p = 0.8). There were no significant changes in PAC1 R transcript in the LPBn 
(CCI:1.15 ± 0.1 vs. Sham 1.00 ± 0.1, t(12) = 1.09, p = 0.3) or CeA (CCI:1.03 ± 0.1 vs. 
Sham: 1.00 ± 0.1, t(12) = 0.45, p = 0.7). n = 6-8 per group, dependent on viability of 
tissue sample during processing. Data represent fold change normalized to 18s; ± SEM.  
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Supplementary Figure 3.2.  The CeA demonstrates lateralization in CCI-induced 
increases in PACAP and pERK immunoreactivity.  CCI (14 days) preferentially 
increased PACAP immunoreactivity and pERK+ cells in the right CeA.  When 
thresholded PACAP immunoreactivity from Figure 3.2 was analyzed with respect to right 
or left CeA, there was a significant main effect of side (A; F(1,28) = 4.87, *p = 0.04), but 
no interaction between side and condition (F(1,28) = 1.63, p = 0.2), with greater PACAP 
immunoreactivity in the right CeA. There was a significant main effect of CCI for 
increased PACAP immunoreactivity (F(1,28) = 17.24, p = 0.0003). There was a similar 
bias in pERK+ cells in the right CeA with a trend for the effect of side (B; F(1,26) = 3.15, 
p = 0.09). There was also a main effect of CCI for increased pERK+ cells (F(1,26) = 
8.85, p = 0.006).  These results appear consistent with the lateralization of CeA pERK 
shown previously in persistent pain, and implicate PACAP in the lateralization of the 
nociceptive process. 
 
 
 
Sh
am
-Le
ft
CC
I-L
eft
Sh
am
-R
igh
t
CC
I-R
igh
t
0
10
20
30
Im
m
un
or
ea
ct
iv
ity
 (µ
m
2 x
10
3 ) 
*
Sh
am
-Le
ft
CC
I-L
eft
Sh
am
-R
igh
t
CC
I-R
igh
t
0
10
20
30
40
pE
RK
+ 
ce
lls
 (n
)
#ShamCCI
Sham
CCI
 148 
 
Supplementary Figure 3.3.  CCI increases PACAP-EGFP expressing L3 and L5 
DRG neurons.  Similar to the L4 DRG (Figure 3.2), unilateral CCI increased the 
number of L3 and L5 DRG PACAP-EGFP+ neurons 14 days postsurgery (B, E) 
compared to sham controls (A, D).  L3 - L5 DRG peripheral sensory axons travel in the 
sciatic nerve with major contributions from L4.  The increase in CCI-induced PACAP-
EGFP+ neuron expression in L3 DRG (C; sham ipsilateral = 5.0 ± 2.1 cells vs CCI 
ipsilateral = 36.3 ± 4.3 cells, *p = 0.0002, n = 3 per group) and L5 DRG (F; sham 
ipsilateral = 4.5 ± 1.5 cells vs CCI ipsilateral = 37.5 ± 10.5 cells, n = 2 per group) was 
not as robust as that in L4 DRG.  Data represent mean cells/unit area ± SEM. 
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Supplementary Figure 3.4.   CeA and BNST PACAP fibers colocalize 
predominantly with vGlut2 immunoreactivity.  CeA (A) and BNST (D) tissues were 
dually processed for PACAP (Alexa Fluor 488, green) and vGlut2 (Cy3, red) to help 
establish neuronal transmitter identity.   CeA and BNST PACAP colocalized with 
glutaminergic marker vGlut2 as shown in their respective isolated merged signals (B, E; 
yellow).  From quantitative image analyses, there was minimal overlap between PACAP 
and vGlut1 or GAD (C, F; see Suppl. Figure 3.5).  Scale bar = 25 µm   
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Supplementary Figure 3.5.  PACAPergic fibers contact BNST pERK+ neurons in 
CCI.  As in the CeLC, CCI increased bilaterally the number of pERK+ neurons in the 
anterolateral BNST compared to sham controls (A - C).  The BNST pERK+ cells (Cy3, 
red) were in close contact with PACAP fibers (D,E; Alexa Fluor 488, green), implicating 
PACAP as a potential mechanism of CCI-induced nociceptive ERK signaling.   There is 
a main effect of CCI (C; F(1,8) = 15.3 p = 0.005, n = 3 per group).  Scale bar = 50µm. 
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Supplementary Figure 3.6.  CeA and BNST PACAP immunoreactivity does not 
colocalize with vGlut1 or GAD.  CeA (A, B) and BNST (E, G) tissues were dually 
processed for PACAP (Alexa Fluor 488, green) and vGlut (Cy3, red) or GAD (Cy3, 
red).  Unlike vGlut2 (Supplementary Figure 3.4), there was little overlap with the 
glutamatergic marker vGlut1 or GABAergic marker GAD in both regions as shown by 
the paucity of merged signals (B, D, F and H; yellow).  Quantitative analyses in Suppl. 
Figure 3.4.  Scale bar = 25 µm 
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Supplementary Figure 3.7.  Acute CeA infusions with inhibitors does not induce 
apoptosis.  To verify that the CeA infusions with drugs to block MEK (PD98059) or 
endocytic mechanisms (Pitstop 2) did not cause overt neurotoxicity and apoptosis to 
impact results, the treated tissues were also processed for nuclear Hoechst staining (A - 
C) and apoptotic marker cleaved caspase-3 immunoreactivity (D - F).  Hoechst nuclear 
staining confirmed there were no apparent signs of substantial cell loss in any of the 
treatment conditions; further, there were no signs of any ongoing apoptosis in the CeA.  
Cleaved caspase 3+ cells were found sporadically throughout the brain; G, an example of 
a cleaved caspase 3+ hippocampal neuron at the same magnification. Scale bar = 50µm 
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 Chapter 4.  
General Discussion 
 
 The studies in this dissertation were aimed to investigate the role of CeA PACAP 
signaling in mediating the emotional components of pain.  Severe emotional 
dysregulation often co-exists in patients with chronic pain, as evidenced by the high rates 
of comorbid affective disorders including post-traumatic stress disorder (PTSD), 
generalized anxiety disorder (GAD), and panic disorder (PD).  Chronic pain carries an 
enormous personal, societal, and economic burden and in the presence of comorbid 
affective disorders, the degree of disability and suffering in these individuals becomes 
greatly amplified.  Moreover, the presence of an affective disorder may not only 
exacerbate pain, but may also act to reinforce the underlying mechanistic processes of 
chronic pain in a self-perpetuating cycle.  As these mechanisms are not well understood, 
studies elucidating the key signaling molecules and neural circuits in this system may 
offer insights to the pathogenesis of these disorders and provide therapeutic approaches to 
break the cycle of chronic pain and affective disorders.  To this end, the studies in this 
dissertation find evidence that PACAP signaling within the parabrachio-amygdaloid tract 
may be a key mediator of the emotional components of pain.   
 
 
 
 
 161 
4.1. Insights into PACAP neurocircuits and plasticity 
PACAP expression in the spino-parabrachioamygdaloid tract 
 In the course of ongoing investigation, our laboratory found dense PACAP fiber 
immunoreactivity in the CeLC and CeL regions of the central amygdala (CeA).  From in 
situ hybridization data,  there appeared to be little endogenous PACAP expression within 
the CeA, indicating that the observed immunoreactivity reflected axonal fiber projections 
of undetermined external origins (Piggins et al., 1996).  Using anterograde tracing with 
10 kDa BDA and excitotoxic lesion studies, we showed that the vast majority CeA 
PACAP immunoreactivity originated from the LPBn (ure 2.3, 2.4).  This finding is of 
particular interest because sensory input converges on the LPBn before projecting to the 
CeLC.  Nociceptive information from the entire body and face are relayed by the spinal 
cord and sensory trigeminal system, respectively, via second order sensory afferents onto 
LPBn neurons.  Additionally, the LPBn also receives visceral input from the vagal nerve 
via relays from the NTS.  Given the involvement of the LPBn in sensory systems, the 
expression of PACAP in the LPBn is suggestive of a role in the processing of nociceptive 
stimuli.   
 The LPBn has major projections to the CeLC, anterolateral BNST (BNSTal), and 
the VMH.  Interestingly, LPBn-BNST projections are either direct or via collaterals from 
axons ultimately projecting to the CeLC (Sarhan et al., 2005).  We found that lesioning 
the LPBn resulted in a substantial loss (~70%) of PACAP expression within the 
ipsilateral BNST, similar to the findings within the CeA (Figure 2.4).  Although the 
source of the remaining BNST PACAP (~30%) was not investigated, the residual 
 162 
PACAP could have originated from the PVH or dorsal vagal complex, or represented 
endogenous BNST expression (Hammack et al., 2009; Kozicz et al. 1998).  Although not 
examined directly in this work, PACAP in the VMH was previously found to originate 
from the LPBn (Resch et al., 2013).  In projecting to the CeLC, BNST and VMH, the 
population of LPBn PACAP neurons may be components of a much enlarged network 
and behave as a sensory distribution hub, relaying discrete information to these three 
regions to coordinate the behavioral and physiological responses to aversive sensory 
input.  Along this line, the effect of PACAP signaling in each of these regions has now 
been investigated.  PACAP infusion directly into the VMH resulted in hypophagia and 
increased thermogenesis (Resch et al., 2011).  BNST PACAP infusion produces anxiety-
like behaviors, hypophagia, weight loss, and HPA axis activation (Hammack et al., 2009; 
Roman et al. 2014; Kocho-Schellenberg et al., 2014; Lezak et al., 2014).  Whereas, CeA 
PACAP was demonstrated in the current studies to produce nociceptive hypersensitivity 
and anxiety-like behavior, CeA PACAP signaling has also recently been reported to 
produce a delayed hypophagia and weight loss (Figure 2.6; Iemolo et al., 2015).  
Interestingly, PACAP signaling in CeA, BNST, and VMH appear to initiate various 
combinations of hypophagia, anxiety-like behavior, and nociceptive hypersensitivity.  
Hence, these responses may represent a behavioral and physiological phenotype that is 
characteristic of sustained or enhanced LPBn activity, as might occur following 
prolonged nociceptive input with chronic pain. 
 Further, PACAP expression in nociceptive pathways is not restricted to LPBn-
CeLC projections, as it is found all along the spino-parabrachio-amygdaloid pathway 
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(Figure 4.1).  PACAP is found within peripheral afferent terminals and within a subset of 
peptidergic DRG cells that also express CGRP and the precursor of substance P (Mulder 
et al., 1994; Usoskin et al., 2015).  PACAPergic fibers from these DRGs project to the 
dorsal horn, and dense PACAP immunoreactivity is found in lamina I/II of the spinal 
cord (Vizzard, 2000).  At the next step of this pathway, neurons in lamina I/II have been 
reported to express PACAP, and although yet to be established, these neurons may 
represent the second-order spinal projection neurons that relay nociceptive information to 
the LPBn (Pettersson et al., 2004).  In our experiments utilizing PACAP-EGFP mice, we 
confirmed PACAP-EGFP expression in a subset of DRG neurons and consistently found 
PACAP-EGFP expressing cells within lamina I/II of the spinal cord (Figure 3.2).  Our 
findings are in agreement with prior work and demonstrate that PACAP is expressed at 
all levels of the spino-parabrachio-amygdaloid pathway.  These PACAP expression 
patterns raise the possibility of PACAP-expressing neurons synapsing onto other PACAP 
neurons (PACAP to PACAP projections) all along the spino-parabrachio-amygdaloid 
tract.  Mechanistically this system would appear plausible, as PACAP signaling was 
found to exhibit positive autoregulation in the sympathetic system, with PACAP receptor 
activation driving more PACAP expression (Braas et al., 2007).  Additionally, the 
existence of PACAPergic fibers synapsing on PACAPergic neurons has been suggested 
in the enteric nervous system (Nagahama et al., 1998).  Further, infusion of PACAP 
appears pro-nociceptive at several levels of the spino-parabrachio-amygdaloid pathway 
(Table 4.1).   Potentially this system could also involve visceral sensory input, as there is 
a substantial population of PACAP neurons within the NTS, corresponding to the 
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location of the primary relay of visceral information to the LPBn.  The possibility of 
PACAP expression at every level of the spino-parabrachio-amygdaloid pathway is 
significant, as it would identify a signaling molecule used along an entire pathway.  
Further, it might indicate that PACAP expression could mark a set of neural circuits 
within the CNS that integrate aversive sensory information with emotional salience.  
Intriguingly, PACAP is the mostly highly conserved peptide in its family and appears to 
be present along one of the more phylogenetically ancient spino-parabrachial nociceptive 
pathway, in comparison to the more evolutionarily recent neospinothalamic pathway 
(Almeida et al., 2004; Sherwood et al., 2000).  Given what is known about its function, 
PACAP-expressing neural circuits may function in the generation of a primitive, whole-
body response to particularly averse and long-lasting challenges, such as prolonged pain.   
 
CEA PACAP is coexpressed with CGRP 
 In addition to PACAP, the CeA also expresses diverse neuropeptides and 
markers, including somatostatin (SST), CRH, parvalbumin (PV), cholecystokinin (CCK), 
calbindin, calretinin and VIP, all of which display characteristic unique or overlapping 
expression patterns (Ehrlich et al., 2009; Kemppainen & Pitkanen, 2000).  The CeA 
PACAP fiber immunoreactivity is confined to the CeLC and CeL, and the PACAP 
terminals form perisomatic basket-type innervations of amygdala neurons.  We found no 
overlap between PACAP and somatostatin or CRH immunoreactivity in the CeA; the 
distribution of each peptide appeared to display non-overlapping, but intermingled 
expression patterns (Figure 2.1).  However, co-labeling with CGRP and PACAP resulted 
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in fairly extensive colocalization in the CeA (Figure 2.2).  CGRP expression in the CeLC 
has been previously shown to originate from the LPBn; thus PACAP and CGRP appear 
to demonstrate high levels of coexpression within LPBn-CeLC projections (Dobolyi et 
al., 2005).  Similarly, within the BNSTal, there is a substantial overlap of PACAP and 
CGRP immunoreactivity, suggesting that this too is part of the LPBn projections.  This 
latter finding was confirmed, as LPBn lesions produced a concomitant loss of CGRP 
immunoreactivity with PACAP in both the BNST and CeLC (Figure 2.2).   
 CGRP signaling could play a similar or complementary role to PACAP in the 
generation of stress-related behavioral responses in the limbic system.  CGRP signaling 
can promote unconditioned fear, as CGRP infusions into the amygdala produced an 
unconditioned freezing response before any aversive stimulus was presented 
(Kocorowski & Helmstetter, 2001).  Further, pretreatment with the CGRP receptor 
antagonist, CGRP(8-37) in the amygdala disrupted cued but not contextual fear 
conditioning.  In the BNST, infusion of CGRP induced anxiety-like responses on the 
elevated plus maze and produced a dose-dependent enhancement of startle (Kelly et al., 
2011).  This effect appeared to be dependent on CRH signaling, since either pretreatment 
with CRHR1 antagonist or virally-mediated siRNA knockdown of CRH expression, 
blocked the ability of BNST CGRP to enhance startle (Sink et al., 2013). CGRP is well 
known as a peripheral modulator of nociceptive transmission and this role may hold true 
within the brain.  Application of CGRP to amygdala sections increases excitatory 
postsynaptic currents (EPSCs) on PBn-CeLC synapses, increasing amplitude but not the 
frequency of miniature EPSCs (Han et al., 2010).  Further, CeA administration of CGRP 
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into awake rats was found to increase audible and ultrasonic vocalizations and produce 
mechanical hypersensitivity.  CeA CGRP may also play a role in feeding behavior.  
Using optogenetic and pharmacogenetic manipulation of CGRP-expressing PBn-CeLC 
projections, activation of these projections strongly suppressed appetite.  Conversely, 
inhibition of CGRP LPBn-CeLC projections increased food intake in situations when 
mice normally do not eat, and prevented starvation after agouti-related peptide (AgRP) 
neuronal ablation, implicating CGRP LPBn-CeLC signaling may be connected to the 
principal feeding circuits within the hypothalamus (Carter et al., 2013).  Interestingly, 
activation of CGRP LPBn neurons was sufficient to induce conditioned taste aversion in 
the absence of an anorexigenic substance, and inhibition of these same neurons 
attenuated conditioned taste aversion to lithium chloride (Carter et al., 2015).  From these 
studies, CGRP LPBn-CeLC projections are thought to encode a type of visceral malaise 
signal.  In sum, the effects of CGRP in the CeA bare some striking similarities to those of 
PACAP, inducing anxiety-like behaviors, nociceptive hypersensitivity, and hypophagia.   
 Given the overlap in expression and functional similarities of PACAP and CGRP 
in the CeLC, these two peptides might play complementary roles.  In mammalian brains 
it has been found that generally when two or more neuropeptides are coexpressed within 
the same neuronal population, they are also co-stored within the same large dense core 
vesicles (Merighi, 2002).  Co-storage would have functional implications; first, it would 
necessitate co-release of both neuropeptides, allowing for interactions between the 
different peptides, and second, it would suggest that regulation of these systems would be 
most readily accomplished through altering rates of synthesis.  Neuropeptides can often 
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work in a synergistic manner.  One of the best-known examples of this is the potentiation 
of CRH by vasopressin in the pituitary gland, where the effect of vasopressin greatly 
increases the amount of adreno-corticotropin releasing hormone (ACTH) that is released 
by CRH binding (Merighi, 2002).  Studies of the ophthalmic artery, suggest the 
possibility of a synergistic interaction between PACAP and CGRP.  In the porcine 
ophthalmic artery, both PACAP and CGRP each induced a concentration dependent 
vasorelaxation, but when both peptides where administered together the amount of 
relaxation substantially increased, beyond what would be predicted individually (Elsas & 
White, 1997).   
 
Pain-related plasticity of PACAPergic neural circuits 
 To examine if there is increased PACAP signaling during persistent pain, we 
performed a set of experiments using a CCI model of neuropathic pain.  At 14 days 
following CCI surgery, PACAP transcript was increased in the LPBn (Figure s3.1).  This 
effect appeared to be specific to the LPBn, as no other CNS regions examined had 
significant alterations in expression.  Increased PACAP transcript levels at 14 days 
corresponded to an increase in PACAP immunoreactivity in the CeA, indicating 
increased PBn PACAP biosynthesis and increased axonal transport of PACAP peptide to 
CeA terminals (Figure 3.1).  Complementary to these studies, tissue from transgenic 
PACAP-EGFP mice was analyzed following CCI.  In agreement, 14 days following CCI 
there was a bilateral increase number of PACAP-EGFP+ cells in the LPBn, compared to 
sham surgery (Figure 3.1).  These results provide strong evidence that CCI increases 
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PACAP signaling in LPBn-CeLC circuits and support PACAP involvement in chronic 
pain-related plasticity. 
In addition to the LPBn-CeLC, CCI induced PACAP expression along multiple 
neural sites within the spino-parabrachial amygdaloid pathway.  Following CCI, PACAP-
EGFP mice displayed marked PACAP-EGFP expression within the proximal sciatic 
nerve and in L3-L5 DRG ipsilateral to the injury (Figure 3.2).  This is consistent with a 
number of previous studies reporting enhanced PACAP expression in peripheral nerve 
and DRG following injuries including axotomy, injection of complete Freund’s adjuvant, 
L5 nerve transection, or capsaicin treatment (Jongsma et al., 2000; Mabuchi et al., 2004; 
Mulder et al., 1999; Nemeth et al., 2006; Pettersson et al., 2004).  In the spinal cord, we 
identified prominent PACAP-EGFP fibers in the dorsal columns/medial lemnisicus tract 
that give off collaterals into lamina III-V (Figure 3.2).  This pathway likely corresponds 
to Aβ fibers conveying non-noxious sensory information to the gracile nucleus.  The 
presence of PACAP within this pathway may be a consequence of its role as a 
prosurvival/injury response factor.  Interestingly, it has been proposed that during 
neuropathic pain, the sprouting of these collateral Aβ fibers from lamina III-V into 
lamina I-II may explain the presence of allodynia (Mannion et al., 1996; Woolf et al., 
1992).  In this model, as a consequence of pain-related sprouting, lamina I neurons would 
now receive non-noxious sensory input, and result in innocuous sensory stimuli leading 
to the perception of pain to normally non-noxious stimuli. However, this interpretation 
has been questioned because of the development of new more precise techniques, raising 
questions about peripheral sprouting of Aβ lamina III-V fibers as a mechanism of 
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sensitization (Hughes et al., 2003; Zhang et al., 2015).  In our studies, the lack of 
PACAP-EGFP fibers in lamina I in either normal conditions or following CCI is 
surprising and might suggest a specific role in non-noxious sensory transmission in the 
periphery.  However, under normal conditions PACAP immunoreactivity has been 
repeatedly found primarily within lamina I and not in lamina III-V (Hannibal, 2002; 
Vizzard, 2000).  The lack of PACAP within lamina I could simply be a result of  native 
EGFP detection limits or differences in cellular mechanisms between different sized 
neuronal fibers and causing EGFP to be found only in larger neuronal fibers.  The 
increased expression of PACAP-EGFP along multiple levels of the spino-parabrachio-
amygdaloid pathway suggests PACAP signaling might contribute to pain-related neural 
transmission and plasticity within distinct nociceptive pathways. 
 All experiments that examined alterations in PACAP expression were performed 
at 14 days following CCI surgery to allow comparisons across different experiments.  
There were several factors in the determination of this time point.  The first is that it 
allowed sufficient time for recovery from surgery, such that the cutaneous incision would 
be healed, and motor deficits could be largely resolved.  This time point also corresponds 
to a time following CCI when hypersensitivity behaviors are fully developed.  Finally, 
given the nature of stress stimuli required in our previous studies, several days of 
persistent pain may be required for the regulation of PACAP in this system.  
Upregulation of PACAP and PAC1R transcript in the BNST was found following 7 days 
of stress, but no change following one acute stressor exposure (Hammack et al., 2009; 
Lezak et al., 2014).  Further, although PAC1R deficient mice have normal stress response 
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to acute restraint stress, longer periods of stress (14-21 days) resulted in a significant 
attenuation of HPA axis activation and stress-induced hypophagia (Mustafa et al., 2015).  
Thus, the induction of PACAP expression and signaling might occur at later time points 
and require a prolonged stimulus.  Future characterization at different time points is 
necessary to determine whether longer durations of pain are required to induce PACAP 
expression in the PBn-CeLC.   Interestingly, the development of anxiodepressive 
behaviors in rats with CCI follows a very gradual timeline, appearing over the course of a 
number of days, in comparison to hypersensitivity which has more immediate 
development in the hours following surgery (Alba-Delgado et al., 2013).  The biological 
mechanisms that could be governing these changes occurring in the timeframe of several 
days and weeks following initial onset are not well understood.  Given the delayed onset 
of many pharmacological antidepressant treatments (Lam, 2012), the factors that mediate 
neural circuit plasticity over longer time courses might be those most valuable for 
treating psychiatric disease.   
 
4.2. The role of PACAP in emotional behaviors 
PACAP as a regulator of anxiety-like behaviors 
 The amygdala plays a principal role in assigning emotional salience to external 
stimuli and coordinating the behavioral and physiological responses to these triggers.  As 
PACAP expression corresponds to a direct nociceptive input into the amygdala, this 
suggests that CeA PACAP could have a role in modifying the attachment of emotional 
salience to nociceptive stimuli.  In agreement with this idea, we found CeA PACAP 
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infusion produced an aversive emotional response, as reflected by an increase in anxiety-
like behaviors on the elevated plus maze (Figure 2.6).  These findings are consistent with 
two prior studies suggesting CeA PACAP signaling can produce negative/defensive 
emotional behaviors.  In the shock-probe fear/defensive burying task, rats are placed in 
an arena with an electrified probe and allowed to explore freely.  After freely 
encountering the probe and receiving an electric shock, the resulting behavioral responses 
are recorded and classified into stereotypical categories.  CeA PACAP infusion created a 
shift towards passive coping strategies characterized by increased immobility time and 
avoidance, in contrast to active behavioral strategies like burying the probe with bedding 
(Legradi et al., 2007).  Another study, found that CeA PACAP signaling may also 
regulate feeding behavior.  Infusion of PACAP in the CeA produced a dose-dependent 
decrease in food intake and resulted in weight loss through mechanisms that required 
melanocortin and TrkB signaling (Iemolo et al., 2015).  In aggregate, these data suggest 
that CeA PACAP signaling appears produce an emotional state characterized by 
increased passive behaviors, decreased exploratory behaviors, and hypophagia. 
 The role of CeA PACAP signaling should be interpreted in the context of the 
neural circuitry of the larger extended amygdala complex that includes the BLA, CeA, 
BNST, and other less studied regions, such as the substantia innominate.  While the terms 
fear and anxiety are often used interchangeably, on the basis of neural circuitry there may 
be rationale for the separation of these into two distinct entities (Davis et al., 2010; 
Walker et al., 2009).  Within the extended amygdala, the CeA is thought to a have a 
greater role in fear responses, which are short phasic responses, and likely best 
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recapitulated in cued fear conditioning and fear-potentiated startle paradigms.  On the 
other hand, the BNST is thought to mediate responses primarily to longer-duration, 
diffuse, or unpredictable threats, and which are more akin to anxiety.  Paradigms such as 
light or CRH-enhanced startle, and learned helplessness were found to be dependent on 
BNST activity (Hammack et al., 2004; Davis et al., 2010; Walker et al., 2009).  With this 
interpretation it might suggest that the emotional responses found following CeA PACAP 
might be related to ongoing fear behaviors or a decreased threshold in the generation of 
the fear response.  Detailed analysis of the behaviors of CeA PACAP on elevated plus 
maze revealed that total locomotor activity was reduced; however this was not the result 
of increased spontaneous freezing responses (a fear response), but rather a selective 
decrease in the choice to enter the open arms.  The traditional extended amygdala model 
is complicated by the fact that previous studies have relied largely on lesion techniques, 
where often the entire CeA was lesioned.  In phasic fear responses, the CeM appears 
critical as an output to brainstem targets to drive fear responses.  The role CeLC and CeL 
is less straightforward, although both areas have prominent projections to the CeM which 
are thought to be important in the release of inhibitory signals on the CeM, to allow the 
expression of fear behaviors through CeM to brainstem projections (Ciocchi et al., 2010; 
Haubensak et al., 2010).  Additionally prominent projections of the CeL and CeLC to the 
BNST have been postulated to be important in the transition from phasic to sustained fear 
(Walker et al., 2009).  A population of CRH neurons within the CeL is the source of the 
majority of CRH fiber immunoreactivity within the BNSTal, and CeA-BNST CRH 
signaling within is thought to be a mediator of conditioned anxiety-like behaviors.  As 
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such, CeA PACAP could produce anxiety-like responses through enhanced neuronal 
activation or CRH release in the BNST (Beckerman et al., 2013).  Previous studies within 
the PVH demonstrate that PACAP can drive CRH expression (Agarwal et al., 2005).  In 
the future, determining which neurons are being activated in the CeLC and CeL by 
PACAP, and defining their projections will be crucial to understanding the role of 
PACAP within these neural circuits and the extended amygdala.   
 One intriguing possibility is that CeA PACAP signaling could lead to plasticity 
within fear circuitry that conveys the unconditioned stimulus (US).  Compared to the 
BLA, the contribution of the PBn in fear conditioning has been relatively unexplored; 
however it has been recently found that following fear conditioning, there is a synaptic 
potentiation of both BLA-CeLC and LPBn-CeLC pathways (Watabe et al., 2013).  This 
appears to be accomplished by both pre- and postsynaptic mechanisms. In addition, there 
was a correlation between BLA-CeLC and LPBn-CeLC synaptic potentiation suggesting 
a heterosynaptic interaction between these two pathways.  In a follow up study, 
inactivation of the LPBn during acquisition of fear conditioning decreased freezing to the 
conditioned stimulus (CS) during testing.  Further, optogenetic activation of LPBn-CeLC 
projections could be paired with a tone and resulted in increased freezing to the 
presentation upon presentation of the tone, suggesting that LPBn-CeLC activation could 
effectively act as a US (Sato et al., 2015).   
 Given the presence of PACAP within LPBn-BNST projections, BNST PACAP 
signaling might also have a role in the emotional components of pain, similar to CeA 
PACAP.   Our previous work has extensively characterized BNST PACAP as it relates to 
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the behavioral and physiological consequences to chronic stress (Hammack et al. 2009; 
Roman et al., 2014; Kocho-Schellengberg et al., 2014, Lezak et al., 2014).  Situations of 
chronic stress can potentiate pain experience, such as in stress-induced hyperalgesia 
(McEwen & Kalia, 2010).  Thus, during chronic stress the BNST might enhance pain 
experience through direct or indirect influences on descending pathways to modulate 
pain.  Further, the existence of the ascending LPBn-BNST projections and that some of 
these projections as collaterals of nociceptive LPBn-CeLC projections, suggests a 
possible role for the BNST in ascending nociceptive modulation.  Unlike the LPBn-CeA 
projections, there have been sparse investigations into the contribution of LPBn-BNST 
projections as they relate to nociception.   An electrophysiological study of anesthetized 
rats found that over a quarter of BNST neurons were excited by noxious stimulation, and 
that this afferent pathway was not a result of indirect input from the amygdala (Casada & 
Dafny, 1992).   
 
PACAP signaling in pain-related behaviors 
 Since neuropathic pain increased PACAP expression in the CeLC, we wanted to 
determine if this heightened PACAP signaling in the CeLC contributed to pain-related 
behaviors.  To examine this, the PACAP receptor antagonist PACAP6-38, a PAC1 and 
VPAC2 receptor antagonist, was injected into the CeA following CCI to examine its 
abilities to attenuate pain-induced hypersensitivity or emotional behaviors.  The CCI 
model has been shown to heighten anxio-depressive behaviors including anxiety-like 
behaviors on the elevated plus maze and increased depressive behaviors in open field and 
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forced swim tests (Roeska et al., 2008; Zeng et al., 2008).  Fourteen days following 
surgery, CeA infusion of PACAP6-38 was able to block heightened anxiety-like 
behaviors in the open field in the CCI condition (Figure 3.3).  There was no effect of 
PACAP6-38 alone on rats with sham surgery, suggesting that ongoing CeA PACAP 
signaling has a role in modulating behavior in the setting of pain, but does not modulate 
behaviors under normal conditions.  Similarly, CeA infusion of PACAP6-38 resulted in 
an attenuation of thermal hypersensitivity in the CCI afflicted hindpaw, but did not alter 
response latency for either the contralateral hindpaw, or for either hindpaws in the sham 
condition (Figure 3.3).  A lack of thermal sensitivity in either condition implies that CeA 
PACAP signaling may modulate sensitivity in situations of persistent pain, but may not 
alter thresholds under normal conditions.  The selective involvement of PACAP in states 
of persistent pain mimics the involvement of several neurotransmitter systems in the CeA 
that selectively contribute to increased CeA activity during pain.   Arthritic pain increased 
expression of metabotropic glutamate receptor 1 (mGluR1) in the CeA; a selective 
mGluR1 antagonist reduced synaptic transmission in the CeA from arthritic animals but 
had no effect in the CeA of control animals (Neugebauer et al., 2003).  Blockade of the 
CGRP1 receptor in the CeA attenuated enhanced synaptic transmission from arthritic 
animals, reducing EPSC amplitude and spike frequency, as well as attenuating 
heightened spinal reflexes and ultrasonic vocalizations, but had no effect in control 
animals (Han, et al., 2005).  Thus, enhanced PACAP signaling might be one of a  
collection of molecular and synaptic changes in the CeA during pain that influences pain-
related behaviors. 
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A mechanism of CeA PACAP signaling via ERK 
 Among intracellular signaling cascades, enhanced ERK signaling within the 
CeLC appears to have prominent roles in pain-related plasticity.  At 4 hours following 
formalin injection into the hindpaw or 2 hours following acid-induced muscle pain, an 
induction of pERK+ cells was found in the CeLC (Carrasquillo & Gereau, 2007; Cheng 
et al., 2011).  Consistent with these observations we found an increase in pERK+ cells in 
the CeLC 14 days following CCI surgery (Figure 3.4).  The induction of CeLC ERK 
signaling in several different pain models signifies that ERK signaling is likely a pain 
signature, and not a response to any one model.  Additionally, the presence of increased 
ERK signaling at 14 days following CCI would suggest that ongoing ERK signaling in 
the CeA may be a component of persistent pain, rather than just part of the initial 
plasticity.   
Further, we found evidence that PACAP signaling may mediate CeLC ERK 
activation.  In cell culture, PACAP signaling in primary neuronal or HEK EGFP-PAC1R 
cells results in potent and sustained ERK activation (May et al., 2010; May et al., 2014).  
In examining the CeA from CCI rats, a majority of pERK+ cells were immediately 
apposed to PACAP-immunoreactive fibers.  CeA PACAP administration resulted in a 
robust induction of pERK+ cells, demonstrating that CeA PACAP signaling activates 
ERK in the amygdala neurons (Figure 3.5).  Further, ERK activation was found to be 
necessary for CeA PACAP to alter nociception, as pretreatment with a MEK inhibitor 
abolished PACAP-induced thermal hypersensitivity.  One remaining question is whether 
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PACAP signaling is the sole mediator of pain-related activation of ERK.  This appears 
unlikely as several other candidates, including signaling through NMDA, mGluR, and 
reactive oxygen species (ROS) have been found to contribute to ERK activation in the 
CeLC (Cheng et al., 2011; Li, Ji, & Neugebauer, 2011).  In this view, ERK signaling 
appears to be a site of convergence for multiple signaling systems in the CeLC to allow 
for diverse modulation and the dynamic regulation of amygdalar circuits.   
 One prominent mechanism through which PACAP may activate ERK is through 
the internalization of PACAP receptors.  Internalization of G-protein coupled receptors 
(GPCRs) was once thought to be primarily a means of receptor desensitization; however, 
more recent studies have suggested GPCR internalization may play a role in receptor 
resensitization and even act as an alternative form of intracellular signaling (Ferguson, 
2001; Sorkin & von Zastrow, 2009).  The most common form of GPCR internalization of 
signaling endosomes is dependent on the binding of β-arrestin scaffolds and the 
formation of clathrin-coated pits, to result in a signaling endosome (Ferguson, 2001; 
Sorkin & von Zastrow, 2009).  Using an EGFP-PAC1 receptor cell line, PACAP/PAC1 
receptor binding and signaling was shown to induce PAC1 receptor internalization, which 
was inhibited by blocking either clathrin (Pitstop) or dynamin I/II (Dynasore) (Merriam 
et al., 2013).  Blocking internalization of the PAC1 receptor was found to strongly reduce 
PACAP-mediated ERK activation.  However, the induction of ERK signaling was not 
completely blocked by inhibiting internalization, as a further reduction of ERK signaling 
was affected by blocking phospholipase C/diacylglycerol/protein kinase C signaling.  
These results demonstrate that PAC1 receptor-mediated ERK activation is accomplished 
 178 
via multiple mechanisms through both internalization/cytosolic signaling and plasma 
membrane signaling (May et al., 2014).  The current work extends these findings in vivo 
and suggests that receptor internalization may occur with CeLC PACAP nociceptive 
signaling.  Blocking endocytosis by using the clathrin inhibitor, Pitstop, attenuated the 
ability of PACAP to activate ERK in the CeA in parallel with a reduction in CeA 
PACAP- induced thermal hypersensitivity (Figure 3.5).  This is the first piece of evidence 
to suggest that PACAP receptors may internalize in vivo and demonstrates a possible 
functional role of this process.  However, an important limitation in this line of studies is 
that Pitstop is not selective to the PAC1 receptor and results in the global inhibition of 
clarthrin-mediated endocytosis.  However, as there were no changes between vehicle and 
Pitstop-treated control animals that did not receive PACAP, it can be reasonably 
concluded that clathrin-mediated endocytosis is required for CeA PACAP signaling to 
fully induce pERK and behavioral hypersensitivity.  To determine conclusively if this 
was a direct effect of the PAC1 receptor would likely require the genetic modification to 
generate a PAC1 receptor incapable of internalization.  One possible role for PAC1 
receptor internalization is that it may provide a mechanism to allow sustained ERK 
activation.  This would be consistent with the findings that in comparison to some other 
neuropeptides, PACAP mediated effects have a more gradual onset but are much longer 
in duration (Shimizu et al 2004) .  As such, PACAP released in the CeA during chronic 
pain might result in a prolonged excitability and heightened plasticity of CeA neurons 
and lead to the strengthening of amygdalar nociceptive and emotional-salience circuits.   
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 One fundamental remaining question is whether CeA PACAP signaling is specific 
to nociception.  Recent experiments utilizing genetic circuit manipulations have resulted 
in the hypothesis that specific subsets of amygdala neurons and their connections may not 
encode specific modalities but rather encode a positive or negative emotional valence 
(Namburi et al., 2015; Redondo et al., 2014).  In this view, CeA PACAP signaling would 
likely be a circuit carrying negative emotional valence, and nociceptive stimuli would be 
one of numerous stimuli that result in PACAP release.  Given that the vast majority of 
CeA PACAP originates from the LPBn, the decisive factor would be determining the 
modality of stimuli that activates the LPBn.  Prior studies which suggest the existence of 
amygdalar circuits for positive and negative valence have been focused on the BLA, a 
region which receives highly polymodal and processed nociceptive information (Namburi 
et al., 2015; Neugebauer et al., 2004; Redondo et al., 2014).   The LPBn, in contrast, 
receives direct nociceptive information from lamina I of the spinal cord and visceral 
inputs from the NTS.  The contrast between the input of BLA compared to the LPBn is 
illustrated by its role in fear conditioning. The BLA is thought to receive afferents related 
to both the US (electric shock) in combination with a host of other environmental sensory 
information (light, tone, etc.). The PBn-CeLC projection is only thought to convey the 
only the US (electric shock), likely due to aversive/nociceptive nature (Paré et al., 2004; 
Sato et al., 2015).  However, a recent study found that the CGRP expressing LPBn-CeLC 
projections (which overlap with PACAP projections) can convey a visceral malaise 
signal to strongly inhibit feeding behavior, such as those induced by lithium chloride 
(Carter et al., 2015).  Even though these results were argued not to reflect nociceptive 
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activation, this was not tested directly (Carter et al., 2013).  Regardless, CGRP LPBn-
CeLC activation can be regarded as a highly aversive interoceptive stimulus.   Further, it 
remains to be determined if inflammatory factors could also result in the activation of 
LPBn-CeA circuits via the NTS.  Although much remains to be determined, CeA PACAP 
signaling may be encoding a negative valence that is associated with a subset of highly 
aversive sensory stimuli.   
 
4.3. Summary 
 PACAP has been well established as neuropeptide that regulates homeostatic 
function.  Several recent lines of research have demonstrated that PACAP signaling 
potently activates both physiological and behavioral responses to stressors and that these 
responses are likely due to PACAP signaling in limbic regions.  Additionally, it had been 
previously established that PACAP might have important roles in nociceptive 
transmission and sensitization in peripheral systems.  In this work, the role of PACAP in 
nociceptive processes was found to extend centrally into limbic regions via the spino-
parabrachio-amgydaloid pathway.  Through this pathway, PACAP functions to potentiate 
many of the emotional components of pain.   
 This work has several key limitations.  The PBn was found to be a substantial 
source of CeA PACAP, thus the effects of infusions of PACAP or PACAP(6-38) on both 
pain and anxiety-related behaviors were attributed to nociceptive PBn-CeA projections. 
However, it cannot be ruled out that PACAP signaling from sources other than the PBn 
or locally within the amygdala could be contributing to these effects.  Additionally, all 
 181 
infusions were performed bilaterally; however our results and others have suggested that 
there may be a lateralization of the CeA in pain processing.  Thus, comparisons of 
injections into the left and right CeA could be performed to explore this area.  A second 
limitation comes from the use of hypersensitivity assessments to measure pain-related 
behaviors. While hypersensitivity assessments may provide a well-used indicator of 
evoked pain-responses, often a larger problem in chronic pain sufferers is the presence of 
spontaneous pain.  However, spontaneous pain often been particularily difficult to model 
in rodents; hence careful design of experiments assessing spotaneous pain behaviors may 
be needed to address these questions.  Finally, while the Pitstop experiments suggest that 
receptor internalization may be required for CeA PACAP-induced thermal 
hypersentivity, the studies did not specifically address whether PAC1 receptor 
internalization was the primary driver of the nociceptive effects or whether the response 
was a consequence of other interacting receptor systems.  Future experiments that 
directly interfere with PAC1 receptor internalization would address this possibility. 
 The results of this work raise a number of important new questions.  Heightened 
levels of PACAP expression were observed 14 days following CCI in the LPBn-CeLC 
pathway.  The time course of induction and the exact nature of the challenge, whether it 
is specific to pain or aversive stimuli, all remain to be determined.  We found that the use 
of PACAP-EGFP mice could offer a powerful tool for investigating these questions.  The 
recent creation of PACAP-Cre mice allows for a whole new set of investigations 
examining circuit specific functions using optogenetic and pharmacogenetic 
manipulations.  The behavioral and physiological role of PACAPergic projections from 
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the LPBn to the CeLC, BNST, and VMH can now be individually stimulated and 
inhibited to allow characterization. PACAPegeric PBn-CeA projections can be directly 
examined by injecting a virus containing a floxed channelrhodopsin directly into the PBn 
of PACAP-Cre mice.  By optogentically stimulating the terminals of CeA fibers, the 
effects of activating only PACAP containing PBn-CeA projections can be examined for 
its effects on pain and anxiety-related behaviors.  In a similar manner, by inhibiting these 
same fibers in a model of chronic pain, the contributions of the PBn-CeA projections can 
be determined in pain-related behavioral changes.  The use of PACAP-specific viral 
tracting will allow for the deciphering of PACAP pain and stress circuits with better 
prescision and resolution in future functional studies.  
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4.4. Figures 
Figure 4.1. Schematic of known pain-related plasticity of PACAP expression within 
the spino-parabrachioamygdaloid pathway 
DRG 
LPBn 
CeLC 
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and neuropathic pain!
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following capsaicin!
  
    !
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neuropathic pain!
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neuropathic pain!
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Region 
 
Compound Behavioral / physiological result 
Amygdala PACAP 
 
 
 
 
PACAP(6-38) 
Thermal sensitivity (Missig et al., 2014) 
Anxiety-like behavior (Missig et al., 2014) 
Food intake (Iemolo et al., 2015) 
Passive-behavior responding (shock-probe) 
(Legradi et al., 2007) 
Pain-induced thermal hypersensitivity 
(unpublished observations) 
Pain-induced anxiety-like behavior 
(unpublished observations 
Spinal Cord PACAP 
 
 
 
 
 
 
 
 
 
 
PACAP(6-38) 
Thermal sensitivity (Ohsawa et al. 2002) 
Aversive licking/scratching behavior (Ohsawa 
et al. 2002) 
NMDA-induced nocifensive responses 
(Ohsawa et al., 2002) 
Tail flick sensitivity (late phase) (Narita et al., 
1996) 
Multireceptive cell excitability (Dickinson et 
al. 1997) 
NMDA currents (Ohsawa et al., 2002) 
 
Nocifensive responses to formalin (Ohsawa et 
al. 2002) 
Sensory 
Afferent Fibers 
PACAP Nocifensive responses to formalin (Sandor et 
al., 2009) 
Heat-injury induced thermal sensitivity 
(Sandor et al., 2009) 
Acetic acid-induced writhing behaviors 
(Sandor et al., 2009) 
Thermal / mechanical sensitivity (baseline) 
(Sandor et al. 2009) 
Activity of knee joint (Sandor et al. 2009) 
n.c.: no change  
Table 4.1. Summary of site-specific actions of PACAP or PACAP(6-38)  
 
  
 
n.c. 
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